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ABSTRACT 
The cardiovasculature is one of the earliest organ systems to develop in the 
mammalian embryo and its formation relies on the transmembrane receptor 
neuropilin (NRP) 1. Thus, the cardiovasculature in NRP1 knockout mice develops 
abnormally. In addition, the cardiac outflow tract (OFT), a transient, embryonic 
vessel located at the arterial pole of the heart, fails to septate in these mutants.  
NRP1 has traditionally been thought to regulate these processes by binding to 
the vascular endothelial growth factor (VEGF) A in the vascular endothelium. 
Nevertheless, NRP1 is also expressed by non-endothelial cells and binds alternative 
ligands of the class 3 semaphorin (SEMA3) family. During my PhD, I contributed to 
two studies examining NRP1’s role in organ vascularisation, which revealed that 
non-endothelial NRP1 is dispensable for vascular development, and that NRP1 does 
not exclusively function as a VEGF-A receptor during this process. I also 
demonstrated that NRP1, instead of being required as a VEGF-A receptor during 
OFT remodelling, acts as a SEMA3C receptor to induce an endothelial-to-
mesenchymal transition that enables OFT remodelling. 
In a complementary project, I investigated the role of vascular precursors 
marked by a novel lineage trace. Vascular progenitors contribute to the formation of 
the earliest embryonic vessels, but their involvement in later developmental and 
pathological vessel growth is less well understood. Using a Csf1r-Cre transgene, 
originally thought to be specific for the monocyte/macrophage lineage, I found that 
this transgene also labels a subpopulation of endothelial cells in brain and retinal 
vessels. This labelling was not caused by endothelial CSF1R or unspecific Csf1r-Cre 
or Rosa
Yfp
 expression. Furthermore, by analysing embryos from 
myeloid/macrophage-deficient mice, I demonstrated that Csf1r-Cre-labelled 
endothelial cells were not derived from the myeloid/macrophage lineage. In adults, 
the analysis of bone marrow and blood from these mice as well as tamoxifen-
inducible Csf1r-Cre mice suggested that Csf1r-Cre labels a bone marrow-derived 
population of cells that contributes to tissue-resident and circulating vascular 
precursors. 
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In conclusion my results have helped further characterise the mechanism by 
which NRP1 regulates cardiovascular development and provided evidence for the 
contribution of vascular progenitors to developmental and pathological blood vessel 
growth.   
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Chapter 1 INTRODUCTION 
1.1 The Formation of the Cardiovascular System 
A circulatory system is crucial for large multicellular organisms, because it 
enables the transport of oxygen and nutrients when diffusion is no longer adequate to 
reach all cells. Moreover, the circulatory system facilitates the effective removal of 
waste products. Thus, animals as well as plants have evolved vascular transportation 
systems: animals the blood vessels, and plants the xylem and phloem. 
The cardiovasculature, consisting of blood vessels and the heart, is the first 
functional organ system to form in the vertebrate embryo. The embryonic processes, 
which result in the generation of the cardiovascular system, have mostly been studied 
in mouse, as they are firstly very similar between murine and human embryos. 
Secondly, due to the thorough knowledge of the murine genome, mouse embryos are 
easily manipulated genetically, allowing the investigation of specific gene functions 
during cardiovascular development (Rossant, 1996). I shall therefore outline the 
developmental processes by focusing on the mouse embryo (Krishnan et al., 2014). 
1.1.1 Heart development 
The heart is the first functional organ to form during mammalian 
development. Initially, it mainly consists of myocardial cells with an endothelial 
lining and simply functions as a pumping tube; nevertheless, throughout 
development the heart gradually remodels into a complex, four-chambered structure 
comprised of cardiomyocytes as well as multiple non-muscular cell lineages such as 
cells of the connective tissue and conductive system.  
 To date, three temporally and spatially distinct cardiac progenitor populations 
have been identified: the cardiogenic mesoderm, the pro-epicardium and the cardiac 
neural crest cells (NCCs). The cardiogenic mesoderm consists of the earliest cardiac 
progenitors, which ultimately give rise to the ventricular, atrial and outflow tract 
(OFT) myocardium. It is generated shortly after gastrulation from a common cardiac 
precursor population, which is characterised by the expression of mesoderm posterior 
1 (MESP 1) (Bondue and Blanpain, 2010, Bondue et al., 2008, Saga et al., 2000). 
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Following their specification, the cardiogenic progenitors initially migrate to an 
anterior lateral position, where they condense into a structure referred to as the 
cardiac crescent. At this stage the progenitors can be divided into two subpopulations 
termed the first (or primary) heart field (FHF) and the second heart field (SHF) 
(reviewed in Harvey, 2002), where the FHF is situated in a more anterior and lateral 
position compared to the SHF (Figure 1.1).  
Due to their position relative to the SHF, the cells of the FHF are exposed to 
higher levels of cytokines of the bone morphogenetic protein (BMP) (Schultheiss et 
al., 1997) and fibroblast growth factor (FGF) family (Reifers et al., 2000). This 
induces the expression of key regulators of the cardiac lineage such as Nkx2.5 (Lints 
et al., 1993), Gata-4 (Arceci et al., 1993, Heikinheimo et al., 1994), Tbx5 (Hiroi et 
al., 2001, Horb and Thomsen, 1999) and Baf60c (Li et al., 2015). Subsequently, the 
FHF cells differentiate into cardiomyocytes, which is marked by their expression of 
contractile proteins such as sarcomeric myosin heavy chain (MHC) and myosin light 
chain-2a (MCL2a). In contrast, the cells within the SHF remain undifferentiated and 
continue proliferating until they are recruited to the heart at a later stage (reviewed in 
Kelly, 2012). Upon differentiation, the cells of the FHF progenitors migrate ventrally 
to the midline, where they merge to form a linear heart tube by E8.0 which starts 
beating as soon as it forms (Ji et al., 2003) (Figure 1.1). Even before heart tube 
formation is completed at its caudal end, the tube starts undergoing a complex right-
ward looping process, which results in the first signs of asymmetry within the 
embryo. In addition, the linear heart tube lengthens due to the proliferation of the 
cardiomyocytes, as well as the recruitment of additional cells from the SHF, which 
are added to both the arterial as well as the venous pole of the heart tube (Figure 1.1) 
(van den Berg et al., 2009, Soufan et al., 2006).  
Whilst there are no specific markers unique to the FHF progenitors, the SHF 
cells can be identified at E8.5 by the expression of certain markers such as Isl-1, 
which is required for their survival as well as proliferation (Cai et al., 2003). Thus, 
the Isl-1-Cre transgene has been utilised to visualise the derivates of the SHF, which 
mainly constitute of the right ventricle as well as the inflow region (atria) of the heart 
(Meilhac et al., 2004). Nevertheless, recent findings have demonstrated that cardiac 
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NCCs are also labelled by Isl-1-Cre (Engleka et al., 2012) and thus studies, which 
have used this Cre to specifically target genes in the SHF, need to be re-examined.  
Upon migration, Isl-1 expression is reduced and SHF cells differentiate into 
cardiomyocytes as well as endothelial and smooth muscle cells (SMCs) in response 
to cytokines of the BMP, Notch and non-canonical Wnt pathway (reviewed in 
Vincent and Buckingham, 2010). By E14.5, the looping and addition of SHF-derived 
cells has transformed the linear heart tube into a four-chambered structure, where the 
FHF-derived cells contribute to the formation of both ventricles and atria, and the 
SHF-derived cells mainly form the right ventricle as well as the myocardium of the 
OFT (Meilhac et al., 2004) (see 1.4.3) (Figure 1.1).  
Further remodelling through the addition of cardiac NCCs (see 1.4.3) and 
epicardium-derived cells (reviewed in Brade et al., 2013), as well as the proliferation 
and regression of cardiomyocytes ultimately results in the adult version of the heart.  
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Figure 1.1. Formation of the heart in the murine embryo. 
Schematic representation of the first and secondary heart field and their relative 
contributions to the mammalian heart. Processes are matched to the indicated stages of 
murine embryonic development. Ca: caudal, Cr: cranial, L: left, R: right. Adapted from 
“Patterning the vertebrate heart” (Harvey, 2002). 
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1.1.2 Blood vessel development 
1.1.2.1 Vasculogenesis 
The first blood vessels are formed by a process called vasculogenesis, in 
which endothelial precursors termed angioblasts coalesce into cords and differentiate 
into lumen-forming ECs (Risau and Flamme, 1995). These angioblasts are derived 
from the intraembryonic mesoderm, and endoderm-derived factors such as Indian 
hedgehog (IHH) are thought to play a role in their specification (Belaoussoff et al., 
1998, Dyer et al., 2001). The angioblasts then migrate to the yolk sac, an extra-
embryonic membrane that is an important site for the maternal-fetal exchange of 
amino acids and ions (King, 1993, Beckman et al., 1996, Lloyd et al., 1996), from 
E7.25 onwards, where they coalesce to form the first blood vessels of the murine 
embryo. The other site, where de novo extra-embryonic vessel formation occurs, is 
the allantois, a transient embryonic structure important for the induction of 
placentation and formation of the umbilical vessels located at the rostral end of the 
embryo (Downs and Harmann, 1997).  
Following this first wave of extra-embryonic vasculogenesis between E7.0 
and E7.5, angioblasts also give rise to vessels within the embryo proper. The 
endocardium and the great vessels such as the dorsal aortae are the first 
intraembryonic endothelial structures. Thus, angioblasts derived from the aortic 
primordial, the mesoderm just lateral to the midline, coalesce and form the dorsal 
aortae by E8.0 (Dzierzak, 2003). These vessels fuse at later stages of development 
and thereby give rise to the adult aorta (Drake and Fleming, 2000).  
Vasculogenesis is thought to only contribute to the earliest embryonic 
vessels, whereas most other vasculature is believed to be formed by angiogenesis 
(see 1.1.2.2). Nevertheless, recent studies have postulated that angioblasts also 
referred to as endothelial progenitor cells (EPCs) might also contribute to the 
development of later embryonic and even adult vessels (reviewed in Drake, 2003) 
(see 1.1.2.4). 
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1.1.2.2 Angiogenesis 
Angiogenesis defines the formation of new vessels from pre-existing ones. 
This process can occur when new vessels sprout from previously formed ones, which 
is termed sprouting angiogenesis. In addition, new vessels can be formed when tissue 
folds are inserted into the lumen of a pre-existing vessel. This is referred to as 
intussusceptive angiogenesis. 
Sprouting angiogenesis arises when a subset of ECs acquire tip cell 
properties, which allow them to invade the surrounding tissue in response to pro-
angiogenic growth factors such as vascular endothelial growth factor (VEGF-A) 
(Gerhardt et al., 2003) (see 1.2). The tip cells are followed by stalk cells, which form 
the trunk of new vessels and maintain connectivity with parental vessels (Blanco and 
Gerhardt, 2013). The specification of tip versus stalk cells is thought to be a dynamic 
process, where cells are constantly competing for the tip cell position (Jakobsson et 
al., 2010, Fantin et al., 2013a). The tip and its trailing stalks cells together form a 
new vessel sprout.  
In contrast to vasculogenesis, angiogenesis also occurs postnatally. Thus, 
vessels continue sprouting after birth and into young adulthood to support the growth 
of tissues. However, once tissue growth is completed, most blood vessels become 
quiescent. The reactivation of angiogenesis in adults only occurs under specific 
circumstances; for example, in the cycling uterus and ovary, in the placenta during 
pregnancy, and during exercise-induced muscle growth (reviewed in Hoeben et al., 
2004). ECs are also stimulated to divide rapidly in response to hypoxia; for instance 
in the ischemic myocardium after myocardial infarction to promote the 
vascularisation of the hypoxic tissue (Tian et al., 2010). However, hypoxia can also 
induce detrimental neoangiogenesis. For instance, both tumours and atherosclerotic 
plaques create a hypoxic microenvironment. In both cases, neoangiogenesis 
promotes disease progression, because blood vessel growth promotes tumour 
expansion and plaque rupture (Virmani et al., 2005). Hypoxia-induced 
neoangiogenesis is also associated with ocular pathologies, such as diabetic 
retinopathy or the ‘wet’ form of age-related macular degeneration (AMD). In such 
diseases, neo-angiogenesis typically leads to the formation of abnormal vessel beds, 
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which prevent effective re-oxygenation of ischemic tissues, and is accompanied by 
excessive vascular permeability that causes tissue oedema.  
In addition to hypoxia, several other signals can induce adult 
neoangiogenesis. For instance, metabolic stress signals such as reactive oxygen 
species (Okuno et al., 2012) and inflammatory molecules, which are released during 
wound healing or exercise-induced muscle growth, can activate adult vessel growth. 
Nevertheless, these molecules are also synthesised by certain tumours or during 
chronic inflammation e.g. during rheumatoid arthritis (Noort et al., 2014), where 
blood vessel growth is detrimental (see above).  
1.1.2.3 Vessel specification 
Following the formation of a primitive vascular network, the homogenous 
vascular plexus is remodelled to generate a hierarchical system composed of arteries, 
veins and capillaries (reviewed in Kume, 2010). Vessel remodelling relies on several 
distinct mechanisms such as intussusceptive angiogenesis, vascular regression, the 
increase in luminal calibre as well as arteriovenous specification. 
During intussusceptive angiogenesis, vessels give rise to smaller vessels 
through insertion of tissue folds and columns of interstitial tissue into its lumen 
(reviewed in Burri and Djonov, 2002). This process is important for the rapid 
formation of capillary plexi, for example in the lung, where the capillary network has 
to dramatically increase in complexity to accommodate the developing alveoli 
(Caduff et al., 1986). Other mechanisms of vascular remodelling include induced 
apoptosis to remove excess vessel segments or unwanted vessel beds. For example, 
in the retina the hyaloid vasculature, which supplies the eye throughout embryonic 
development, regresses in humans during the last weeks of gestation to attain a 
transparent visual axis. In the mouse, this process also occurs, albeit postnatally (Ito 
and Yoshioka, 1999, Mitchell et al., 1998) (see 1.5.2.1). In addition during 
embryonic development, vessels acquire specific properties depending on their later 
function in the adult. Thus, blood vessels, which will ultimately be part of the 
arterial, high-pressure system, develop thick muscular layers, whereas the venous 
vasculature develops valves, which aid blood flow back to the heart.  
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 Arteriovenous specification was initially believed to occur only in response to 
varying hemodynamic forces in different vessel beds following the formation of the 
primary vascular plexus. Whilst hemodynamic forces are important for this process 
(le Noble et al., 2004), several studies since have demonstrated that arteriovenous 
specification occurs much earlier in development. Thus, vessels already become 
specified before the onset of circulation due to the expression of distinct genes. For 
example, already within the primary plexus the receptor ephrin B2 (EFNB2) is only 
expressed by arterial vessels, whereas its ligand (EPHB4) is found exclusively on 
venous cells (Wang et al., 1998). This signalling pathway is critical for vessel 
identity, as mice lacking Efnb2 or Ephb4 display defective remodelling of the 
primary plexus and lack clear boundaries between arterial and venous vessels 
(Gerety et al., 1999, Adams et al., 1999). Nevertheless, arteriovenous specification is 
not completely abolished in these mutant mice, demonstrating that additional 
pathways are also involved. Efnb2 and Ephb4 expression are regulated by multiple 
signals; zebrafish studies, for instance, have revealed that sonic hedgehog (SHH) is 
secreted by the notochord, which induces arterial specification in angioblasts by up-
regulating ephrin B2 expression. Accordingly, SHH-deficient zebrafish embryos lack 
arteries; instead, their dorsal aorta adopts a venous morphology (Lawson et al., 
2002).  
Another important step during blood vessel development is mural cell 
recruitment, which is essential for vascular stability. For example, the recruitment of 
smooth muscle cells (SMCs) plays an important role in arterio-venous specification. 
Thus, in particular larger arteries are covered in a thick muscular coat with 
vasomotor properties, which is essential for the formation of a regulated high 
pressure arterial network. Moreover, pericytes, together with astroglial cells, are 
critical for the formation of the blood-brain barrier.  
Finally, ECs within specific vessel adopt features depending on their 
physiological requirements. Thus, the ECs in endocrine glands become discontinuous 
and fenestrated to allow the passage of peptide hormones, whereas the endothelium 
of the central nervous system (CNS) becomes highly impermeable by forming tight 
junctions (Kniesel and Wolburg, 2000).  
 27 
 
1.1.2.4 Endothelial progenitors 
Apart from the earliest vessels of the yolk sac and embryo, the remaining 
vessels are thought to arise exclusively through sprouting angiogenesis. 
Nevertheless, in recent years a growing amount of literature has suggested that 
angioblasts, also referred to EPCs, might continue to contribute to blood vessel 
growth throughout embryonic as well as adult life (reviewed in Yoder, 2012).  
EPCs were first described in the adult human peripheral blood by Asahara et 
al. (Asahara et al., 1997). They found that by sorting blood cells positive for the cell 
surface markers cluster of differentiation (CD) 34 or VEGF receptor 2 (VEGFR2), 
they could isolate circulating cells with the ability to differentiate into ECs in vitro 
and incorporate into sites of active angiogenesis in vivo. VEGFR2 and CD34 were 
chosen as markers, as it was believed that ECs and haematopoietic cells emerge from 
the same precursor. Thus, CD34 and VEGFR2 are both expressed by the embryonic 
mesoderm during angioblast specification (see 1.1.2.1) (Cortes et al., 1999), and by 
the earliest hematopoietic progenitors (Matthews et al., 1991, Millauer et al., 1993, 
Krause et al., 1994), but are down-regulated once the cell becomes committed. Since 
then, however, evidence suggests that haematopoietic and ECs arise from separate 
precursors, with the exception of the earliest erythrocytes which share a lineage with 
the earliest ECs of the yolk sac during primitive haematopoiesis (see 1.3.1). Thus, 
EC are usually derived from angioblasts or pre-existing ECs, whereas haematopoietic 
stem cells (HSCs) are generated from the hemogenic endothelium (see 1.3.2) (Zovein 
et al., 2008, Chen et al., 2009b). Furthermore, both CD34 and VEGFR2 are 
expressed by multiple cell types. For instance, CD34 is expressed by some 
mesenchymal, epithelial and even cancer stem cell populations (Hirschi et al., 2008), 
and VEGFR2 is also expressed by multiple cell types such as blood, endothelial and 
cardiac cells and thus fails to be a helpful discriminator. As a result, the cells isolated 
by Asahara et al. will have contained a heterogeneous group of progenitors including 
mesenchymal stem cells and differentiated ECs aside from the putative EPCs. 
Since Asahara et al.’s initial description of EPCs, other studies have tried to 
include additional markers to make the isolation procedure more specific to EPCs. 
For instance, Peichev et al. (2000) included the marker CD133, also referred to as 
 28 
 
prominin 1, which is a glycoprotein expressed by hematopoietic, as well as epithelial, 
and cancer stem cells (Peichev et al., 2000). They argued that hematopoietic cells 
expressing all of these progenitor markers (CD34, VEGFR2 and CD133) were more 
immature than the cells expressing either marker on their own. By analysing 
circulating cells for these markers, they found that many CD34
+
VEGFR2
+
 cells also 
expressed CD133. Furthermore, after plating CD34
+
 cells from the liver on collagen 
they found that the cells stopped expressing CD133 and differentiated into cells with 
an endothelial morphology, suggesting that CD133 is required to maintain EPC 
identity in the blood. In addition, they found that CD34
+
CD133
+
VEGFR2
+
 cells 
transplanted into human patients colonised the surface of engrafted left ventricular 
assistance devices (Peichev et al., 2000). However, with respect to the definition of 
these cells as EPCs, this study had possible caveats. Thus, all three antigens used to 
isolate EPCs, i.e. CD34, CD133 and VEGFR2, are also expressed by subpopulations 
of haematopoietic progenitor cells. Furthermore, this study did not address whether 
the putative EPCs properly differentiated into ECs in vitro and engrafted into the 
endothelium in vivo. It is therefore not clear if the cells studied by Peichev et al. 
(2000) were EPCs or pro-angiogenic accessory cells. 
Nevertheless, numerous subsequent studies demonstrated that the number of 
the putative CD34
+
CD133
+
VEGFR2
+
 EPCs is reduced in patients at increased risk 
for cardiovascular disease, but enhanced in response to acute vascular injury. Thus, 
smoking, old age and diseases such as acromegaly are all associated with a reduction 
of this cell fraction (Fadini et al., 2014, Vasa et al., 2001, Kondo et al., 2004). 
Conversely, other studies have shown that the number of these cells is enhanced in 
patients with endothelial damage for example following burn injuries or myocardial 
infarction (Gill et al., 2001, Massa et al., 2005). Nevertheless, another study that 
investigated the potential of the CD34
+
CD133
+
VEGFR2
+
 cells to differentiate into 
ECs in vitro demonstrated that these cells only gave rise to haematopoietic 
progenitors and did not form any ECs (Case et al., 2007). This study further revealed 
that the majority of CD34
+
CD133
+
VEGFR2
+
 cells expressed the hematopoietic 
lineage-specific antigen CD45 and thus constituted immature haematopoietic 
progenitors (Case et al., 2007). In contrast, analysis of CD34
+
CD45
-
 cells 
demonstrated that these cells only gave rise to endothelial, and not haematopoietic 
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cells, suggesting that this is the cell population that contains EPCs. Accordingly, the 
correlation between CD34
+
CD133
+
VEGFR2
+
 cell number and disease identified by 
Peichev et al. (2000) and others needs to be re-evaluated, as it may have identified 
important contributions of hematopoietic lineage cells in addition to or instead of 
EPCs.  
Regarding the origin of adult EPCs, Asahara et al. (1999) suggested that 
EPCs are derived from the bone marrow, as the transplantation of bone marrow into 
irradiated mice gave rise to donor-derived ECs within neo-angiogenic vessels of the 
host animal (Asahara et al., 1999). In agreement with this idea, the administration of 
agents such as colony stimulating factor 1 (CSF1) or the small molecule Me6TREN, 
which induce the mobilisation of EPCs (defined as VEGFR2
+ 
SCA1
+
 in this study) 
from the bone marrow, promote vascular repair in patients with ischemic disease 
(Chen et al., 2014, Takahashi et al., 1999). 
Other studies have suggested the existence of tissue-resident angioblasts that 
may act as EPCs. Thus, a recent study using a P0-Cre transgene for lineage tracing 
identified stellate cells within the retina that were able to differentiate into ECs in 
vitro and contribute to vessel growth in vivo (Kubota et al., 2011). Thus, whilst 
retinal ECs did not express P0, the stellate cells expressed this gene albeit only at 
mRNA level. In addition, these cells were negative for pericyte, astrocyte or 
haematopoietic markers such as PDGFRβ, PDGFRα and CD45, respectively. 
Instead, the vascular precursors were VEGFR2
+
, and importantly the deletion of 
Vegfr2 in these cells resulted in defective retinal vascularisation. 
Several studies have also demonstrated that subsets of ECs within the aorta or 
the lung microvasculature are highly proliferative in vitro (Nishimura et al., 2014). 
These cells, referred to as endothelial colony forming cells (ECFCs), are also thought 
to release ECs into the circulation, which contribute to endothelial repair (reviewed 
in Yoder, 2010).  
In support of non-bone marrow-derived EPC populations a study used 
parabiosis to demonstrate that more EPCs (defined as KIT
+
CD45
-
 in this study) 
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derived from the liver or intestine incorporated into new vessels formed following 
hindlimb ischemia than from the bone marrow (Aicher et al., 2007).  
In summary, it is likely that EPCs comprise a heterogeneous population of 
cells with multiple origins, including the bone marrow as well as other tissues, and 
that these cells are released into the blood as circulating progenitors of varying 
degrees of commitment along a hematopoietic or endothelial lineage. Furthermore, it 
is conceivable that these progenitors migrate into the tissue parenchyma of several 
organs, where they reside until activated. 
EPCs are of great therapeutic interest, as they could potentially be used to 
stimulate vascular repair in adult patients, in whom vessels are mostly quiescent or 
neoangiogenesis typically gives rise to dysfunctional, leaky vessels (see 1.1.2.2). For 
example, it has been shown that the administration of bone marrow-derived CD34
+
 
cells can promote vessel growth following myocardial infarction, thus preventing 
cardiomyocyte apoptosis and improving cardiac function (Kocher et al., 2001, 
Strauer et al., 2002). In addition, EPCs are thought to contribute to pathological 
vessel growth; for example, in patients with pancreatic cancer the number of 
CD34
+
CD133
+
 cells is increased, and the transplantation of murine CD34
+
CD133
+
 
cells into littermates promotes tumour angiogenesis (Li et al., 2011). Conversely, 
reducing the mobilisation of EPCs from the bone marrow by the administration of 
agents such as dopamine treatment or the deletion of the C-X-C chemokine receptor 
type 2 (CXCR2) impairs tumour angiogenesis (Chakroborty et al., 2008, Li et al., 
2011). EPCs are also of interest in the context of retinal disease. For example, 
vascular degeneration in diabetic retinopathy is thought to be exacerbated by the 
inability of EPCs to promote vascular repair. Thus, CD34
+
 cells isolated from 
diabetic patients demonstrated an impaired ability to re-endothelialise damaged 
retinal vessels compared to CD34
+
 cells collected from healthy patients (Caballero et 
al., 2007). EPCs are also thought to contribute to the formation of abnormal retinal 
vessels in sight-threatening diseases such as AMD and retinopathy of prematurity 
(see 1.1.2.2). For instance, transplantation studies demonstrated that donor-derived 
bone marrow cells gave rise to ECs within newly formed vessels in models of retinal 
or choroidal neovascularisation (CNV) (Grant et al., 2002, Espinosa-Heidmann et al., 
2003a).  
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Despite the large amount of literature supporting the idea that EPCs or EPC-
like cells exist in the adult and contribute to vessel growth by vasculogenesis, 
multiple studies have suggested that EPCs are in fact pro-angiogenic cells, which 
express endothelial markers, but do not differentiate into ECs (reviewed in 
Timmermans et al., 2009). Thus, platelet microparticles, which are positive for 
multiple endothelial markers such as CD31, may contaminate blood cell cultures 
resulting in the false endothelial classification of haematopoietic cells (Prokopi et al., 
2009). Moreover, several studies have postulated that most EPC types studied to date 
actually constitute pro-angiogenic macrophages or their monocyte-precursors 
(Rehman et al., 2003). Firstly, as mentioned above, cell populations isolated for 
CD34, VEGFR2 and CD133 expression include haematopoietic progenitors, which 
give rise to cells of the myeloid lineage. Secondly, macrophages are known to 
acquire EC-like properties in vitro when cultured with endothelial growth factors; for 
instance, cultured macrophages over-expressing VEGF-A adopt an endothelial 
morphology and express EC markers such as CD31, VEGFR2 and vascular 
endothelial-cadherin (VEC) (Yan et al., 2011). In addition, macrophages and 
monocytes are known to promote vessel growth by releasing pro-angiogenic 
molecules such as VEGF-A (see 1.3.3.2), tumour necrosis factor α (TNFα), and 
interleukin-8 (IL-8) (Berse et al., 1992, Leibovich et al., 1987, Koch et al., 1992). 
Furthermore, macrophages secrete proteases such as matrix metalloproteinase-2 
(MMP-2), MMP-9 and cyclooxygenase-2 (COX2), which break down the 
extracellular matrix (ECM), releasing membrane-bound growth factors and allowing 
angiogenic sprouts to infiltrate the surrounding tissue (Giraudo et al., 2004, Klimp et 
al., 2001). Unsurprisingly, therefore, an increased number of macrophages is 
associated with enhanced tumour angiogenesis (Salvesen and Akslen, 1999), and the 
depletion of macrophages by synthetic compounds or irradiation reduces tumour 
vascularisation (Ehling et al., 2014, Evans, 1977a, Evans, 1977b). Some studies that 
have observed beneficial effects of EPCs on vessel growth may therefore have 
described pro-angiogenic roles of macrophages/monocytes. Future studies that 
unequivocally discriminate between the two cell types are therefore needed before 
the contribution of EPCs in adult and embryonic vessel growth can be fully 
understood.  
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1.2 Molecular control of vascular development 
The formation of a vascular network, which is able to deliver sufficient 
nutrients and oxygen to the entire body consisting of tissues with varying metabolic 
rates, is a complex process that relies on the interaction of multiple signalling 
molecules. Out of these, the most potent and well-characterised molecule regulating 
vascular development is VEGF-A, which I shall describe in the following passages. 
1.2.1 VEGF-A: An essential regulator of angiogenesis that is expressed in 
several isoforms 
VEGF-A belongs to the cysteine-knot superfamily of secreted glycoproteins 
that is characterised by its eight conserved cysteine residues and includes VEGF-B, 
VEGF-C, VEGF-D and placental growth factor (PlGF, also known as PGF), as well 
as the viral VEGF-E (reviewed in Olsson et al., 2006). These proteins form an anti-
parallel dimer that allows receptor binding at both poles to bridge two receptor 
molecules (Muller et al., 1997). Whilst homodimerisation is typical, VEGF-A and 
PlGF can also form heterodimers with each other (De Falco et al., 2002), which are 
less angiogenic than the VEGF-A homodimers. Accordingly, overexpression of 
PlGF, which results in the increased formation of VEGF-A/PlGF heterodimers at the 
expense of the pro-angiogenic VEGF-A homodimers, reduces tumour angiogenesis 
and thus growth. Nevertheless, the physiological role of these heterodimers still 
remains to be established (reviewed in Dewerchin and Carmeliet, 2012). 
VEGF-A is an essential paracrine factor for all stages of vascular 
development (Ruhrberg, 2003). It is critical for EC differentiation, proliferation and 
migration and is thus integral to both vasculogenesis and angiogenesis (Ruhrberg, 
2003). Accordingly, loss of even one allele of the VEGF-A gene (Vegfa) abolishes 
blood vessel formation in the embryo, demonstrating that Vegfa is a critical and 
haploinsufficient gene (Carmeliet et al., 1996).  
VEGF-A is synthesised as a collection of several isoforms that are produced 
by alternative mRNA splicing (Figure 1.2A). During development splicing is 
regulated to generate various tissue- and stage-specific ratios of these VEGF-A 
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isoforms, which contain abundant information necessary for the multiple processes 
involved in vascular growth (reviewed in Ruhrberg, 2003). 
Molecularly, the VEGF-A isoforms differ in their amino acid length 
depending on the presence or absence of domains encoded by exons 6 and 7 (Figure 
1.2A). Thus, out of the most widely studied human VEGF-A isoforms, the shortest is 
generated from mRNA lacking both exon 6 and 7. This isoform is 121 amino acids 
long and thus referred to as VEGF121. In contrast, the longest isoform, VEGF189, is 
generated from mRNA containing both exon 6 and 7. The intermediate isoforms, 
VEGF145 and VEGF165 contain exon 6 or 7, respectively. In mice, the 
corresponding mouse isoforms are all shorter by one amino acid and therefore 
referred to as VEGF120, VEGF144, VEGF164 and VEGF188 (Ruhrberg, 2003, 
Fantin et al., 2009) (Figure 1.2A). 
As exon 6 and 7 both encode heparin-binding domains, the VEGF-A 
isoforms differ in their affinity for heparin in vitro, which is thought to reflect their 
ability to bind heparan sulfate proteoglycans (HSPGs), which are present in the ECM 
of cultured cells and in vivo. Thus, VEGF189, which contains both exon 6 and 7, has 
the highest ECM affinity and is therefore retained in the matrix unless it is released 
by proteases (Park et al., 1993). In contrast, VEGF121 is highly soluble, whereas 
VEGF145 and VEGF165 are partly diffusible (Poltorak et al., 1997). In this fashion, 
the isoforms cooperate to form chemotactic VEGF-A gradients that guide vessel 
sprouts to sites, where VEGF-A is upregulated (Ruhrberg et al., 2002, Gerhardt et al., 
2003). The importance of these gradients is demonstrated by the great reduction of 
blood vessel branching and therefore vascular complexity, for example in the brain 
and retina, in mice in which the VEGF-A gradients are disrupted (Ruhrberg et al., 
2002, Gerhardt et al., 2003, Stalmans et al., 2002).  
In addition to their differential affinity for ECM components, the isoforms 
also differ in their affinity for three distinct vascular VEGF-A receptors, which are 
all required for normal angiogenesis (see 1.2.2, 1.2.3) and described in the following 
sections. 
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1.2.2 Tyrosine-kinase VEGF-A receptors in angiogenesis 
VEGF-A binds to its two tyrosine kinase receptors with high affinity (Gille et 
al., 2001). They are termed VEGFR2, also known as kinase insert domain-containing 
receptor (KDR) or foetal liver kinase 1 (FLK1), and VEGFR1, also referred to as 
fms-like tyrosine kinase 1 (FLT1). Both receptors are transmembrane glycoproteins, 
which upon ligand-binding undergo autophosphorylation that in turn activates the 
kinase activity of these proteins (Olsson et al., 2006). 
VEGFR2 is critical for EC differentiation and accordingly mice lacking this 
receptor (Flk
-/-
) do not form any blood vessels, resulting in embryonic lethality by 
E9.5 (Shalaby et al., 1995). Nevertheless, tissue culture models have been used to 
demonstrate that VEGFR2 also promotes EC proliferation, migration and survival 
(Koch et al., 2011). In addition, VEGFR2 has been implicated as a regulator of EC 
junction stability and therefore vascular permeability (Gavard and Gutkind, 2006), as 
well as a promoter of arteriogenesis (Lanahan et al., 2010). This receptor is thus 
essential for all aspects of vascular development and this versatility is reflected in its 
ability to activate a multitude of downstream signalling pathways after VEGF-A 
binding (Koch et al., 2011). 
In comparison to VEGFR2, VEGFR1 is essential for vascular development. 
Accordingly, VEGFR1-deficient mice (Flt1
-/-
) display endothelial overgrowth 
preventing network assembly, leading to embryonic death before E10.5 (Fong et al., 
1995). Nevertheless, in contrast to VEGFR2, which exerts essential kinase activity, 
the main function of VEGFR1 is to sequester excess VEGF-A with its extracellular 
domain. Thus, mice only expressing a tyrosine kinase-deficient form of VEGFR1 
(Flt1
TK-/-
) do not display any defects in blood vessel formation, branching or 
remodelling (Hiratsuka et al., 1998). The phenotype observed in Flt1
-/- 
mice has thus 
been interpreted as a failure of cell fate decision based on the increased availability 
of VEGF-A to signal through VEGFR2 (Fong et al., 1999). Despite not having a role 
in developmental angiogenesis, studies have suggested that the kinase activity of 
VEGFR1 might be involved in pathological angiogenesis. For example, Flt1
TK-/-
 
mice display reduced tumour vascularisation (Autiero et al., 2003a, Hiratsuka et al., 
2001). In addition, antibodies against VEGFR1 reduce neovascularisation in tumour 
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models, as well as ischemic retinopathy (Luttun et al., 2002, Wu et al., 2006). 
Nevertheless, VEGFR1 is also expressed by macrophages and Flt1
TK-/-
 mice 
demonstrate impaired macrophage migration in response to VEGF-A (Hiratsuka et 
al., 1998). Thus, these observations suggest an indirect, rather than direct role of 
VEGFR1’s kinase activity in pathological angiogenesis.  
1.2.3 Non-tyrosine kinase VEGF-A receptor, NRP1   
In addition to VEGFR1 and VEGFR2, VEGF-A also binds to the non-
tyrosine kinase receptor, neuropilin (NRP) 1; however, whilst VEGFR1 and 
VEGFR2 have a high affinity for all VEGF-A isoforms, NRP1 mainly binds to 
VEGF165 and VEGF189 (Gitay-Goren et al., 1996, Soker et al., 1996, Soker et al., 
1998, Tillo et al., 2015). NRP1 is a single-pass transmembrane glycoprotein of 130 
kDa (Fujisawa et al., 1995). Before being identified as a receptor for VEGF165 
(Gitay-Goren et al., 1996, Soker et al., 1996), NRP1 was originally discovered as an 
axonal adhesion protein in the developing xenopus optic tectum (Takagi et al., 1995), 
where it was named after its expression within the neuropils of specific regions 
within the CNS. It was also independently discovered as a receptor for secreted axon 
guidance cues of the class 3 semaphorin (SEMA3) family (He and Tessier-Lavigne, 
1997, Kolodkin et al., 1997).  
Besides NRP1, the neuropilin family also includes NRP2 (Chen et al., 1997), 
which binds both VEGF165 and VEGF145 (Soker et al., 1998, Gluzman-Poltorak et 
al., 2000). Despite sharing only 44% sequence homology on the amino acid level, 
NRP1 and NRP2 possess an identical domain structure (Chen et al., 1997). Thus, 
both receptors consist of a short secretion signal followed by a large extracellular 
domain of 840 amino acids, a ~24 amino acid-short transmembrane domain and a 
small cytoplasmic tail consisting of ~40 amino acids. NRP1 mostly exerts its 
biological functions as a homodimer; nevertheless, NRP1 heterodimers with NRP2 
have also been described (Herzog et al., 2011). 
1.2.3.1 NRP1 domain organisation 
The multiple functions of NRPs are reflected in the complex organisation of 
their large extracellular domain, which contain 5 domains termed a1, a2, b1, b2 and c 
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(Figure 1.2B). These domains mediate distinct NRP functions, whereby the a and b 
domains bind ligands, whilst the c domain promotes oligomerisation (Fujisawa, 
2002, Schwarz and Ruhrberg, 2010) (Figure 1.2B). Thus, the extracellular NRP 
domain contains two complement-binding homology (CUB) domains, called a1 and 
a2, which mediate binding to SEMA3s (Gu et al., 2003). Whilst the a1 and a2 
domain within the extracellular domain of NRP1 mediate binding to SEMA3A, the 
corresponding domains of NRP2 mediate binding to SEMA3F (Chen et al., 1997). 
Furthermore, both receptors bind to SEMA3C (also known as SEMAE) (Chen et al., 
1997, Kolodkin et al., 1997). These domains are followed by two coagulation factor 
V/VIII homology domains, termed b1 and b2 that mediate binding of heparan sulfate 
and promote adhesion to other cell types. These domains also bind to VEGF-A via 
distinct VEGF-A binding sites (Mamluk et al., 2002, Gu et al., 2002, Shimizu et al., 
2000, Lee et al., 2003). Following the b1 and b2 domain, the extracellular domain 
also contains the meprin (MAM) or c domain, which promotes dimerisation and 
interaction with other receptors within the plasma membrane (Lee et al., 2003). The 
short intracellular/cytoplasmic domain of NRP1 is thought to lack catalytic activity, 
however, it contains a C-terminal SEA motif that recruits the PSD-95/Dig/ZO1 
(PDZ) domain-containing protein synectin, also known as GIPC or NRP interacting 
protein NIP (Cai and Reed, 1999, De Vries et al., 1998, Gao et al., 2000).  
In addition to the full length versions of NRPs, several isoforms of these 
receptors are synthesised by alternative splicing (reviewed in Geretti et al., 2008). 
Thus, soluble forms of NRP1 and NRP2 lacking the c, tm or cytoplasmic domains 
exist. To date four soluble isoforms of NRP1 (s12NRP1, s11NRP1, sIIINRP,1 and 
sIVNRP1) and one soluble variant of NRP2 (s9NRP2) have been identified (Gagnon 
et al., 2000, Gluzman-Poltorak et al., 2000). In contrast to NRP1, alternate 
transmembrane isoforms of NRP2 are also synthesised and termed NRP2a, including 
NRP2a(17) and NRP2a(22), and NRP2b, including NRP2b(0) and NRP2b(5). The 
expression profiles of these isoforms are tissue-specific. For example, NRP2a is 
highly expressed within the placenta, but only found at low levels within the lung or 
skeletal muscle, whereas NRP2b displays the opposite expression profile (Rossignol 
et al., 2000). However, the biological significance of alternative NRP splicing 
remains to be established.  
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Figure 1.2. Schematic representation of VEGF-A and NRP1 domain structure. 
(A) VEGF-A isoforms: VEGF isoforms are generated by alternative splicing. The VEGF 
isoforms differ by the presence of two heparin-binding domains encoded by exons 6 and 7 
(highlighted in yellow). Thus, the VEGF188 mRNA contains both exon 6 and 7, VEGF164 
and VEGF144 only exon 7 and 6, respectively, and VEGF120 contains neither exon 6 nor 7. 
(B) NRP1 organisation and ligand binding. The extracellular part of NRP1 contains two 
domains termed a1 and a2 (green), which bind SEMA3s, two domains called b1 and b2 
(red), which bind VEGF164 and VEGF188 and play a role in cell adhesion, one 
oligomerisation domain (c), and a transmembrane domain (tm). The relatively short 
cytoplasmic tail (yellow) contains an SEA motif, which binds to GIPC/synectin. This 
domain is dispensable for developmental angiogenesis, but involved in arteriogenesis. 
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1.2.3.2 NRP1 in angiogenesis 
In contrast to VEGFR1 and VEGFR2, NRP1 is not required for 
vasculogenesis; instead, it is particularly important for organs vascularised by 
angiogenesis, such as the brain and retina (Kawasaki et al., 1999, Gerhardt et al., 
2004, Raimondi et al., 2014), and for intersomitic vessel sprouting in the zebrafish 
(Lee et al., 2002). The cardiovascular deficiencies caused by the loss of NRP1 result 
in embryonic lethality between E10.5 and E14.5 in mouse depending on the genetic 
background (Jones et al., 2008, Schwarz et al., 2004). Conversely, NRP1 
overexpression is also embryonic lethal, as it promotes excessive vessel growth; 
however, the vessels are leaky and haemorrhagic (Kitsukawa et al., 1995). In contrast 
to NRP1, NRP2-deficient mice survive postnatally with lymphatic, but not blood 
vessel defects (Yuan et al., 2002). So far, the physiological significance of VEGF-A 
isoform binding to NRP2 has not been established; however, double NRP1/NRP2 
knockouts display more severe vascular defects than single NRP1 knockouts 
(Takashima et al., 2002), raising the possibility that NRP2 can partially compensate 
for NRP1 function in some aspects of vascular development. 
NRP1 expression is prominent on developing blood vessels (Fantin et al., 
2010, Kawasaki et al., 1999). Furthermore, endothelial deletion of NRP1 results in 
severe vascular defects (Gu et al., 2003). Thus, NRP1 is thought to exert most of its 
functions necessary for embryonic angiogenesis within the endothelium. However, 
NRP1 is also expressed on many other embryonic cell types, for example neurons 
and their axonal processes (Tillo et al., 2015, Erskine et al., 2011) as well as tissue 
macrophages (Fantin et al., 2013a), which raises the possibility that non-endothelial 
NRP1 might also be involved in angiogenesis. A study investigating the role of non-
endothelial NRP1 during developmental angiogenesis (Fantin et al., 2013a), which I 
contributed to, is described in Chapter 3. 
The essential role of NRP1 in vascular development is commonly attributed 
to its ability to act as a VEGF165 receptor in ECs (Soker et al., 1998). For example, 
the reduced neural tube vascularisation of mice lacking NRP1 specifically in the 
endothelium has been interpreted as evidence that VEGF165 signals through NRP1 
to promote angiogenesis (Gu et al., 2003). Furthermore, Vegfa
120/120
 mice, which 
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express VEGF120 at the expense of the NRP1-binding VEGF-A isoforms, display 
defects in angiogenesis, which were attributed to a lack of VEGFA signalling 
through NRP1 (Stalmans, 2005). However, the vascular defects caused by loss of 
NRP1 are different to those in Vegfa
120/120 
mice. For example, perisomitic vessels 
branch poorly in E10.5 Vegfa
120/120
, but normally in Nrp1-null mutants (Ruhrberg et 
al., 2002). The hindbrain vascular defects in both types of mutants are also 
qualitatively different: Vegfa
120/120 
mice have less vessel branching in the hindbrain, 
however the vascular diameter is increased due to the perturbation of VEGF-A 
gradients (Ruhrberg et al., 2002, Fantin et al., 2010). By contrast, hindbrain vessels 
in Nrp1-null mutants terminate in blind-ended bulbous vessel structures that are rare 
in Vegfa
120/120 
mutants (Gerhardt et al., 2004). A recent study by our group in 
collaboration with Prof Ian Zachary (Rayne Institute, UCL) investigated the role of 
VEGF-A signalling through NRP1 during vascular development using a mouse 
mutant that lacks VEGF-A binding to NRP1 (Nrp1
Vegfa/Vegfa
). This study and my 
findings that contributed to this publication are outlined in Chapter 3.  
In addition to VEGF165, NRP1 also binds to SEMA3s via distinct domains 
(Appleton et al., 2007). SEMA3s are secreted glycoproteins, which have mostly been 
investigated in the context of axonal guidance or neuronal migration (reviewed in 
Pasterkamp, 2012). Despite initial reports that SEMA3A binding to NRP1 modulates 
EC migration in vitro (Miao et al., 1999, Serini et al., 2003), studies since have 
demonstrated that SEMA3 signalling through both neuropilins is dispensable for 
embryonic angiogenesis in mouse (Gu et al., 2003, Vieira et al., 2007). In zebrafish, 
however, decreasing the levels of the two SEMA3A orthologs impairs vascular 
development (Shoji et al., 2003, Torres-Vazquez et al., 2004). To date it is not 
known, why SEMA3A is required vascular development in fish, but not mouse 
embryos.  
Whilst SEMA3s are dispensable during developmental angiogenesis, mouse 
knockout studies have demonstrated that SEMA3 signalling through NRP is required 
for cardiac development. Thus, SEMA3A-deficient mice display enlarged atria 
(Behar et al., 1996) and Sema3c-knockout mice have unseptated OFTs, which 
normally remodel to form the base of the aorta and pulmonary artery (see 1.4.3). 
Furthermore, studies have demonstrated that SEMA3A has a role in pathological 
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angiogenesis. Thus, exogenous delivery of SEMA3A impairs tumour angiogenesis 
and growth in mice (Maione et al., 2009, Casazza et al., 2013) by eliciting EC 
apoptosis and normalising pericyte coverage of tumour vessels (Maione et al., 2009). 
In addition, SEMA3A secreted by ischemic neurons also prevents vascular 
regeneration in a mouse model of oxygen-induced retinopathy (OIR) that models 
retinopathy of prematurity (Joyal et al., 2011) (Figure 1.5C). 
In addition to binding SEMA3s and VEGF-A, NRP1 also exerts important 
vascular functions by regulating the adhesive properties of ECs (Murga et al., 2005). 
Thus, in agreement with its initial discovery as an adhesion molecule (Takagi et al., 
1995), NRP1 can bind to components of the ECM via its adhesion domains 
(Raimondi et al., 2014, Murga et al., 2005), which reside in the b1 and b2 region of 
the extracellular part of the receptor (Shimizu et al., 2000) (Figure 1.2B). 
Furthermore, NRP1 can modulate cell adhesion by directly interacting with integrins 
(Fukasawa et al., 2007, Valdembri et al., 2009). A recent publication by our group 
has further demonstrated that NRP1 is stimulated by the integrin ligand fibronectin, 
which plays a role in EC migration in vitro and angiogenesis in vivo (Raimondi et al., 
2014).  
1.2.3.3 Mechanism of NRP1 signal transduction in the vasculature 
In the nervous system, NRP1 recruits type A and D plexins to transduce 
semaphorin signals; accordingly, NRP1’s cytoplasmic tail is dispensable for this 
process (Nakamura et al., 1998). In analogy, it was proposed that NRP1 transduces 
VEGF165 signals in the vasculature by recruiting co-receptors such as the VEGF-A 
receptor tyrosine kinases (see 1.2.2) (Gluzman-Poltorak et al., 2001, Soker et al., 
1998). Thus, NRP1 can interact with VEGFR1 and VEGFR2, and the most common 
model of NRP1 function in angiogenesis suggested that complex formation between 
VEGF165, NRP1 and VEGFR2 promotes VEGFR2 signalling in angiogenesis (e.g. 
Prahst et al., 2008, Soker et al., 2002, Whitaker et al., 2001, Becker et al., 2005, 
Soker et al., 1998). In support of this idea, a recent study by our group analysing 
mice lacking the cytoplasmic domain of NRP1 (Nrp1
Cyto/Cyto
) demonstrated that these 
mice did not have any defects in angiogenesis; instead, they were viable 
demonstrating only mild defects in arteriovenous patterning (Fantin et al., 2011). 
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Nevertheless, there is also evidence suggesting that NRP1 might function 
independently of VEGFR2. For instance, fusion of the extracellular domain of the 
epidermal growth factor (EGF) receptor to the transmembrane and cytoplasmic 
domains of NRP1 creates a chimeric receptor that promotes EC migration in 
response to EGF (Wang et al., 2003). Furthermore, the NRP1 cytoplasmic domain 
promotes VEGF-induced EC migration via p130CAS (CRK-associated substrate) 
without affecting VEGFR2 phosphorylation (Evans et al., 2011). Nevertheless, 
because this NRP1 domain is dispensable for developmental angiogenesis (Fantin et 
al., 2011), these tissue culture studies may have identified signalling pathways that 
are selectively important for EC migration under pathological circumstances or in 
non-endothelial migratory cells. For example, NRP1 also promotes the VEGF-
dependent migration of neurons (Schwarz et al., 2004) and cancer cells (Jia et al., 
2010). 
In addition, a recent publication from our lab has demonstrated that NRP1 
can induce EC migration independently of VEGF-A/VEGFR2 by forming a complex 
with the tyrosine kinase, ABL1 (Raimondi et al., 2014). In this context, fibronectin, a 
component of the ECM, stimulates the NRP1-dependent activation of ABL, which 
then phosphorylates the focal adhesion component paxillin (PXN) and promotes 
actin remodelling, which is critical for EC migration in vitro and angiogenesis in 
vivo. 
In summary, it is clear that NRP1 plays an essential role in angiogenesis, but 
the conflicting data obtained in tissue culture, zebrafish and mouse models need to be 
resolved to fully understand the signalling mechanisms of NRP1 during angiogenesis 
in vivo. Furthermore, future studies may wish to elucidate the mechanism by which 
NRP1 regulates angiogenesis by investigating effects on the cytoskeleton, EC 
proliferation etc.  
1.2.3.4 Role for NRP1 in arteriovenous patterning  
NRP2 is enriched in the venous and NRP1 in the arterial parts of vascular 
networks in chick, mouse and zebrafish (e.g. Herzog et al., 2001, Jones et al., 2008, 
Fantin et al., 2011). Whilst Nrp2-null mice develop to term without obvious 
arteriovenous or indeed any other type of blood vascular defects (Yuan et al., 2002), 
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arterial differentiation is compromised by loss of NRP1. Thus, specific arterial 
markers are missing from arterioles and arteries in full and endothelial-specific Nrp1 
knockouts (Jones et al., 2008, Mukouyama et al., 2005). 
Both zebrafish and mouse knockdown studies have suggested that 
NRP1/Synectin signalling is involved in arterial development. Thus, morpholino-
induced Synectin knockdown results in zebrafish embryos with severe defects in 
arteriogenesis including impaired formation of the dorsal aorta causing lethality by 3 
days post fertilisation (Chittenden et al., 2006). Nevertheless, these embryos also 
display defective angiogenesis such as reduced intersomitic vessel branching 
(Chittenden et al., 2006), which agrees with previous zebrafish studies that 
demonstrated that the cytoplasmic domain of NRP1 is also required for 
developmental angiogenesis (Wang et al., 2006b). Thus, the arterial phenotype in 
Synectin-deficient zebrafish embryos is presumably exacerbated by defective 
angiogenesis. In mice, deletion of either Synectin or the cytoplasmic domain of 
NRP1 does not impair developmental angiogenesis and thus these mice are viable; 
however, these mutants demonstrate defects in arteriogenesis. Thus, Synectin-
deficient mice display impaired mural cell recruitment to retinal blood vessels (Paye 
et al., 2009) and reduced arterial branching in development and disease (Chittenden 
et al., 2006). Whilst Nrp1
Cyto/Cyto
 mice do not recapitulate the reduction in mural cell 
recruitment observed in Synectin-deficient mice, these mutants also display reduced 
developmental arteriolar branching as well as in response to injury (Lanahan et al., 
2013).  
NRP1 is thought to regulate arteriogenesis by tethering a VEGF-A-bound 
NRP1/VEGFR2/Synectin complex to an intracellular trafficking machinery that 
ensures the enrichment of activated VEGFR2 in signalling endosomes (Lanahan et 
al., 2013). Accordingly, VEGF-A/VEGFR2 signalling is reduced in Synectin-nulls 
and Nrp1
Cyto/Cyto
 mice (Lanahan et al., 2013, Lanahan et al., 2010). Furthermore, 
mice that express a mutated version of NRP1 unable to bind VEGF-A (Nrp1
Vegfa/Vegfa
, 
see Chapter 3) demonstrate defective arteriogenesis (Fantin et al., 2014).  
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1.3 Haematopoiesis 
The cardiovascular system acts as a conduit for cells of the haematopoietic 
system, which are critical for oxygen delivery as well as protecting the body against 
pathogens. The generation of these blood cells, which is termed haematopoiesis, 
occurs from E7.0 onwards in the mouse and E17 in humans, and it continues 
throughout adult life to replenish ageing blood cells and to support the immune 
system. In the vertebrate embryo, haematopoiesis occurs in two waves, which are 
referred to as the primitive and the definitive wave of haematopoiesis (reviewed in 
Jagannathan-Bogdan and Zon, 2013). These distinct stages of haematopoiesis differ 
both in the site as well as the type of blood cell generation, as outlined in the 
following sections. 
1.3.1 Primitive haematopoiesis 
Primitive haematopoiesis occurs within the mammalian and avian yolk sac 
(Dzierzak and Speck, 2008) (Figure 1.3). Its primary purpose is to generate primitive 
red blood cells from erythroid progenitors, which together with the emerging blood 
vessels enable tissue oxygenation when diffusion is no longer adequate. Thus, 
primitive haematopoiesis is initiated concomitantly with the generation of the first 
blood vessels.  
The first haematopoietic cells, the erythroid precursors, arise within the blood 
islands of the yolk sac (reviewed in Ferkowicz and Yoder, 2005). These structures 
were already described by Florence Sabin at the beginning of the 20
th
 century, when 
she noted that clusters of haematopoietic cells emerge within the earliest vessels of 
the yolk sac. The close spatial and temporal association of primitive erythrocytes and 
ECs led to the postulation of a common mesodermal precursor for these two lineages 
called the “haemangioblast”, which was thought to migrate into the yolk sac and then 
form the blood islands. Nevertheless, this idea still remains contentious. Thus, 
experiments have to date failed to demonstrate that a mesodermal progenitor that is 
selective to only blood and ECs migrates to the yolk sac to generate the blood 
islands. Thus, whilst studies demonstrated that a population of embryonic stem cells, 
which expresses both the endothelial marker VEGFR2 and the mesodermal marker 
brachyury, gave rise to both endothelial and blood cells in culture; these cells also 
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generated vascular SMCs (Huber et al., 2004). As SMCs are the only other 
mesodermal cell population found in the yolk sac at this embryonic stage, this cell 
population most likely constitutes a general mesodermal progenitor.  
Instead, lineage-trace studies have suggested that blood and haematopoietic 
progenitors are independently fated during gastrulation. Thus, experiments using 
lacZ-labelled mesodermal progenitors showed that when these cells were 
transplanted into E7.75 mouse embryos, they either gave rise to ECs or 
haematopoietic cells within the blood islands (Kinder et al., 1999). Likewise, a study 
analysing blood island formation in embryos generated from fluorescently-labelled 
tetrachimeras found that the blood islands were never derived from only one 
progenitor population contradicting the haemangioblast theory (Ueno and Weissman, 
2006). Similar results were achieved in zebrafish experiments, where cells were 
labelled by laser-activated caged fluorescein dextran at gastrulation and their 
progeny assessed. This revealed that most cells either gave rise to blood or ECs 
(Vogeli et al., 2006) within the blood islands. A small subpopulation of fluorescein-
labelled progenitors, however, also gave rise to both haematopoietic and ECs. 
Nevertheless, as the labelled progeny was not analysed over time, it is currently not 
known whether these cells derived from a true haemangioblast or whether the blood 
cells were in fact derived from labelled ECs at a later stage. Thus, further 
experiments are required to establish the origins of the earliest blood and ECs within 
the yolk sac. Be that as it may, once the progenitors have migrated into the yolk sac 
the cells with a haematopoietic fate form a circumferential band (Ferkowicz et al., 
2003) and differentiate into primitive erythrocytes. Subsequently, these cells are 
ensheathed by ECs giving rise to the first blood cell-filled vessels.  
The primitive erythrocytes differ from the mature red blood cells in that they 
contain a nucleus and express embryonic forms of globin (Brotherton et al., 1979). 
This results in haemoglobin with a stronger affinity for oxygen, which greatly 
facilitates the uptake of oxygen from the maternal erythrocytes at the placental 
interface (reviewed in Carter, 2012). 
In addition to the primitive erythrocytes, the yolk sac also gives rise to a 
subset of macrophages termed the tissue-resident macrophages. These cells stem 
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from erythromyeloid precursors (EMP), which arise from E8.5 onwards and also 
give rise to erythrocytes expressing the adult globin (Figure 1.3) (Bertrand et al., 
2007, Yoder et al., 1997a, Chen et al., 2011b). These cells are thought to arise from a 
subset of ECs within the yolk sac (Chen et al., 2011b). In contrast to the 
macrophages produced during definitive haematopoiesis, these cells bypass the 
monocytic stage (Ginhoux et al., 2010). They colonise the embryo through the blood 
as soon as the circulation is established between E8.5 and E10, and play important 
roles during development (see 1.3.3.2) (Ginhoux et al., 2010). 
The progenitors generated during the primitive wave of haematopoiesis differ 
from the HSCs formed during definitive haematopoiesis, as they do not have the 
ability to self-renew or give rise to cells of all haematopoietic lineages (Figure 1.3). 
Accordingly, transplantation studies have demonstrated that these cells, in contrast to 
HSCs, cannot repopulate the bone marrow of irradiated mouse pups (Yoder et al., 
1997b). 
1.3.2 Definitive haematopoiesis 
Definitive haematopoiesis entails the formation of HSCs, which are able to 
generate all cells of the haematopoietic lineage including lymphocytes (B, T and 
natural killer cells), erythrocytes, megakaryocytes, granulocytes, and mononuclear 
phagocytes (monocytes and macrophages) (Figure 1.3). In addition, HSCs are able 
to self-renew, allowing them to continuously replenish blood cells with limited half-
lives such as monocytes throughout adult life.  
HSCs are generated from a specialised endothelium, referred to as hemogenic 
endothelium, within certain tissues depending on the stage of embryonic 
development (reviewed in Hirschi, 2012). Thus, the site of HSC generation changes 
throughout mammalian embryonic development. It first takes place in the extra-
embryonic tissues such as the yolk sac at E8.25 (Palis et al., 1999), and vitelline 
artery, umbilical vein (de Bruijn et al., 2000) and placenta by E9.5 (Robin et al., 
2009, Gekas et al., 2005). Within the embryo proper definitive haematopoiesis 
begins at E10.0, where the major site of HSC generation is found in the aorto-gonad-
mesonephros (AGM) region (Medvinsky and Dzierzak, 1996). Nevertheless, recent 
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studies have also shown HSC generation in other intra-embryonic tissues such as the 
endocardium (Nakano et al., 2013) and cephalic arteries (Li et al., 2012). 
The AGM-derived HSCs differ in their multi-lineage properties compared to 
the earlier yolk sac- or placenta-derived progenitors. Thus, they are able to 
reconstitute bone-marrow irradiated adult mice (Muller et al., 1994, Medvinsky and 
Dzierzak, 1996), whereas the earlier yolk sac-derived progenitors are only able to 
reconstitute irradiated neonates (Yoder et al., 1997b). It has been proposed that this 
reflects the immature nature of the yolk sac-derived progenitors, which are thought to 
require further maturation signals from the embryonic or neonatal liver (see below) 
in order to function as “true” HSCs. As the liver does not provide adequate signals in 
the adult, the yolk sac progenitors fail to develop into proper HSCs when they are 
transplanted into adult mice (Yoder et al., 1997b). 
HSCs are generated from specialised ECs referred to as hemogenic 
endothelial cells (HECs). The endothelial origin of HSCs was uncovered through 
endothelial lineage tracing as well as genetic knockout studies. Thus, a study using 
an inducible VEC Cre line demonstrated that HSCs were labelled despite not 
expressing VEC (Zovein et al., 2008). In addition, the endothelial deletion of Runx1, 
which is critical for the generation of HSCs, abolished HSC formation (Chen et al., 
2009b).  
The specification of HECs occurs from E8.25 onwards, when the primitive 
vascular plexus remodels into a hierarchical network of blood vessels (Goldie et al., 
2008, Nadin et al., 2003, Silver and Palis, 1997). The earliest HECs, which arise in 
the yolk sac, can be identified by the co-expression of VEGFR2 and haematopoietic 
stem cells marker KIT, and the lack of the expression of the haematopoietic marker 
CD45 (Goldie et al., 2008, Nadin et al., 2003). In addition HECs are characterised by 
their Hoechst dye-efflux properties, a phenotype that is also common to adult HSCs 
(Goodell et al., 1996, Kubota et al., 2003). The mechanism underlying HEC 
specification is still not completely understood; however, it is thought to rely on 
retinoic acid (RA) signalling. Thus, studies revealed that >90% of yolk sac and AGM 
HECs exhibit active RA signalling. Furthermore, embryos lacking retinaldehyde 
dehydrogenase 2 (RALDH2), an enzyme responsible for RA generation, lack HECs 
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(Goldie et al., 2008). RA is required to regulate the proliferation of ECs and thus it 
has been proposed that RA is involved in HEC specification by promoting cell cycle 
exit and subsequent differentiation. A recent study has provided evidence for this by 
showing that RA regulates KIT expression, which in turn promotes the expression of 
p27, a cyclin-dependent kinase inhibitor (Marcelo et al., 2013). Thus, KIT expression 
is reduced in Raldh2-deficient embryos; however, re-expression of KIT in Raldh2
-/-
 
mutants increases p27 expression and thus inhibits cell cycle progression rescuing 
HEC generation.   
Following the initial generation of HSCs from the AGM and extra-embryonic 
tissues, these cells enter the circulation and colonise first the liver and then the bone 
marrow (Houssaint, 1981). The liver is unable to generate de novo HSCs; instead, it 
serves as the main organ for HSC expansion and differentiation until late gestation. 
Thus, in contrast to the adult HSCs found in the bone marrow, the fetal HSCs 
undergo rapid, symmetrical self-renewing divisions (Morrison et al., 1995, Harrison 
et al., 1997, Rebel et al., 1996).  
The skeletal system develops during the third week of murine development 
and is vascularised from E15.5 onwards. Nevertheless, HSCs are only found in the 
bone marrow from approximately E17.5 onwards, when molecules such as stromal 
derived factor 1 (SDF1) are secreted to attract HSCs (Ara et al., 2003). Within the 
bone marrow, HSCs are located in specialised niches, which are important to 
regulate the appropriate balance between self-renewal and differentiation (Arai et al., 
2004). For instance, molecules secreted by osteoblasts such as angiopoietin-1 
(ANG1) affect proliferation and survival rates of HSCs (Arai et al., 2004). 
Furthermore, HSCs are commonly found closely associated with the bone 
microvasculature. This is firstly thought to facilitate the entry of blood cells into the 
circulation; secondly, ECs are thought to play an important role in blood cell 
differentiation. Thus, the interaction of haematopoietic progenitors with endothelial 
molecules such as vascular cell adhesion molecule 1 (VCAM1) during trans-
endothelial migration is important for megakaryocyte maturation (Rafii et al., 1997, 
Rafii et al., 1995). 
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Figure 1.3. The formation of the haematopoietic system. 
Schematic representation of primitive haematopoiesis in the yolk sac and definitive 
haematopoiesis in the AGM and bone marrow. Arrows indicate lineage relatedness. AGM: 
aorta-gonad-mesonephros, HSC: haematopoietic stem cell, NK: natural killer, EMP: 
erythromyeloid progenitor.  
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1.3.3 Monocytes and macrophages 
Monocytes and macrophages are mononuclear phagocytes that constitute an 
essential part of the innate immune system. Both cell types play crucial parts during 
inflammation by phagocytosing pathogens, releasing cytokines and organising an 
immune response. In addition, macrophages are essential for development and tissue 
homeostasis.  
Monocytes are a conserved population of mononuclear leukocytes with bean-
shaped nuclei that are present in all vertebrates (Figure 1.3). In mice and humans 
they constitute 4% and 10%, respectively, of the nucleated cells in the blood, with 
considerable reserves in the spleen and lungs that can be mobilised in response to 
inflammatory signals (van Furth and Sluiter, 1986, Swirski et al., 2009). In humans, 
monocytes can be identified through the expression of specific markers such as 
CD11b, CD11c and CD14, whereas in mice they are recognised by the expression of 
CD11b and F4/80. Within the blood, monocytes can be separated into several distinct 
subpopulations, which differ in their function and expression of specific markers 
(reviewed in Ginhoux and Jung, 2014). In humans, monocytes can broadly be split 
into two main populations, the “classical” population, which is CD14+CD16
-
, and the 
“non-classical” population, which is CD14
-
CD16
+
. These populations correspond to 
the two main monocyte populations found in the mouse, in which the classical 
population is defined as LY6C
hi
CCR2
+
CD62L
+
CX3CR1
mid
, whereas the non-
classical population is LY6C
low
CD43
+
CX3CR1
hi
.  
In both mice and humans, the classical monocytes comprise the majority of 
monocytes in the blood. These cells only have a half life of 20 h and function as the 
“inflammatory subset” of monocytes (Geissmann et al., 2003). They circulate within 
the blood, from where they are recruited to sites of inflammation by CCR2 and 
release cytokines and/or differentiate into macrophages to activate an immune 
response (Figure 1.3).  
In contrast, the non-classical monocytes only comprise 15% of total 
monocytes in healthy mice and humans. These cells have a longer half life of 5 days 
and play an important role in patrolling the lumen of blood vessels and surveying the 
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endothelium for damage. They are often referred to as “resident monocytes”, because 
they are also found in non-inflamed tissue (Geissmann et al., 2003). In response to 
tissue injury, these cells can extravasate and coordinate an immune response by 
differentiating into macrophages and secreting cytokines (Auffray et al., 2007). 
Accumulating evidence suggests that, in the steady state, the blood monocyte 
subsets represent stages in a developmental sequence with the classical LY6C
hi
 
monocytes eventually differentiating into LY6C
low
 cells (Yona et al., 2013, Varol et 
al., 2007). In support of this idea, recent studies have also discovered monocyte 
populations that display intermediate LY6C expression levels.  
Macrophages are large, phagocytic cells, which are characterised by the 
expression of surface markers such as F4/80, CSF1R, CD11b and CD68 (also known 
as MAC1). In contrast to their monocytic precursors, these cells have a long life 
span, which can range from several months to years. These cells are found in 
multiple tissues, where they play a critical role in tissue development and 
homeostasis. Depending on the tissue, macrophages can also become specialised to 
their environment and are referred to as Kupffer cells (liver), Langerhans cells (skin), 
osteoclasts (bone) and microglia (CNS) (reviewed in Gordon and Taylor, 2005).  
Macrophages also comprise an essential part of the innate immune system 
and can be activated to launch distinct immune responses, sometimes referred to as 
M1 and M2- a terminology that is based on different in vitro responses to distinct 
cytokines (reviewed in Martinez and Gordon, 2014). This nomenclature mimics the 
names used to describe the polarisation of T helper cells in response to 
environmental stimuli. Thus, T helper cells can either launch a TH1 (cell-mediated) 
or TH2 (antibody-mediated) immune response. 
In vitro, macrophages can adapt a pro-inflammatory phenotype, which is 
termed M1, in response to pathogenic stimuli such as lipopolysaccharides (LPS) or 
inflammatory cytokines such as interferon-γ or TNF-β. M1 activation results in the 
release of multiple, pro-inflammatory cytokines e.g. IL-12, TNF, IL-6, and IL-1β and 
chemokines e.g. C-C motif ligand 2 (CCL2), and the upregulation of antigen 
presenting molecules. In addition, macrophages increase their production of toxic 
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intermediates such as nitric oxide (Herbst et al., 2011, Thomas et al., 1997, Piedrafita 
et al., 2001). Altogether these factors activate additional immune cells and contribute 
to the destruction of invading pathogens and malignant tumour cells. 
In contrast, the anti-inflammatory macrophage phenotype termed M2 results 
in macrophages promoting tissue remodelling and repair. This response is triggered 
by various stimuli such as IL-4, a product of the TH2 response, IL-10 and 
glucocorticoids (Varin et al., 2010, Mantovani et al., 2004, Deng et al., 2012). These 
factors result in the enhanced expression of scavenger and mannose receptors and the 
reduced secretion of pro-inflammatory cytokines. The M2 macrophages, thus, 
promote repair by taking up debris, promoting vascularisation and tissue 
remodelling.  
1.3.3.1 Monocyte and macrophage development 
Monocytes were originally thought to constitute the exclusive precursor of 
macrophages; nevertheless, recent studies have revealed that a subset of tissue 
resident-macrophages stems from a separate yolk sac-derived precursor termed the 
EMP (Figure 1.3). The EMPs are generated in the yolk sac during primitive 
haematopoiesis and give rise to macrophages directly without first generating the 
monocyte stage. These yolk sac-derived macrophages spread through the circulation 
and into the embryonic tissues when circulation starts between E8 and E12. Within 
their target tissues they proliferate and ultimately give rise to tissue-resident 
macrophages, which are critical during development, as they promote and regulate 
tissue vascularisation (DeFalco et al., 2014, Fantin et al., 2010, Okuno et al., 2011).  
The first monocytes are generated from HSC-derived myeloid precursors in 
the liver and then bone marrow during definitive haematopoiesis (see 1.3.2). Their 
generation is dependent on the transcription factor MYB, which is required for HSC 
formation (Gomez Perdiguero and Geissmann, 2013, Schulz et al., 2012). In contrast, 
yolk sac-derived macrophages develop in a MYB-independent fashion. As a result, 
Myb-null mice display normal tissue macrophage populations, whilst all other blood 
cells are lacking (Schulz et al., 2012).  
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Following monocyte generation, a subset of these cells also extravasates and 
differentiates into macrophages. Monocytes thus also provide a source of tissue-
resident macrophages. Nevertheless, this process is highly tissue-specific (reviewed 
in Ginhoux and Jung, 2014); thus, monocytes are the predominant source of 
Langerhans cells, the tissue-resident macrophages in the skin (Hoeffel et al., 2012). 
In addition, they give rise to the alveolar macrophages of the lung (Guilliams et al., 
2013). They do not, however, contribute to the generation of microglia, the tissue-
resident macrophages of the CNS (Ginhoux et al., 2010). The varying contribution of 
monocytes to tissue-macrophage populations of distinct tissues is thought to be an 
adaption to the relative exposure of certain tissues to pathogens. Thus, the skin and 
lung are readily exposed to multiple pathogens and macrophages will be depleted 
more quickly than within the CNS, which is mostly sterile. In addition, monocyte-
derived macrophages are also thought to predominantly contribute to tissues with a 
continuous cyclic recruitment of macrophages such as the uterus or ovary (reviewed 
in Italiani and Boraschi, 2014).  
The differentiation of monocytes and macrophages depends on the E26-
transformation-specific (ETS) family transcription factor PU.1. Thus, mice deficient 
in Pu.1 (also known as Spi1 Jego et al., 2014, Batliner et al., 2012) completely lack 
mature myeloid cells (McKercher et al., 1996). This protein is also required for B 
cell and neutrophil differentiation (McKercher et al., 1996) and it is thought that 
PU.1 levels regulate haematopoietic cells towards their lymphoid or myeloid fate. 
Accordingly, PU.1 is expressed at intermediate levels in progenitors and is down-
regulated during B- and T-cell development, but is expressed at higher levels in cells 
that develop into macrophages (DeKoter and Singh, 2000, Anderson et al., 2002, 
Spooner et al., 2009, Carotta et al., 2010). PU.1 regulates the expression of another 
gene that is critical for myeloid differentiation, Csf1r (Krysinska et al., 2007). 
CSF1R is a type III tyrosine kinase receptor for the ligand CSF1, a growth 
factor that plays an important part in both monocyte generation, as well as 
macrophage differentiation and function (Byrne et al., 1981, Guilbert and Stanley, 
1980, Tanaka et al., 1993, Dai et al., 2002). Accordingly, mice homozygous for the 
naturally occurring, inactivating osteopetrotic mutation in the coding region of the 
Csf1 gene (Csf1
Op/Op
) (Marks and Lane, 1976, Yoshida et al., 1990) lack tissue 
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macrophages and thus display multiple defects such as osteopetrotic bones due to the 
lack of osteoclasts. Interestingly, microglia only show a 30% reduction (Ginhoux et 
al., 2010). Mice lacking the CSF1R receptor (Csf1r
-/-
) recapitulate all defects 
displayed by the Csf1
Op/Op
 mouse (Wiktor-Jedrzejczak et al., 1990). In addition, they 
exhibit a complete absence of all tissue macrophages including the microglia in the 
CNS (Dai et al., 2002). This discrepancy can be explained by the other CSF1R 
ligand, IL-34, which presumably plays a role in microglia development or survival 
(Lin et al., 2008). 
1.3.3.2 Role of macrophages in vascular development  
Tissue-resident macrophages play an integral part during development 
(reviewed in Pollard, 2009). For instance, they contribute to tissue remodelling by 
removing redundant tissues such as the hyaloid vasculature in the eye (see 1.5.2.1) 
(Diez-Roux et al., 1999). Furthermore, they are required in developing organs that 
are formed when epithelial sprouts invade underlying mesenchyme, for instance in 
the mammary gland or pancreatic islets. In these tissues, macrophages enable lumen 
formation and ductal branching. Accordingly, Csf1
Op/Op
 mice display atrophic 
mammary glands and abnormal postnatal islet morphogenesis (Geutskens et al., 
2005, Gouon-Evans et al., 2000). 
In addition, tissue-resident macrophages are essential for tissue 
vascularisation by promoting the anastomosis of sprouting vessels (Fantin et al., 
2010, Okuno et al., 2011). Thus, mice deficient in macrophages display less complex 
vascular beds. The mechanism underlying this process is currently not well 
understood; however, it is thought to be independent of VEGF-A signalling. Instead, 
VEGF-C has been implicated in this process. Thus, microglia located near vessel 
branch points secrete VEGF-C, whereas vascular sprouts express the VEGFC 
receptor VEGFR3 (Benedito et al., 2012). Furthermore, retinas of Vegfc
+/-
 mice have 
reduced vessel branching, whilst sprouting is increased (Tammela et al., 2011). 
Nevertheless, it remains to be shown in what way this signalling pathway contributes 
to vessel anastomosis. In addition, it is currently not clear whether macrophages are 
attracted by tip cells or vice-versa.  
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1.3.3.3 Role of macrophages in pathological angiogenesis 
During inflammation, a large number of immune cells including monocytes 
and macrophages are recruited to the site of injury. There, depending on the 
inflammatory milieu, macrophages usually either elicit a M1-like pro-inflammatory 
or M2-like anti-inflammatory/pro-angiogenic response (see 1.3.3). For example, the 
presence of pathogens usually triggers an M1-like response in which the 
macrophages recruit other immune cells and up-regulate their phagocytic activity. 
Other factors such as hypoxia will instead promote macrophages to adopt an M2-like 
phenotype, in which they mostly contribute to wound healing by scavenging debris 
and promoting angiogenesis. This behaviour is mostly beneficial. For example, 
following hindlimb ischemia, macrophages elicit an M2-like response clearing 
necrotic tissue and promoting revascularisation (Arras et al., 1998, Patel et al., 2013). 
However, in situations such as cancer or atherosclerosis, macrophages may wrongly 
adopt an M2-like response, resulting in pathological angiogenesis and thus disease 
progression rather than resolution. In cancer for example, tumour cells actively 
recruit macrophages and monocytes into their microenvironment by expressing 
attractants such as VEGF-A and CSF1 (Zhou et al., 2015, Leek et al., 2000, Sullivan 
and Pixley, 2014, Ueno et al., 2000). As a result, tumour-associated macrophages 
(TAMs) are usually found in close association with tumour cells. In addition, tumour 
cells secrete cytokines such as periostin, which polarise the TAMs towards the anti-
inflammatory M2-like program (see 1.3.3.1).  
M2-like macrophages promote tumour progression in several ways. Firstly, 
they release immunosuppressive cytokines e.g. IL-10 (Wu et al., 2010). Secondly, 
they promote tumour angiogenesis by releasing multiple pro-angiogenic cytokines 
such as TNF-α and VEGF-A (Lewis et al., 2000, Leibovich et al., 1987), as well as 
metalloproteinases such as MMP-9. Accordingly, a higher number of TAMs often 
correlates with an increased tumour vascularisation (Bolat et al., 2006, Dirkx et al., 
2006, Mantovani et al., 2006). Furthermore, tumour growth and metastasis are 
reduced in macrophage-deficient mice despite tumour initiation not being affected 
(Lin et al., 2001). 
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Macrophages are also at the centre of proliferative neovascular eye diseases. 
For instance, they are thought to promote pathological angiogenesis from the 
choriocapillaris into the sub-retinal space and retina in certain cases of AMD (Lim et 
al., 2012). Accordingly, an increased number of macrophages is found in patients 
with CNV (Jager et al., 2008, Hageman et al., 2001). Macrophages also promote 
neoangiogenesis in a laser-induced mouse model of CNV. Thus, macrophage 
depletion results in decreased lesion size and severity (Espinosa-Heidmann et al., 
2003b). In comparison to tumour angiogenesis, macrophages are thought to elicit an 
inappropriate “wound-healing” or M2 response, which results in the secretion of pro-
angiogenic molecule such as VEGF-A (Liu et al., 2013). Accordingly, VEGF-A 
expression levels correlate with the peak of macrophage recruitment (Sakurai et al., 
2003), and macrophage depletion severely reduced VEGF-A levels in laser-treated 
retinas (Itaya et al., 2007). The macrophages are thought to be polarised towards an 
M2 response by the ingestion of debris of the damaged retinal pigment epithelium; 
nevertheless, the exact mechanism remains to be established (Liu et al., 2013). 
1.4 Neural crest-mediated remodelling of the cardiovascular system 
After the primitive cardiovasculature consisting of a heart and vascular tree has 
formed, the great vessels around the heart undergo remodelling to lay the foundation 
for transit from life in utero to postnatal life. Specifically, the embryonic circulation 
of all mammals bypasses the lungs and instead relies on the placenta for 
oxygenation; however, a switch to the pulmonary circulation at birth is essential to 
allow oxygen uptake through the lungs. To achieve this switch, vessel remodelling of 
two types is required: the pharyngeal arch arteries (PAAs) remodel to form the aortic 
arch, carotid arteries and smaller vessels, and the OFT septates into the base of the 
aorta and the pulmonary artery (Figure 1.4C,D). Both of these remodelling 
processes depend on a population of cells called the cardiac NCCs.  
1.4.1 Neural crest 
 Cardiac NCCs, like other NCC populations, are a vertebrate-specific cell 
population that is derived from the dorsal part of the embryonic neural tube through 
epithelial-to-mesenchymal transition. Even though NCCs were already described in 
1868 by Wilhelm His as the “Zwischenstrang” (intermediate cord) and were 
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subsequently renamed “neural crest” by Arthur Marshall in 1879, NCCs with 
specific functions in heart development were not discovered until the 1980s through 
transplantation and lineage tracing experiments in avian embryos by Margaret Kirby 
and colleagues (Kirby et al., 1983, Kirby, 1987, Creazzo et al., 1998). Thus, Kirby 
and colleagues described how NCCs delaminating from the neural tube between the 
otic placode and the 3
rd
 somite colonise the embryonic pharyngeal arches and OFT of 
the heart. They further demonstrated that ablation of this NCC subset causes 
developmental defects that resemble common congenital heart defects in human 
patients, such as a common arterial trunk (CAT; also known as persistent truncus 
arteriosus, PTA). This groundbreaking research initiated an intense era of research to 
identify the molecular and cellular mechanisms that govern NCC-induced 
cardiovascular development and the role of NCCs in congenital heart disease 
(reviewed in Keyte and Hutson, 2012).  
1.4.2 Cardiac NCCs enable PAA remodelling into the aortic arch 
After cardiac NCCs have delaminated from the neural tube, they migrate 
ventrally into the circumpharyngeal ridge (Figure 1.4A,B). Here, they pause whilst 
the PAAs form by vasculogenesis (see 1.1.2.1) to generate a bilateral series of artery 
pairs, which in the mouse occurs between E8.5 and E9.5. As the 1
st
 and 2
nd
 artery 
pairs remodel into the mandibular and hyoid arteries, respectively, the cardiac NCCs 
invade the pharyngeal arches in 3 streams to sequentially associate with the 3
rd
, the 
4
th
 and 6
th
 PAA pairs, reflecting the order of artery formation along the rostrocaudal 
axis (Hiruma et al., 2002). Notably, current PAA nomenclature refers to the six 
artery pairs that exist in fish, as the existence of a 5
th
 PAA pair in mammals has been 
contentious. Nevertheless, certain congenital malformations can only be explained by 
the persistence of a 5
th
 PAA. Furthermore, a recent study demonstrated that in a 
small subset of human embryos a structure resembling a 5
th
 PAA was detectable 
(Bamforth et al., 2013).  
Having colonised the PAAs, which initially consist only of a sheath of ECs, 
the cardiac NCCs differentiate into SMCs (Bergwerff et al., 1998). This process, 
which occurs between E10.5 and E13.5 in the mouse, is thought to be important for 
subsequent PAA remodelling (Figure 1.4C). 
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The 3
rd
 PAAs extend to form the right common carotid and basal part of the 
left internal carotid in both birds and mammals. In mammals, the right 4
th
 artery 
regresses and becomes part of the right subclavian artery, whereas the left 4
th
 artery 
persists and forms the segment of the aortic arch that connects the aortic sac to the 
descending aorta. Moreover, the proximal right 6
th
 PAA contributes to the base of the 
pulmonary artery, whereas the distal segment regresses (Schneider and Moore, 
2006). The left 6
th
 PAA gives rise to the ductus arteriosus, an embryonic structure 
that connects the pulmonary artery with the descending aorta; this shunt allows blood 
from the right ventricle to bypass the lungs, because the fetal blood is oxygenated 
through the placenta. At birth, the ductus arteriosus collapses due to a rise in oxygen 
levels, and de-oxygenated blood is now able to enter the pulmonary circulation 
(Leonhardt et al., 2003). The non-functional vestige of the ductus arteriosus persists 
throughout life and is called ligamentum arteriosus. 
Ultimately, the asymmetric remodelling of the PAAs in mammals gives rise 
to a vascular tree in which the aortic sac connects via the left 4
th
 PAA to the 
descending aorta to form the left-looping aortic arch. In birds, remodelling of the 4
th
 
and 6
th
 PAAs occurs in the reverse configuration (Wang et al., 2009): the right 4
th
 
artery remodels into the definitive aortic arch, the left 6
th
 PAA forms the proximal 
segment of the pulmonary artery and the right 6
th
 PAA forms the ductus arteriosus, 
which collapses at hatching. In contrast to mammals, the right 4
th
 PAA persists and 
the aortic arch therefore curves to the right.  
In both birds and mammals, formation of an asymmetric aortic arch and 
pulmonary artery is a pre-requisite for blood from the ventricles to enter two distinct 
circulations. Whilst the aortic arch directs the oxygenated blood into the systemic 
circulation, the pulmonary artery directs the de-oxygenated blood into the pulmonary 
circulation. Accordingly, defects in the remodelling process are often lethal or 
severely impair cardiovascular performance. When cardiac NCCs are ablated in 
chick or mouse embryos, the PAAs form normally, but regress or persist 
inappropriately (Kirby et al., 1983, Waldo et al., 1996, Porras and Brown, 2008). For 
example, a common defect in mouse mutants with abnormal cardiac NCC behaviour 
is the regression of the left 4
th
 PAA. This defect results in an interrupted aortic arch 
(IAA) and is referred to as a type b interruption. Despite a multitude of mouse 
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models with defective cardiac NCC behaviour, only a limited number of the 
signalling pathways involved have been discovered, and the exact cellular 
interactions by which cardiac NCCs orchestrate PAA remodelling and survival 
remain incompletely understood  
1.4.3 OFT remodelling into the base of the aorta and pulmonary artery 
Congenital heart defects are a leading cause of perinatal mortality and 
morbidity, affecting 1% of all live births in the Western world (Hoffman and Kaplan, 
2002). A CAT is a rare defect caused by faulty remodelling of the heart OFT during 
embryogenesis. The OFT is a transient embryonic structure at the arterial pole of the 
heart that initially functions as a conduit for blood flowing from the right ventricle 
into the aortic sac (Figure 1.4B,D). Subsequently, the OFT wall rotates and septates 
to generate the base of the ascending aorta and pulmonary trunk, which enables the 
separation of the arterial and venous circulation (Figure 1.4D). A failure of OFT 
septation during embryogenesis, therefore, results in inappropriate mixing of 
oxygenated and de-oxygenated blood at birth and has an unfavourable clinical 
prognosis, because surgical correction is difficult (Williams et al., 1999).  
Initially, the OFT comprises a solitary tube, which extends from the arterial 
pole of the heart to the pericardial wall, where it becomes continuous with the aortic 
sac. At this stage, the OFT possesses a dog-leg bend, which allows the OFT to be 
separated into a proximal and distal part (reviewed in Anderson et al., 2003). The 
proximal part describes the section closest to the heart, which will eventually 
generate the ventricular outflow regions including the segment where the arterial 
valves are formed. The distal OFT, instead, refers to the part of the vessel, which will 
ultimately form the intrapericardial parts of the aorta and pulmonary artery.  
During early development, when the OFT is first identifiable, it is simply 
lined by ECs and surrounded by a myocardial layer. The space in between the two 
layers is filled with an acellular “cardiac jelly” consisting of ECM components. 
Subsequently, this space is infiltrated by cells from several distinct sources, pushing 
the endothelium on either side of the tube towards to lumen. These swellings are 
termed the principal endocardial cushions and they extend the entire length of the 
OFT spiralling around each other due to the rotation of the OFT itself.  
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The endocardial cushions are critical for the subsequent septation (Markwald 
et al., 1981, Eisenberg and Markwald, 1995) and their formation and fusion relies on 
the interaction of three distinct cell types: cardiac NCCs, SHF-derived (Figure 1.1) 
cells and ECs. Thus, cardiac NCCs migrate from the PAAs into the distal endocardial 
cushions of the OFT in two streams.  Due to their densely stained appearance in the 
centre of both endocardial cushions, they have historically also been referred to as 
“prongs” or “rods” (reviewed in Anderson et al., 2003). The colonisation of the OFT 
by cardiac NCCs also correlates with an endothelial-to-mesenchymal transition 
(endoMT) of the OFT endothelium, which provides additional mesenchymal cells for 
the endocardial cushions (Sugishita et al., 2004). Whilst the endocardial cushions 
expand due to the recruitment of the aforementioned cell populations, the aortic sac 
at the most distal part of the OFT also remodels. This generates a small transverse 
protrusion in the posterior wall between the fourth and sixth PAA, which is referred 
to as the aortico-pulmonary septum. When the endocardial cushions have swollen to 
a sufficient size, the ECs on opposing cushions abut enabling the fusion of the OFT 
endothelium in the centre of the OFT. This fusion begins in the distal OFT and 
progresses to the proximal part of the tract.  Whilst it is currently not known what 
initiates the fusion of the ECs, it is interesting to note that the cardiac NCC “prongs” 
take on a “whorl”-like appearance at the site of ongoing OFT septation. The fusion of 
the endocardial cushions within the distal segment of the OFT and the connection of 
their distal surface to the aortic-pulmonary septum generates the intra-pericardial 
parts of the aorta and pulmonary artery by E11. In addition, the distal vessel walls 
remodel to adopt an arterial phenotype and eventually become completely septated. 
In contrast, the proximal OFT remains encased by a myocardial wall and the fused 
endocardial cushions are still distinguishable at this stage. 
 By E12.5 the proximal OFT can be divided into two parts, the medial and the 
proximal OFT, where the proximal part refers to the vessel segment closest to the 
heart. The two parts can be distinguished by the fact that two extra cushions, called 
the intercalated cushions, have formed in the opposite quadrants of the medial OFT, 
whereas the proximal OFT only contains the two principal cushions. Within the 
medial OFT, the fused principal cushions along with the intercalated cushions 
remodel to form the three arterial valve leaflets and sinuses in each vessel, whereas 
in the proximal OFT, the two principal endocardial cushions are still unfused at this 
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stage. Nevertheless, by E13.0 the proximal parts of the OFT have also fused, which 
relies on the recruitment of mesenchymal cells through the process of endoMT (Bai 
et al., 2013). In addition, whilst the medial OFT wall gradually loses its myocardial 
cuff and becomes arterialised, myocardial tissue is gradually added to the proximal 
OFT through a process called “myocardialisation” (van den Hoff et al., 1999). These 
myocardial cells also migrate into the septal bridge, which transforms it into a 
muscular septum. Eventually, the leading edge of the muscular septum becomes 
attached to the roof of the right ventricle. This attachment gradually remodels to 
finally connect the septal bridge to the interventricular septum, fusing the base of the 
aorta to the left ventricle and the base of the pulmonary artery to the right ventricle. 
Thus, blood leaving the left and right ventricle enters distinct circulations. 
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Figure 1.4. Cardiac NCC contribution to murine OFT and PAA development.  
Schematic representation of cardiac NCC migration (A). Visualisation of NCCs and their 
derivatives in an E10.5 Wnt1-Cre;Rosa
LacZ
 mouse embryo (B). The higher magnification 
image shows two prongs of cardiac NCCs in the OFT. PAA remodeling into the aortic arch 
(C). Ink injections into embryonic hearts at E10.5 and E13.5 show the 3
rd
, 4
th
, and 6
th
 PAAs 
and their remodelled derivatives. Cardiac NCC colonisation of the E12.5 OFT (D). Xgal 
staining of an E12.5 Wnt1-Cre;Rosa
LacZ
 heart shows accumulation of cells from the cardiac 
NCC lineage in the OFT; the dotted line indicates the level at which a section was taken to 
illustrate the position of the cardiac NCCs within the OFT in the adjacent panel. Double 
staining with the endothelial marker PECAM and the myocyte marker SMA illustrates OFT 
anatomy at E12.5. Scale bars: 1 mm (B), 500 μm (C,D).  
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1.4.4 Signalling pathways in cardiac NCC-mediated vascular remodelling 
A number of genes involved in cardiac NCC-induced PAA remodelling and 
OFT septation have been uncovered through the analysis of mouse mutants with 
congenital heart defects (reviewed in Gruber and Epstein, 2004). Several key genetic 
pathways activated by members of the TGFβ, fibroblast growth factor (FGF), VEGF-
A and SEMA3 families of secreted signalling molecules regulate cardiac NCC 
induction or their migration, survival and differentiation.  
The TGFβ superfamily comprises a large group of secreted polypeptides that 
includes the bona fide TGFβs and the bone morphogenetic proteins (BMPs), with 
both types of proteins shown to play a role in cardiac NCC-regulated vascular 
remodelling (reviewed in Keyte and Hutson, 2012). BMP2 and BMP4 are generally 
required for NCC induction, migration, differentiation and survival, and knockout 
studies of their receptors have shed light into the role of BMP signalling in regulating 
cardiac NCC behaviour. For instance, the BMP receptor ALK2 is required by cardiac 
NCCs for their migration into the PAAs and the OFT, and, accordingly, the NCC-
specific ALK2 deletion results in CAT and IAA (Kaartinen et al., 2004). In contrast, 
the NCC-specific deletion of the alternative BMP receptor BMPR1A does not affect 
cardiac NCC migration, but impairs endocardial cushion formation and consequently 
results in an unseptated OFT (Stottmann et al., 2004).  
TGFβ2 appears to be particularly important for cardiac NCC-mediated 
vascular remodelling. Thus, addition of exogenous TGFβ2 to whole-embryo cultures 
causes OFT and aortic arch remodelling defects (Kubalak et al., 2002). Moreover, 
TGFβ2 knockout mice have defects in the development of several tissues, including 
the OFT and the aortic arch; in contrast, similar defects are not observed in TGFβ1 
and TGFβ3 knockouts (Sanford et al., 1997).  
TGFβ signalling may also have a cell autonomous role in cardiac NCCs. 
Thus, the loss of TGFβ receptor 2 (TGFβR2) in cardiac NCCs prevents their 
differentiation into myocytes and therefore perturbs remodelling of both the OFT and 
PAAs in mice (Wurdak et al., 2005). Furthermore, loss of the TGFβ receptor ALK5 
in the NCC lineage also causes PAA and OFT defects by impairing post-migratory 
cardiac NCC survival (Wang et al., 2006a).  
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To date, twenty FGFs have been described, all of which are small, heparin-
binding secreted proteins. Nevertheless, out of these, only FGF8 has been implicated 
in cardiac NCC development (Frank et al., 2002). Even though FGF8 deletion causes 
embryonic death at mid-gastrulation (Sun et al., 1999), FGF8 hypomorphic mice 
secrete enough FGF8 to survive gastrulation elucidating the role of this molecule in 
cardiac NCC function. Thus, these mice have defective cardiac NCC migration into 
the pharyngeal arches (Frank et al., 2002), as FGF8 is secreted by the pharyngeal 
ectoderm and endoderm as a guidance cue for migrating cardiac NCCs (Sato et al., 
2011). It also promotes the survival of the cardiac NCCs that colonise the 4
th
 PAAs 
(Abu-Issa et al., 2002, Macatee et al., 2003). Accordingly, the conditional FGF8 
deletion in pharyngeal ectoderm impairs 4
th
 PAA formation, whilst conditional 
deletion in the endoderm prevents OFT septation (Park et al., 2006). 
VEGF-A is a secreted polypeptide most commonly studied in regard to its 
critical role in vasculogenesis, angiogenesis and arteriogenesis (see 1.2.1). In 
addition, VEGF-A has been reported to act as a guidance cue for cranial NCCs that 
invade the 2
nd
 PAAs to contribute to craniofacial tissues (McLennan et al., 2010). In 
contrast, VEGF-A is thought to not play a major role in cardiac NCC migration 
(Stalmans et al., 2003, Kirby and Hutson, 2010). Nevertheless, genetic studies in the 
mouse have implicated specific isoforms of VEGF-A in OFT and PAA remodelling. 
Thus, the exclusive expression of VEGF120 at the expense of VEGF164 and 
VEGF188 in Vegfa
120/120
 mice, or the exclusive expression of VEGF188 at the 
expense of VEGF120 and VEGF164 in Vegfa
188/188
 mice, has revealed an essential 
role for VEGF164 in OFT and PAA remodelling (Stalmans et al., 2003). Thus, 
similar cardiac and aortic arch malformations are observed in most Vegfa
120/120
 and 
some Vegfa
188/188
 mice, with the former suffering additional fatal cardiac defects. 
Aortic arch malformations include IAA type b, double aortic arch, right-sided aortic 
arch and different aberrations in the formation of the carotid and subclavian arteries, 
while cardiac defects arising from defective OFT septation included Tetralogy of 
Fallot, CAT, hypoplasia of the pulmonary trunk and VSDs (Stalmans et al., 2003). 
Given that cardiac NCC migration is thought to be at least grossly normal in 
VEGF-A isoform-deficient mice (Stalmans et al., 2003, Kirby and Hutson, 2010), the 
mechanistic reasons for OFT and PAA defects in these mice are not well understood. 
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The prevailing model suggests that these defects are due to loss of VEGF164 
signalling through NRP1 in OFT endothelium, because the complete absence of 
NRP1, or genetic ablation specifically of endothelial NRP1, impairs OFT and PAA 
remodelling (Kawasaki et al., 1999, Gu et al., 2003). However, I recently contributed 
to a study, which demonstrated that mice with a mutated NRP1 receptor unable to 
bind VEGF-A are viable (Fantin et al., 2014) (see Chapter 3), an observation that is 
not compatible with the hypothesis that VEGF-A signals through NRP1 in 
endothelium to enable OFT septation, as defective OFT septation should cause 
lethality at birth. It is, therefore, likely that VEGF-A signals in the OFT through 
another receptor, such as VEGFR2, and that endothelial NRP1 acts as a receptor for 
another ligand. However, prior to my thesis work, neither hypothesis had been tested 
experimentally (see Chapter 3). 
SEMA3 proteins are secreted glycoproteins best known for their role in axon 
guidance (Rohm et al., 2000, Ruediger et al., 2013). One particular family member 
termed SEMA3C is secreted within the OFT and PAAs at the time when cardiac 
NCCs migrate into these tissues, and loss of SEMA3C causes CAT and IAA (Feiner 
et al., 2001). It has been proposed that SEMA3C acts as an attractive signal for 
cardiac NCCs, as knockdown of NRP1 in cardiac NCCs perturbs their migration in 
chick (Toyofuku et al., 2008). Agreeing with a similar role for SEMA3C in 
mammals, mice lacking semaphorin signalling through both NRP1 and NRP2 also 
have aortic arch and OFT defects (Gu et al., 2003). However, experimental proof for 
a role of NRPs in SEMA3C-induced cardiac NCC migration in mammals is still 
lacking. 
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1.5 Models of blood vessel development 
Abnormal blood vessel growth or function is the cause of many prevalent, yet 
devastating diseases such as diabetic retinopathy or atherosclerosis. In addition, 
stimulating blood vessel growth to revascularise ischemic tissues, for example after 
stroke or myocardial infarction, has great therapeutic potential. In accordance, there 
is a great need to understand the cellular functions and signalling pathways involved 
in vascular biology. There are currently several mouse models, which are exquisitely 
suited to analyse particular aspects of vessel growth in vivo. In the following 
passages, I shall describe three of these models, which I have all used in my thesis: 
First, the embryonic hindbrain as a model to study embryonic angiogenesis; second, 
the retina as a model of postnatal developmental angiogenesis; and third, the oxygen-
induced retinopathy (OIR) model as a method to study pathological angiogenesis. 
1.5.1 Embryonic hindbrain 
1.5.1.1 Hindbrain vascularisation 
The mouse hindbrain is vascularised by angiogenesis in a highly stereotypical 
fashion (Ruhrberg and Bautch, 2013, Plein et al., 2015b). At E9.5, the first blood 
vessels enter the neuroectodermal tissue by sprouting from the underlying perineural 
vascular network. These sprouts break through the pial membrane and sprout radially 
into the hindbrain parenchyma in response to VEGF-A secreted by neural 
progenitors (Breier et al., 1992, Haigh et al., 2003, Raab et al., 2004). By E10.5, the 
vessel sprouts reach the subventricular zone, where they change their direction of 
growth by ~90 degrees to grow laterally. The vessels then continue sprouting 
additional vessels, which then fuse with adjacent sprouts forming a honey-comb 
shaped vascular network termed the subventricular vascular plexus (SVP) (Ruhrberg 
et al., 2002, Fantin et al., 2010) (Figure 1.5A). This vascular network can easily be 
imaged between E10.5 and E12.5 after dissecting the hindbrain, staining the 
endothelium with a lectin such as isolectin B4 (IB4) or antibodies against CD31 
(PECAM), for example, and then flatmounting and imaging the hindbrain (Figure 
1.5A), as published previously (Plein et al., 2015b, Fantin et al., 2013c) (see 
Appendix – co-authored publications).  
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1.5.1.2 Advantages of the hindbrain as a model system for angiogenesis 
The embryonic mouse hindbrain provides several advantages as a model 
system to study angiogenesis. As described above, the hindbrain vasculature forms in 
a highly stereotypical fashion to generate a vascular plexus of a simple geometric 
nature, including a one dimensional (1D) pattern of radial vessels on the pial side, 
and a 2D network of SVP vessels on the ventricular side (Ruhrberg et al., 2002, 
Fantin et al., 2013c). This arrangement greatly facilitates the quantitation of vessel 
parameters, such as vessel number, diameter, branchpoints or filopodia number 
(Ruhrberg et al., 2002, Fantin et al., 2013c). In contrast, the vascularisation of organs 
such as the kidney and lung occurs in a 3D and less stereotypical fashion, 
complicating quantification.  
In addition, the comparatively early vascularisation of the hindbrain from 
E9.5 onwards permits the analysis of mutants that are embryonic lethal, as long as 
they survive beyond E10.5. For example, mouse embryos lacking NRP1 are lethal 
around E12.5 on an outbred background (Kawasaki et al., 1999) and can be analysed 
easily with the hindbrain model (Gerhardt et al., 2004, Fantin et al., 2013a).  
Another advantage of the hindbrain model is that the cellular interactions, 
which govern tissue vascularisation, are less complex than those in perinatal models. 
Accordingly, the angiogenic hindbrain environment predominantly contains neural 
progenitors alongside few neural subtypes and microglia. The angiogenic hindbrain 
also forms a particularly homogenous capillary bed suitable for accurate quantitative 
analysis, because arteriovenous differentiation and vascular remodelling occur after 
SVP formation.  
1.5.2 Postnatal retina  
1.5.2.1 Retinal vascularisation 
Another well established model of developmental angiogenesis is the 
postnatal murine retina (Gariano and Gardner, 2005). Thus, in mice, the retina is 
vascularised by sprouting angiogenesis from postnatal day (P) 0 onwards, when 
vessels from the artery at the optic nerve head spread radially just underneath the 
inner limiting membrane, the vitreal surface of the retina (Figure 1.5B) (Connolly et 
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al., 1988). This is in contrast to humans, where retinal vascularisation begins at 36 
weeks of gestation and is complete at birth (reviewed in Stahl et al., 2010). In 
contrast to the hindbrain, retinal angiogenesis and arterial specification occur 
concomitantly in the retina, resulting in the remodelling of the capillary bed soon 
after it has formed (Fruttiger, 2007). The extending angiogenic sprouts of the retina 
rely on astrocytes, which form a mesh preceding the vascular front and guide 
growing vessels by providing components of the ECM (Dorrell et al., 2009, Scott et 
al., 2010, Stenzel et al., 2011). The vascular network continues sprouting to form a 
dense planar network, which reaches the periphery of the retina around P7. This 
network also termed the primary plexus extends in a 2D fashion, as VEGF-A in the 
underlying layers is titrated by VEGFR2 expressed by the developing neurons 
(Okabe et al., 2014). Nevertheless, after P7 VEGFR2 expression in the underlying 
layers drops and the retinal vessels start sprouting into the deeper layers forming first 
the deep vascular plexus and then the intermediary plexus. All three plexi are 
completed by P21 (Milde et al., 2013). The primary plexus can easily be analysed 
after dissecting as published previously (Powner et al., 2012), staining vessels with a 
lectin such as IB4 or antibodies, and then flatmounting and imaging the retina 
(Figure 1.5B). 
1.5.2.2 Advantages of the retina as a model system for postnatal angiogenesis 
In comparison to the SVP of the hindbrain, the primary plexus of the retina 
develops in a 2D manner. This greatly facilitates the visualisation of the vasculature 
in flatmounted dissected retinas and the analysis of vascular phenotypes. Thus, 
vascular deficiencies can manifest as a reduced extension of the vascular plexus 
indicative of impaired EC proliferation or migration, as well as decreased branching 
suggesting defects in tip cell specification. In contrast to the hindbrain, in the retina 
arteriovenous specification occurs concomitantly with the formation of the capillary 
vessel plexus. Whilst this feature complicates the quantitation of angiogenic 
sprouting, it allows the analysis of arteriovenous differentiation. Thus, the retinal 
model has been used to demonstrate the importance of molecules such as SOX17 and 
the VEGF-A/NRP1 pathway for arteriovenous specification (Corada et al., 2013, 
Stalmans et al., 2002, Fantin et al., 2014). A specific feature of the murine retina as a 
model for angiogenesis is that vascularisation occurs postnatally, and thus this model 
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is not suitable for the analysis of mutants that are lethal antenatally. Nevertheless, 
certain genes for which the full knockout is embryonic lethal can be investigated 
postnatally by using tissue-or ligand-specific mutations, or deleting the gene 
postnatally (see 2.2.1.5 and 2.2.1.6). For instance, Nrp1-nulls die at E12.5 (Kawasaki 
et al., 1999), whereas Nrp1
Vegfa/Vegfa
 mutants survive until P14 (Fantin et al., 2014). 
Furthermore, endothelial-specific NRP1 mutants die perinatally (Gu et al., 2003); 
however, the postnatal deletion of endothelial NRP1 (Pdgfb-Cre
ERT
;Nrp1
fl/fl
) allowed 
the demonstration that NRP1 is required for angiogenesis in the postnatal retina 
(Raimondi et al., 2014).  
The fact that the retina is vascularised postnatally also has the advantage that 
it allows the manipulation of vascular development with compounds and 
environmental factors. For instance, the retina has been used to show that Notch and 
ABL inhibitors are important for angiogenesis (Suchting et al., 2007, Raimondi et al., 
2014). Furthermore, oxygen levels have been shown to affect retinal vascularisation 
by modifying VEGF-A levels (Shortt et al., 2004, McColm et al., 2004, Scott et al., 
2010) (see 1.5.2.3).  
1.5.2.3 The retina as a model for pathological angiogenesis: Oxygen-induced 
retinopathy (OIR) 
Besides being a model for normal angiogenesis, the mouse retina can also be 
used as a tool to investigate pathological angiogenesis. In the OIR model, P7 pups 
are subjected to hyperoxia (>80% oxygen) for five days, which results in the 
regression of the vessels within the central retina (vaso-obliteration) (Figure 1.5C). 
Thus, the increase in the partial pressure of oxygen results in vasoconstriction, as 
well as capillary regression to regulate oxygen levels. Subsequently, the pups are 
returned to normoxia (20% oxygen) for six days (P12-P17), which renders the vaso-
obliterated area of the retina hypoxic and promotes the secretion of pro-angiogenic 
factors such as VEGF-A from Müller and glial cells (Ozaki et al., 1999). This excess 
of pro-angiogenic factors induces the formation of normal as well as abnormal 
neovascular tufts (Figure 1.5C) (Alon et al., 1995, Scott et al., 2010, Pierce et al., 
1995). These vascular tufts extend into the normally avascular vitreous and resemble 
neovascular lesions associated with retinopathy of prematurity. Thus, premature 
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babies, which are born before their retinas are fully vascularised, are often placed 
into high oxygen chambers to provide adequate oxygenation despite their immature 
lungs (reviewed in Tin and Gupta, 2007). Nevertheless, as seen in the OIR model the 
high oxygen levels cause vaso-obliteration and thus often result in the formation of 
neovascular lesions once the infant is returned to ambient oxygen levels (Chen and 
Smith, 2007, Pau, 2008, Phelps, 1995). 
The OIR model thus presents an excellent model to analyse vessel regression 
and hypoxia-induced vessel formation, which is relevant to human disease. Vessels 
can be analysed easily by staining with IB4 or antibodies against endothelial 
epitopes, flatmounting and imaging (Figure 1.5C). 
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Figure 1.5. Mouse models of developmental and pathological angiogenesis 
Hindbrain model: Schematic representation of hindbrain dissection from E12.5 embryo. Low 
and high magnification of E12.5 hindbrain immunolabelled for PECAM (A). Retina model: 
Schematic representation of P7 eye dissection and retina. Low and high magnification of P7 
retina immunolabelled with IB4 (B). OIR model: Schematic representation of oxygen 
induced vaso-obliteration and vascular tufts formed in normoxia. Low and high 
magnification of P17 retina following OIR immunolabelled with IB4. Arrowheads indicate 
neovascular tufts. HB: hindbrain, a: artery, v: vein. Scale bars: 250 µm, 50 µm (A); 200 µm, 
20 µm (B,C). 
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1.6 Aims of this Study 
The formation of the vasculature is critical for life of higher vertebrates and 
relies on complex cellular as well as molecular interactions. The aims of my PhD 
research have been to contribute to our understanding of cardiovascular development 
by firstly investigating the role of the transmembrane receptor NRP1 in angiogenesis 
and cardiac OFT remodelling, and secondly by examining whether endothelial 
labelling of the Csf1r-Cre transgene indicates the contribution of a novel type of 
vascular precursor to angiogenesis.  
Nrp1 knockout mice display severe cardiovascular defects, such as impaired 
angiogenesis and unseptated OFTs (see 1.2.3) (Kawasaki et al., 1999). The main 
consensus by which NRP1 functions during angiogenesis was that endothelial NRP1 
binds to VEGF-A, which enhances VEGF-A signalling through VEGFR2 (Soker et 
al., 2002). Nevertheless, NRP1 is also expressed by non-ECs (e.g. Tillo et al., 2015, 
Fantin et al., 2010). Furthermore, previous observations of mouse mutants with 
defective VEGF-A binding to NRP1 (Nrp1
Vegfa/Vegfa
) by our group had revealed that 
these mice are viable; however, they demonstrated increased perinatal mortality. 
Thus, using cell type-specific NRP1 mouse mutants my first aim was to elucidate the 
function of non-endothelial NRP1 during vascular development by analysing the 
vascular phenotypes of these mice (see Chapter 3). In addition, I sought to 
investigate the cause underlying the reduced survival of Nrp1
Vegfa/Vegfa
 mice after 
birth (see Chapter 3). 
NRP1 mutants also display defective OFT remodelling, which was previously 
attributed to VEGF-A signalling through NRP1 on the OFT endothelium and cardiac 
NCC-derived NRP1 being essential for the SEMA3C-mediated migration of these 
cells into the OFT (Gu et al., 2003, Toyofuku et al., 2008). By analysing cell type- 
and ligand-specific Nrp1 mutants, my second aim has been to understand the role of 
endothelial versus cardiac NCC-derived NRP1, and SEMA3C versus VEGF-A 
binding to NRP1 during OFT remodelling (see Chapter 4). Furthermore, by 
examining serial OFT sections of these mutants, I have sought to understand which 
specific aspect of OFT septation was defective, including endothelial fusion, 
endoMT and cardiac NCC migration.  
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Preliminary observations by Dr Fantin, a prior PhD student in the Ruhrberg 
lab, had shown that a Csf1r-Cre transgene could be used to lineage trace a subset of 
ECs. This finding was reminiscent of a previous publication by Kubota et al. (2011), 
which suggested that P0-Cre labelled the vascular endothelium, because the 
transgene was targeting a tissue-resident vascular progenitor (Kubota et al., 2011). 
Thus, my third aim was to substantiate Dr. Fantin’s observations and relate them to 
the work of Kubota et al. (2011) (see Chapter 5). I, therefore, carried out Csf1r-Cre 
lineage tracing in two tissues undergoing developmental angiogenesis: the embryonic 
hindbrain and postnatal retina (see 1.5). I further investigated the origin and 
reliability of endothelial lineage tracing with Csf1r-Cre by analysing CSF1R 
expression patterns and examining additional Csf1r-Cre transgenes and alternative 
lineage reporter alleles. Furthermore, I analysed whether macrophages contributed to 
the endothelium during angiogenesis by examining Csf1r-Cre labelling in mice 
lacking macrophages (Pu.1
-/-
). Finally, I examined whether the Csf1r-Cre lineage 
trace labelled vascular precursor cells similar to those labelled by the P0-Cre 
transgene or isolated from the blood using EPC-specific markers.  
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Chapter 2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 General Laboratory Materials 
All chemicals were obtained from Sigma Aldrich, except where indicated 
otherwise. Glassware was obtained from VWR International and plastic items were 
purchased from Corning or Nunc. 
2.1.2 General Laboratory Solutions 
Water was used after purification by a MilliRo 15 Water Purification System 
(Millipore) and, where necessary, water was further purified using the Milli-Q 
reagent Grade Water Ultrafiltration System (Millipore). RNAse and DNAse-free 
water was supplied by Sigma and absolute ethanol, methanol and isopropanol were 
obtained from Fischer Scientific.  
1X PBS 137 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 
7.2 
4% PFA 4% (w/v) formaldehyde, prepared freshly from paraformaldehyde, in 
1X PBS 
1X PBT 1X PBS + 0.1% (v/v) Triton X-100 
1X TE  10 mM Tris-HCl, 1 mM EDTA, pH 8.0 
1X TAE 40 mM Tris-acetate, 1 mM EDTA, pH 8.0 
1X TBS 25 mM Tris pH 7.5, 150 mM NaCl, 3 mM KCl 
 74 
 
2.2 Methods 
2.2.1 Animal Methods 
All animal research was carried out according to institutional and United 
Kingdom Home Office guidelines. 
2.2.1.1 Animal Maintenance and Husbandry 
To generate embryos of a defined gestational age, mice were paired in the 
evening and the presence of a vaginal plug the following morning was defined as 
E0.5.  
2.2.1.2 Genetic mouse strains 
All mice were on mixed CD1 and C57Bl/6 genetic backgrounds. Please see 
table 2.1 for details on the genetic mouse strains used. 
  
 75 
 
Table 2.1: Genetic mouse strains and published reference 
Genetic mutation Reference 
Nrp1-null (Nrp1
-/-
) (Kitsukawa et al., 1997) 
Nrp1 flox (Nrp1
fl/fl
) (Gu et al., 2003) 
Nrp1
Sema/Sema
 (Gu et al., 2002) 
Nrp1
Vegfa/Vegfa
 (Fantin et al., 2014) 
Nrp2-null (Nrp2
-/-
) (Giger et al., 2000) 
Plxnd1-null 
(Plxnd1
-/-
) 
(Gitler et al., 2004) 
Tie2-Cre (Kisanuki et al., 2001) 
Wnt1-Cre (Jiang et al., 2000) 
Nes-Cre (Petersen et al., 2002) 
Sm22a-Cre (Holtwick et al., 2002) 
Csf1r-Cre (Deng et al., 2010) 
Csf1r-eGFP (Sasmono et al., 2003) 
Csf1r-Cre
ERT
 (Qian et al., 2011) 
Pu.1 null (Pu.1
-/-
) (McKercher et al., 1996) 
Vegfa
120/120
 (Ruhrberg et al., 2002) 
Vegfa
LacZ
 (Miquerol et al., 1999) 
Vegfa
fl/fl
 (Gerber et al., 1999) 
Sema3c flox 
(Sema3c
 fl/fl
) 
Unpublished 
Rosa
Yfp/Dta/LacZ
 
(Soriano, 1999, Srinivas et al., 
2001, Ivanova et al., 2005) 
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2.2.1.3 Tissue-specific gene targeting 
To delete genes in specific tissues, a genetic approach based on the Cre/lox 
recombination system was used (reviewed in Nagy, 2000). This method utilises the 
properties of the enzyme CRE recombinase, which was initially discovered in the P1 
bacteriophage. This enzyme catalyses the recombination between its two 34 bp 
recognition sites, which are called loxP (locus of recombination) sites (Hamilton and 
Abremski, 1984). By flanking a DNA sequence with these sites, the enzyme is able 
to bind and create either an inversion or deletion of the sequence depending on the 
orientation of the loxP sites. This recombination can be made tissue-specific by 
creating a Cre transgene under the control of a tissue-specific promoter. Thus, the 
enzyme will only be expressed and sequence deletion will only occur in the cell type 
of interest. For instance, to delete Nrp1 in ECs, mice with a Cre transgene under the 
control of the endothelial Tie2 promoter (Kisanuki et al., 2001) were mated to mice, 
which were heterozygous for the Nrp1-null allele. The Tie2-Cre;Nrp1
+/-
 offspring 
were then mated with mice homozygous for the “floxed” NRP1 allele (Nrp1fl/fl) to 
generate Tie2-Cre;Nrp1
fl/-
 mice.  
2.2.1.4 Tissue-specific lineage trace 
A similar approach was utilised to perform a tissue-specific lineage trace. In 
this case mice containing a Cre transgene such as Tie2-Cre or Csf1r-Cre were mated 
to mice possessing the Rosa
Yfp
 (Soriano, 1999) or Rosa
LacZ
 reporter allele. These 
alleles of the Rosa locus contain the sequence for the enhanced yellow fluorescent 
protein (Yfp) or β galactosidase enzyme (lacZ) downstream of a stop-cassette flanked 
by two loxP sites, which has been knocked in to the constitutively expressed Rosa26 
locus. Thus, YFP and β galactosidase are only expressed in cells once the Cre 
transgene has excised the stop codon. Furthermore, as this genetic event is 
permanent, the progeny of these cells are also YFP/ β galactosidase-positive.  
2.2.1.5 Cre-mediated in vivo genetic ablation 
In order to ablate a specific cell lineage, Cre transgenes such as Csf1r-Cre 
were crossed to mice containing the Rosa
Dta
 allele. Analogous to the Rosa
Yfp
 or 
Rosa
LacZ
 reporter, this allele only expresses the diphtheria toxin fragment A (DTA) 
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after Cre-mediated stop cassette excision (Ivanova et al., 2005). The expression of 
the toxin results in cell death and thus allows the in vivo ablation of a transgene-
specific lineage (Breitman et al., 1990, Ivanova et al., 2005).  
2.2.1.6 Temporally regulated Cre activation 
To temporally control the expression of the Csf1r-Cre, we obtained mice 
containing the Csf1r-Cre
ERT
 transgene. This transgene consists of a Cre mutant 
murine oestrogen receptor (ERT) double-fusion protein (Cre
ERT
) under the control of 
the Csf1r promoter (see 2.2.1.3). Unlike the normal oestrogen receptor, which binds 
to 17'-oestradiol, the CRE
ERT
 recombinase binds to the synthetic compound 4-
hydroxytamoxifen (tamoxifen) (Danielian et al., 1998). CRE
ERT
 is normally 
sequestered within the cytoplasm by the cytoplasmic protein, HSP90 (Mattioni et al., 
1994, Picard, 1994); however, upon tamoxifen binding to the receptor, this 
interaction is prevented and thus allows the enzyme to translocate to the nucleus. 
Therefore, Cre-mediated DNA recombination will only occur once tamoxifen has 
been administered to the mouse. To analyse the postnatal lineage trace of Csf1r-
Cre
ERT
, I collaborated with Dr Alessandro Fantin, who prepared the tamoxifen 
solution by dissolving 4-OHT in absolute ethanol at 50 mg/ml and diluting it in 
peanut oil to 5 mg/ml. A volume of 25 µl per gram of body weight was injected 
intraperitoneally into Csf1r-Cre
ERT
;Rosa
Yfp
 pups from P4-P6. 
2.2.1.7 Compound mutant mice 
To generate compound Nrp1
Sema/Sema
;Nrp2
-/-
 mouse mutants, mice 
heterozygous for the Nrp1
Sema
 mutation were crossed to mice heterozygous for the 
Nrp2-null allele. Subsequently, offspring heterozygous for both mutations were 
mated providing mice homozygous for both mutant alleles at a probability of 1/16. 
To generate Wnt1-Cre;Nrp1
fl/fl
;Nrp2
-/-
 compound mutants, mice carrying the Wnt1-
Cre transgene were mated the mice heterozygous for the Nrp2-null allele. The 
resulting offspring, which carried both the Wnt1-Cre and the Nrp2-null allele, were 
then mated to mice homozygous for the conditional Nrp1 allele (Nrp1
fl/fl
). By 
crossing offspring from this cross to Nrp2
+/-
;Nrp1
fl/+
 compound mutants, Wnt1-
Cre;Nrp1
fl/fl
Nrp2
-/-
 were generated at a possibility of 1/16.  
 78 
 
2.2.1.8 Genotyping of mouse strains 
The majority of genotyping was performed by Laura Denti with the 
assistance of Andy Joyce and Valentina Senatore from the Ruhrberg group. Where 
conditional Sema3c (Sema3c
fl/fl
) mice were used, genotyping was performed by Dr 
Amelie Calmont from Prof Pete Scambler’s group (ICH, UCL). DNA was extracted 
either from embryonic tail snips or adult ear punches using a previously published 
method (Laird et al., 1991). Briefly, cells were lysed by incubating them overnight at 
55°C with gentle agitation in 500 µl of lysis buffer (100 mM Tris-HCl pH 8.5, 5 mM 
EDTA, 0.2% SDS, 200 mM NaCl) with freshly added proteinase K (100 µg/ml). 
Following enzymatic digestion, DNA was precipitated by adding 1 ml of 100% 
ethanol, and collected following a 3 min centrifugation at 13000 rpm. DNA was 
resuspended in 70% ethanol and collected following another centrifugation using the 
aforementioned conditions. Subsequently, DNA was air-dried for 10 min at RT and 
reconstituted in 100 µl TBE buffer (2 mM Tris pH 8.0, 0.2 mM EDTA) for 5-30 min 
at 55°C. 
The genomic DNA was amplified by PCR using primers specific to the DNA 
sequence of interest (see table 2.2) on a BioRad C1000 Touch Thermal Cycler. Per 
PCR reaction, 2 µl of DNA were added to 8 µl Megamix (Microzone, containing Taq 
polymerase, 1.1X reaction buffer, 220 µM dNTPs, loading dye) and 0.1 µg of both 
the forward and reverse primer using the relevant annealing temperature and number 
of amplification cycles (see table 2.3, 2.4). 
The PCR products were analysed using electrophoresis through a 2% (w/v) 
agarose (BDH Electran) in TAE gel containing 2 µl of nucleic acid staining solution, 
RedSafe (iNtRON). For each reaction, a negative control consisting of 2 µl sterile 
water instead of the DNA solution was used, as well as a positive control comprising 
of 2 µl previously validated DNA.  
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Table 2.2: Oligonucleotide primers used for genotyping 
Gene Primer Sequence 
Nrp1, 
Nrp1
fl
 
NP1Neo 5’-CGTGATATTGCTGAAGAGCTTGGC-3’ 
NP1F 5’-CAATGACACTGACCAGGCTTATCATC-3’ 
NP1R 5’-GATTTTTATGGTCCCGCCACATTTGTC-3’ 
Nrp1
Sema
 
P1 5’-AGGCCAATCAAAGTCCTGAAAGACAGTCCC-3’ 
P2 5’-AAACCCCCTCAATTGATGTTAACACAGCCC-3’ 
Nrp1
Vegfa
 
Zac1 5’-ATTGCTGGGATTACAGGCGTGAACC-3’ 
Zac2 5’-GTGTGCTGATCTGGGAAGGTAGGCAG-3’ 
Zac3 5’-GGAGACGGGAGCAACCAGAGTGC-3’  
Nrp2 
NP2Neo 5’-CAGTGACAACGTCGAGCACAG-3’ 
NP2F 5’-TCAGGACACGAAGTGAGAAGC-3’ 
NP2R 5’-GCTCAATGTAGCTAAGTGGAGGG-3’ 
Plxnd1 
PD1WF 5’-GGTTAAGGTCGAAGGTGAAGAGCTT-3’ 
PD1WR 5’-ACCGCAGAACCGGTCACCGTGTT-3’ 
PD1MF 5’-CTCTCGCCGCCTCC-3’ 
PD1MR 5’-CCATTGCTCAGCGGTGCTGTCCATC-3’ 
Tie2-Cre 
Tie2Pro 5’-CCCTGTGCTCAGACAGAAATGAGA-3’ 
Cre2 5’-GTGGCAGATGGCGCGGCAACACCATT-3’ 
Wnt1-Cre 
Wnt1F 5’-TAAGAGGCCTATAAGAGGCGG-3’ 
Wnt12 5’-GTGGCAGATGGCGCGGCAACACCATT-3’ 
Nes-Cre 
Nes8F1 5’-GAATACCCTCGCTTCAGCTC-3’ 
CreB 5’-GCATTTTCCAGGTATGCTCAG-3’ 
Csf1r-Cre, 
Csf1r-Cre
ERT 
Sm22a-Cre 
FMS-F 5’-GCCACCATGTGTCCGTGCTT-3’ 
FMS-R 5’-ACCCAGAGCCCCCACAGATA-3’ 
Csf1r-eGFP 
EGFP-F 5’-CCAGGAGCGCACCATCTTCT-3’ 
EGFP-R 5’-GTAGTGGTTGTCGGGCAGCAG-3’ 
Pu.1 KO2 5’-GCCCCGGATGTGCTTCCCTTATCAAAC-3’ 
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920 5’-GCCCCGGATGTGCTTCCCTTATCAAAC-3’ 
Vegfa
120
 
Neo2 5’-CGCACGGGTGTTGGGTCGTTTGTTCGG-3’ 
120F2 5’-CAGTCTATTGCCTCCTGACCTTCAGGGTC-3’ 
120E2 5’-TTCAGAGCGGAGAAAGCATTTGTTTGTCCA-3’ 
Vegfa
LacZ
 
120R2 5’-CTTGCGTCCACACCGTCACATTAAGTCAC-3’ 
V-WT 5’-ATGTGACAAGCCAAGGCGGTG-3’ 
V-Ex8 5’-TGGCGATTTAGCAGCAGATA-3’ 
Vegfa
 fl
 
V-LacZ 5’-GGTAGGGGTTTTTCACAGAC-3’ 
VF-F 5’-CCTGGCCCTCAAGTACACCTT-3’ 
VF-R 5’-TCCGTACGACGCATTTCTAG-3’ 
Sema3c
fl 
 
SC-F 5’-GAATCTGGCAAAGGACGATG-3’ 
SC-R 5’-GACCACTGGGCTTGAGAGAG-3’ 
Rosa
Yfp/LacZ/Dta
 
WT F1 5’-AAAGTCGCTCTGAGTTGTTAT-3’ 
WT R1 5’-GGAGCGGGAGAAATGGATATG-3’ 
KO R1 5’-GCGAAGAGTTTGTCCTCAACC-3’ 
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 Table 2.3: PCR parameters for specific primer pairs 
Gene Hot Start Denaturing Annealing Extension Cycles End 
Nrp1, 
Nrp1
fl
 
94°C, 3 min 94°C, 40 s 66°C,1 min 72°C, 1 min 35 72°C, 5 min 
Nrp1
Sema
 94°C, 3 min 94°C, 30 s 69°C,1 min 72°C, 1 min 35 72°C, 5 min 
Nrp1
Vegfa
 94°C, 3 min 94°C, 1 min 66°C, 30 s 72°C, 1 min 35 72°C, 5 min 
Nrp2 94°C, 3 min 94°C, 1 min 66°C,1 min 72°C, 1 min 35 72°C, 5 min 
Plxnd1 94°C, 3 min 94°C, 1 min 68°C,1 min 72°C, 1 min 35 72°C, 5 min 
Tie2-Cre 94°C, 3 min 94°C, 1 min 67°C,1 min 72°C, 1 min 32 72°C, 5 min 
Wnt1-Cre 94°C, 3 min 94°C, 40 s 62°C,1 min 72°C, 1.5 min 35 72°C, 5 min 
Nes-Cre 94°C, 3 min 94°C, 1 min 62°C,1 min 72°C, 1 min 32 72°C, 5 min 
Sm22a-Cre 94°C, 3 min 94°C, 1 min 62°C,1 min  72°C, 1.5 min 35 72°C, 5 min 
Csf1r-Cre, 
Csf1r-CreERT 
94°C, 3 min 94°C, 1 min 61°C,1 min 72°C, 1.5 min 35 72°C, 5 min 
Csf1r-eGFP 94°C, 3 min 94°C, 1 min 66°C, 1 min 72°C, 1.5 min 35 72°C, 5 min 
Pu.1 94°C, 3 min 94°C, 40 s 60°C, 1 min 72°C, 2 min 35 72°C, 5 min 
Vegfa
120
 94°C, 3 min 94°C, 1 min 52°C, 1 min 72°C, 1 min 5 72°C, 5 min 
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60°C, 1 min 72°C, 1 min 28  
Vegfa
LacZ
 94°C, 3 min 94°C, 1 min 55° C,1 min 72°C, 1 min 35 72°C, 5 min 
Vegfa
fl
 
94°C, 3 min 94°C, 1 min 52°C, 1 min 
60°C, 1 min 
72°C, 1 min 
72°C, 1 min 
5 
28 
72°C, 5 min 
 
Sema3c
fl
 94°C, 3 min 94°C, 1 min 62 C, 1 min 72°C, 1 min 35 72°C, 5 min 
Rosa
Yfp/LacZ/Dta
 94°C, 3 min 94°C, 1 min 61°C, 1 min 72°C, 1 min 35 72°C, 5 min 
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2.2.1.9 Tissue fixation 
Pregnant dams were culled by cervical dislocation in accordance to Home 
Office and institutional animal guidelines. The gravid uterus was excised and placed 
in ice-cold 1X PBS. Using fine Dumont forceps, the embryos were dissected from 
the uterus and yolk sac. To remove hindbrains, embryos were dissected as published 
previously (Plein et al., 2015b, Fantin et al., 2013c). Retinal dissections were 
performed as outlined in (Pitulescu et al., 2010). 
Retinas and embryonic tissue pre mid-gestation were fixed in 4% PFA for 2 h 
at 4°C, mid-embryonic and postnatal tissues were fixed overnight at 4°C. Following 
fixation, all samples were washed twice with 1X PBS for 5 min at RT to remove any 
residual PFA and either processed immediately or stored in 1X PBS at 4°C (short-
term). Samples stored for the long-term were dehydrated down a methanol gradient 
comprised of 25%, 50% and 75% (v/v) absolute methanol in 1X PBT and then stored 
in 100% methanol at -80°C until use. 
2.2.1.10 Oxygen-induced retinopathy (OIR) 
The mouse model of OIR was performed as published previously (Connor et 
al., 2009). Briefly, P7 pups and their mothers were subjected to 80% oxygen for 5 
days, which results in vaso-obliteration (Smith et al., 1994). At P12 mice were 
returned to normoxia (21%), which causes both normal vessel re-growth, as well as 
the formation of vascular tufts. Pups were culled at P17 for retinal dissection, as 
vascular tuft formation is maximal at this time point, before regressing between P17 
and P25.  
2.2.2 Immunolabelling 
2.2.2.1 Cryosectioning 
After fixation embryos were washed in 1X PBS and dehydrated in 20% 
sucrose in 1X PBS for cryoprotection. Once embryos had sunk in the solution, 
samples were placed into optimal cutting temperature embedding compound (OCT, 
Sakura Tissue-Tek) and rapidly frozen on dry ice. Following this step, samples were 
stored at -20°C for the short term (-80°C for long-term storage) or immediately 
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sectioned into 20  m thick slices using a histology cryostat (Leica CM1850). The 
sections were collected on Superfrost Plus slides (VWR International), air-dried for 
an hour at RT and then either stored at -20°C or immediately processed for 
immunolabelling. 
2.2.2.2 Vibratome sectioning 
Pre-stained hindbrains were washed in 1X PBS and embedded in 3% molten 
agarose. After the agarose had set, samples were sectioned at 100 µm using the 
Vibratome 1000Plus Sectioning System (IntraCel). Sections were collected on glass 
slides and mounted using 90% (v/v) glycerol in 1X PBS. 
2.2.2.3 Immunolabelling of wholemounts 
Samples were initially washed with 1X PBT for 5 min at RT to permeabilise 
the tissue and allow antibody penetration. Samples to be stained with horseradish 
peroxidase (HRP)-tagged secondary antibodies were bleached with hydrogen 
peroxide (1% (v/v) H202 in 1X PBT) for 30 min at RT to remove any endogenous 
peroxidases and washed twice with 1X PBT. Subsequently, samples were blocked 
using a blocking solution consisting of either 10% (v/v) NGS in 1X PBT or 10% 
(v/v) serum free block (Dako) in 1X PBT depending on the primary antibody used in 
the following steps (see table 2.4). After blocking, the primary antibody/ies were 
diluted in the aforementioned blocking solutions (see table 2.4) and applied to 
sections for 2 h at RT or overnight at 4°C. The antibody solution was removed and 
slides were washed 3 times with 1X PBT for 10 min each at RT. Secondary 
antibodies raised against the host animal of the primary antibody were diluted 1:200 
in either 10% NGS or 10% serum free block (see table 2.4 for primary antibody host 
species and appropriate blocking solutions). Sections were incubated with secondary 
antibody solution for 1 h at 4°C in the dark to protect fluorophores. Samples were 
washed 3 times with 1X PBS for 10 min and either post-fixed for 10 min with 4% 
PFA at RT or HRP-labelled samples were developed using diaminobenzidine 
(DAB)and hydrogen peroxide (SigmaFast) followed by post-fixing. Samples thinner 
than 50 µm were flatmounted directly with a glass cover slip on a glass slide using 
the SlowFade antifade reagent kit (Life Technologies). For samples thicker than 50 
µm, such as the hindbrain, several layers of black electrical tape were stuck on a 
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glass slide. Using a scalpel, pockets of an appropriate size were cut and samples were 
placed inside and mounted using the SlowFade antifade reagent kit. 
2.2.2.4 Immunolabelling of sections 
Slides were initially washed with 1X PBS to remove the OCT. Using a PAP-
PEN (Daido Sangyo) a hydrophobic barrier was drawn along the edge of the slide, 
which prevents loss of staining solution. Subsequent staining steps were performed, 
as detailed in section 2.2.2.3. Following the staining procedure, sections were 
mounted using Mowiol solution. Mowiol solution was made up by incubating 6 g of 
glycogen and 2.4 g of Mowiol 4-88 (Calbiochem) in 6 ml of water for 2 h at RT and 
then adding 12 ml of Tris (0.2 M, pH 8.5) and 2.5% (w/v) DABCO, and incubating 
for several hours at 55°C until dissolved. 
2.2.2.5 Immunofluorescent staining of explants 
Explants were washed twice with 1X PBS and fixed for 15 min on ice in 4% 
PFA. Samples were blocked using 10% NGS in 1X PBT for 30 min at RT and 
incubated in the primary antibody solution, which was prepared according to 
guidelines listed in table 2.3 for 2 h at RT. After 3 10 min washes with 1X PBT at 
RT, the secondary antibody solution containing the antibody at a dilution of 1:200 
was added to the explants for 1 h at RT. After 3 10 min washes with 1X PBS, 
samples were post fixed for 5 min with 4% PFA at RT. Using fine forceps, collagen 
gels were carefully removed from the 24-well plate and mounted on a glass slide 
using Mowiol solution.  
2.2.2.6 BrdU labelling 
To analyse cell proliferation in vivo, bromodeoxyuridine (BrdU, Sigma) was 
injected into mice. BrdU is a synthetic analogue of thymidine and thus gets 
incorporated during DNA synthesis of dividing cells. Pups were injected 
intraperitoneally with 300 mg/kg of BrdU (10 mg/ml) and culled at the required time. 
Immunostaining for BrdU was carried out at described in section 2.2.2.3; however, 
the BrdU antibody can only access the BrdU after DNA has been denatured. 
Therefore, staining for BrdU first included a denaturation step, which constituted of 
serial incubations with 1 M HCl for 10 min on ice, followed by 2 M HCl for 10 min 
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at RT and then 10 min at 37°C. Subsequently, the acid was neutralised by incubating 
samples in borate buffer (0.1 M) for 10 min at RT. The denaturation step is damaging 
for many epitopes and thus immunostaining for other markers was performed first, 
followed by the acid treatment and then the BrdU antibody staining. 
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Table 2.4: Primary antibody parameters  
Primary Antibody 
 
Company Dilution Species Secondary 
Antibody 
 
Blocking Solution 
IB4 Sigma 1:250 n/a (biotinylated) strepdavidin 10% NGS in PBT 
anti-BrdU Abcam 1:200 rat goat anti-rat 10% NGS in PBT 
anti-activated 
CASPASE 3 
Cell Signalling 1:200 rabbit goat anti-rabbit 10% NGS in PBT 
anti-CD45 Serotec 1:200 rat goat anti-rat 10% NGS in PBT 
anti-CSF1R Santa Cruz 1:500 rabbit goat anti-rabbit 10% NGS in PBT 
anti-ENDOMUCIN Santa Cruz 1:50 rat goat anti-rat 10% NGS in PBT 
anti-F4/80 Serotec 1:500 rat goat anti-rat 10% NGS in PBT 
anti-GFAP Abcam 1:500 chick goat anti-chick 10% NGS in PBT 
anti-KIT BD Biosciences 1:1000 rat/biotinylated goat anti-
rat/strepdavidin 
10% NGS in PBT 
anti-NG2 Millipore 1:200 rabbit goat anti-rabbit 10% NGS in PBT 
anti-NRP1 R&D Systems 1:100 goat FAB anti-goat  10% Dako in PBT 
anti-PECAM BD Pharmingen 1:200 rat goat anti-rat 10% NGS in PBT 
FITC-conjugated Sigma 1:40 n/a n/a 10% NGS in PBT 
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anti-phalloidin 
anti-PLXNA2  R&D Systems 1:100 goat FAB anti-goat  10% Dako in PBT 
anti-PHH3 Millipore 1:400 rabbit goat anti-rabbit 10% NGS in PBT 
anti-SLUG Cell Signalling 1:100 rabbit goat anti-rabbit 10% NGS in PBT 
cy3-conjugated anti- 
smooth muscle actin 
Sigma 1:200 n/a n/a 10% NGS in PBT 
FITC-conjugated 
anti-smooth muscle 
actin 
Sigma 1:200 n/a n/a 10% NGS in PBT 
anti-Sm22α Abcam 1:200 rabbit goat anti-rabbit 10% NGS in PBT 
anti-VEGFR2 R&D Systems 1:200 goat FAB anti-goat 10% Dako in PBT 
anti-YFP Aves 1:1000 chick goat anti-chick 10% NGS in PBT 
anti-YFP MBL 1:500 rabbit goat anti-rabbit 10% NGS in PBT 
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2.2.3 Xgal staining 
Xgal staining was used to visualise the expression of the enzyme β-
galactosidase in mice, which had the sequence for this enzyme (lacZ) inserted into a 
gene of interest. Embryos were collected and fixed for 30 min at 4°C. After fixation 
samples were washed 3 times with 0.02% (v/v) NP-40 in 1X PBS for 15 min at RT. 
The staining solution was made up freshly by adding the Xgal reagent (40 mg/ml in 
DMF) at a dilution of 1:40 to the staining buffer (5 mM K3Fe(CN)6, 5 mM 
K4Fe(CN)6.3H20, 2 mM MgCl2, 0.01% (v/v) sodium deoxycholate, 0.02% NP-40 in 
1X PBS). The sample was incubated in the staining solution in the dark at 37°C until 
a sufficient staining intensity was achieved. To stop the reaction, samples were 
briefly washed in 1X PBS and post-fixed for 10 min in 4% PFA. 
2.2.4 AP-binding assay 
Plasmids containing AP only and VEGFA-AP were kindly provided by Prof 
Chenghua Gu.  
2.2.4.1 AP-probe generation 
HEK293 cells were transfected with plasmids containing the VEGFA-AP or 
AP sequence. Briefly, to transfect a 60% confluent T75 flask, 18.75 µg plasmid 
cDNA and 37.5 µl of Lipofectamine (Life Technologies) were each mixed with 750 
µl of DMEM and incubated for 15 min at RT. Subsequently, both solutions were 
mixed together and incubated for 15 min at RT. Following the incubation, the 
previous medium was removed from the T75 flask, and cells were briefly washed 
with PBS. Subsequently, the transfection solution was diluted in a further 7.5 ml of 
DMEM and the solution added to the T75 flask. Cells were incubated with 
transfection solution for 4 h and subsequently the solution was replaced with normal 
growth medium. After 72 h, the medium containing the AP fusion protein was 
collected and used in subsequent experiments.  
2.2.4.2 AP-probe binding  
Following cryosectioning (see 2.2.2.1) sections were briefly fixed with ice-
cold methanol and washed 3 times with AP wash buffer (4 mM MgCl2 in 1X PBS) 
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for 5 min at RT. Sections were then blocked using 10% (v/v) FBS in AP wash buffer 
for 30 min at RT and incubated overnight at 4°C with the medium containing the AP 
fusion protein. Sections were then washed 5 times with PBS for 5 min each at RT 
and the AP probe binding was fixed using 4% PFA for 5 min at RT and subsequently 
washed 3 times with PBS for 5 min each. Next, endogenous phosphatases were 
inactivated by incubating sections within coplin jars containing PBS for 3 h at 65°C. 
After washing with PBS twice, sections were first incubated with AP staining buffer 
(100 mM Tris pH 9.5, 100 mM NaCl, 5 mM MgCl2) and then in AP staining buffer 
with 3.75 µl NBT and 3.5 µl BCIP per 1ml of buffer until the staining developed. 
Subsequently, the reaction was stopped by washing sections with PBS for 5 min and 
the staining was fixed using 4% PFA for 5 min. Finally, slides were mounted with a 
glass coverslip using glycerol. 
2.2.5 In situ hybridisation 
All solutions and equipment used during this protocol were kept RNase-free. 
Plasmid containing the SEMA3C probe sequence was provided by Jonathan Raper.  
2.2.5.1 Bacterial culture of probe plasmid 
2 µl of plasmid were added to 100 µl of chemically competent bacterial cells 
in a 1.5 ml Eppendorf tube and incubated on ice for 10 min. Subsequently, cells were 
heat shocked by placing tubes in a 42°C water bath for 45 s and then on ice for 10 s. 
500 µl of LB medium (10 g/l bacto-tryptone, 5 g/l yeast extract, 10 g/l NaCl, pH 7.5) 
was added and cells were incubated at 37°C for 30 min. Bacterial culture was evenly 
spread over a sterile LB agar plate (LB medium,100 µg/ml ampicillin, 25 g/l agar) 
and incubated overnight at 37°C. The following day, a colony was picked using a 10 
µl pipette tip and grown in 2 ml LB medium containing 100 µg/ml ampicillin for 12 
h at 37°C.  
2.2.5.2 Plasmid digestion 
The plasmid was isolated from cultured bacterial cells by using the Qiagen 
Qiaprep Spin Miniprep kit according to manufacturer’s instructions. Briefly, bacteria 
were pelleted by centrifuging tubes for 5 min at 12000 rpm and resuspended in 250 
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µl of cold P1 buffer. Subsequently, cells were lysed by adding 250 µl of P2 buffer 
and gently mixing the solutions. After no more than 5 min of lysis reaction time, 350 
µl of the neutralizing buffer N3 was added and gently mixed. Next, tubes were 
centrifuged for 10 min at 13000 rpm and the supernatant was applied to a Qiaprep 
spin column. Columns were centrifuged for 1 min at 13000 rpm and washed by 
adding 750 µl PE buffer followed by a centrifugation for 1 min at 13000 rpm. 
Subsequently, columns were air-dried by centrifugation for 1 min at 13000 rpm. 
DNA was eluted by adding 50 µl of water to the column, centrifuging for 1 min at 
13000 rpm and collecting the flow-through in a fresh 1.5 ml eppendorf.  
Plasmid was linearised by digesting it with the appropriate restriction enzyme 
(New England Biolabs). Briefly, 2.5 µl of plasmid, 1 µl of restriction enzyme, 4 µl 
of 10X buffer, 4 µl of 10X BSA and 22 µl of water were incubated at 37°C for 2.5 h. 
DNA was extracted by phenol/chloroform extraction and resuspended in 16 µl of 
water. To validate plasmid, 1 µl of digested DNA was visualised alongside 
undigested plasmid by electrophoresis through a 2% (w/v) agarose (BDH Electran) 
in TAE gel containing 2 µl nucleic acid staining solution, RedSafe (iNtRON). 
2.2.5.3 RNA probe synthesis 
A DIG-labelled RNA probe was synthesised from linearised plasmid by 
incubating 14.5 µl of DNA, 2 µl of 10X buffer, 2 µl of 10X DIG, 1 µl of a promoter-
specific reverse transcriptase enzyme and 0.5 µl RNAse inhibitor (Roche) for 2.5 h 
at 37°C. 1 µl of transcription product was visualised by performing electrophoresis 
through 2% (w/v) agarose (BDH Electran) in TAE gel containing 2 µl nucleic acid 
staining solution, RedSafe (iNtRON). RNA was precipitated by adding 300 µl 
absolute ethanol, 100 µl water, 8 µl 5 M LiCl and incubating at -80°C for 1 h. RNA 
was pelleted by high speed centrifugation at 4°C for 30 min, washed with 70% (v/v) 
ethanol and air-dried for 10 min at RT. RNA was resuspended in 40 µl water and 
stored at -80°C. 
2.2.5.4 In situ hybridisation 
Samples were fixed overnight in 4% PFA at 4°C and dehydrated for 4 h at 
4°C in 20% (w/v) sucrose in 1X PBS. Samples were cryosectioned as described in 
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section 2.2.2.1, air-dried for 30 min at RT and placed into a wet chamber. Each 
section was incubated overnight at 65°C with 200 µl of hybridisation solution 
consisting of 1X Salt solution (200 mM NaCl, 5 mM EDTA, 10 mM Tris-HCl pH 
7.5, 5 mM NaH2PO4.7H20, 5 mM Na2HPO4), 0.1 mg/ml tRNA, 10% (w/v) Dextran 
sulphate, 1X Denhardts and 200 ng/ml of the RNA probe. Dehydration was avoided 
by placing RNAse-free cover slips on top of sections and sealing chamber with tape. 
Sections were washed 3 times for 30 min each in coplin jars containing pre-heated 
washing buffer consisting of 50% (v/v) formamide, 1X SSC pH 4.5, 0.1% (v/v) 
Tween-20 at 65°C. Subsequently, sections were washed twice for 30 min each with 
1X MABT (100 mM maleic acid, 150 mM NaCl, 0.1% (v/v) Tween-20, pH 7.5) at 
RT and blocked with 500 µl of blocking solution consisting of 2% (w/v) blocking 
reagent (Roche), 10% (v/v) NSS in 1X MABT for 1 h at RT. Slides were incubated 
overnight with anti-DIG AP-conjugated antibody (Roche) diluted at 1:1500 in 
blocking solution at 4°C and washed 3 times for 15 min each in 1X MABT at RT. 
Sections were washed twice for 5 min each with NTMT (0.1 M NaCl, 0.1 M Tris-
HCl pH 9.5, 0.05 M MgCl2, 1% (v/v) Tween-20) and incubated in the dark with 
staining buffer (3.5 µl BCIP, 4.5 µl NBT per ml of NTMT) until sufficient staining 
intensity was achieved. The reaction was stopped by washing with water and post-
fixed for 10 min with 4% PFA. Slides were mounted using the SlowFade antifade 
reagent kit.  
2.2.6 Ex vivo endoMT assay  
The endoMT assay was performed as published previously (Bai et al., 2013). 
Briefly, OFTs were dissected from E10.5 embryos and cultured with the 
endocardium facing downwards in DMEM Glutamax (Life Technologies) 
supplemented with 10% (v/v) FBS in a 24-well plate coated with 1 mg/ml collagen 
(BD Biosciences) at 37°C for 72 h. Explants were fixed on ice for 30 min with 4% 
PFA and stained with FITC-conjugated phalloidin to detect F-actin and DAPI to 
identify nuclei. In some experiments, explants were immunolabelled for YFP or 
PECAM. The extent of endoMT was quantified by counting cells contributing to the 
explant outgrowth. In some experiments, wildtype explants were cultured in growth 
medium containing low serum (1%) and treated with 400 ng/ml mouse SEMA3C 
(R&D Systems). Nrp1-null explants were cultured in medium supplemented with 1% 
or 10% serum in the presence or absence of 400 ng/ml SEMA3C. 
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2.2.7 Imaging 
Fluorescently labelled samples were imaged using either an Olympus SZX16 
fluorescent stereomicroscope equipped with a Micropublisher camera (Perkin-
Elmer) or a LSM710 laser scanning confocal microscopes (Zeiss). Images were 
processed with Adobe Photoshop CS4 (AdobeSystems, Inc.). 
2.2.8 Fluorescence-activated cell sorting (FACS) 
Tissues were isolated and homogenised in ice-cold RPMI1640 medium (Life 
Technologies) containing 5% (v/v) FBS, 2.38 g/L HEPES and 1.5 g/L sodium 
hydrogen carbonate according to their tissue-specific requirements. Thus, spleens 
and yolk sacs were homogenised using a scalpel, whereas bone marrow cells were 
obtained by flushing RPMI buffer through isolated femurs using a 23 G needle 
syringe. Blood was collected in heparin-lined tubes (BD Biosciences) and 
erythrocytes were lysed by treating samples for 5 min with red blood cell lysis buffer 
before centrifuging at 1200 rpm for 5 min. The resulting supernatant was used for 
FACS analysis. To generate single cell suspensions, homogenates were passed 
through a 70 µm filter. Cell suspensions were incubated with Fc block (BD 
Biosciences) for 5 min at RT to prevent non-specific binding of antibodies. Samples 
were stained using the following directly conjugated antibodies (BD Biosciences): 
PECAM-APC, CD45-Brilliant Violet 570, KIT-PerCP-Cy5.5 and DAPI to identify 
dying or dead cells. Labelled cells were analysed with a BD LSR II flow cytometer 
(BD Biosciences). Samples from unstained controls and Csf1r-Cre–negative 
embryos were used to identify appropriate fluorescence voltage and gate parameters 
(Tung et al., 2007).  
2.2.9 qRT-PCR 
All solutions were maintained RNAse free. 
2.2.9.1 RNA extraction 
Total RNA was extracted from samples using the RNeasy Micro kit (Qiagen) 
according to manufacturer’s instructions. Briefly, tissue samples were homogenised 
with a 23 G needle syringe in 350 µl of RLT lysis buffer containing β-
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mercaptoethanol (10 µl/ml). An equal volume of 70% (v/v) ethanol was added to 
lysates and solutions were transferred to individual spin columns. RNA was 
transferred to membranes by centrifuging columns at 8500 rpm for 15 s. 
Subsequently, membrane-bound RNA was washed with 350 µl of RW1 buffer. 
Genomic DNA was removed by digestion with DNase 1 solution for 15 min at RT 
and a subsequent wash with 350 µl of RW1 buffer. Membrane-bound RNA was first 
washed with 500 µl of RPE buffer and then 80% (v/v) ethanol. Finally, RNA was 
eluted in 14 µl of RNAse free water. 
2.2.9.2 Reverse transcription 
First strand cDNA synthesis was performed using the SuperScript 
Transcriptase III kit (Invitrogen). For each reaction 500 ng of RNA, 250 ng of 
random primers, 1 µl of 10 mM dNTPs were mixed and the volume was adjusted to 
13 µl with water. The mixtures were heated to 65°C for 5 min and chilled on ice for 
1 min. 4 µl of 5X First-Strand Buffer, 1 µl of 0.1 M DTT, 1 µl of RNaseOUT and 1 
µl of the enzyme SuperScript III (200 units/µl) were added to each sample. 
Subsequently, samples were incubated for 10 min at 25°C, 50 min at 42°C and 10 
min at 70°C. Finally, cDNA quality and concentration was determined using a 
NanoDrop 1000 spectrometer (Thermo Scientific). Unless qPCR reactions were 
performed immediately after, cDNA was stored at -20°C.  
2.2.9.3 qRT-PCR 
qRT-PCR was performed on a 96-well plate using a 7900HT Fast Real-Time 
PCR System (Applied Biosystems). For each reaction 12.5 µl of Power SYBR Green 
PCR Master Mix (Applied Biosystems) were added to 250 ng of sample cDNA and 
1.5 µM of the forward and reverse oligonucleotide primer, which were designed 
using the Primer3 software and synthesised to order by Sigma (see table 2.5). For 
each gene, the reaction was run in triplicate and for each primer pair a no template 
control was included. After a 10 min enzyme activation step at 95°C, 40 PCR cycles 
consisting of a 15 s denaturation step at 95°C followed by an annealing and 
extension step at 60°C were carried out. Data was collected using the Sequence 
Detector Software (SDS version 2.2; Applied Biosystems) and the presence of 
primer dimer formation was excluded by examining dissociation curves and DNA 
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amplification in no template controls. Expression levels were extrapolated from PCR 
data using DART-PCR software (Peirson et al., 2003) and normalised using Gapdh 
expression as a reference. Final data was presented as a fold change from control 
samples.  
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Table 2.5: Oligonucleotide primers designed for qRT-PCR  
Gene Primer Sequence 
Gapdh 
G-F 5’-TGCGACTTCAACAGCAACTC-3’ 
G-R 5’-CTTGCTCAGTGTCCTTGCTG-3’ 
Nrp1 
Np-F 5’-GAAGGTGAAATCGGAAAAGG-3’ 
Np-R 5’-GGTCTGTTGGTTTTGCACAG-3’ 
Slug 
Sl-F 5’-TTCAACGCCTCCAAGAAGCC-3’ 
Sl-R 5’-GGGTAAAGGAGAGTGGAGTGG-3’ 
Snail 
Sn-F 5’-CCCAGTCGCGGAAGATCTT-3’ 
Sn-R 5’-CAGTGGGAGCAGGAGAATGG-3’ 
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2.2.10 Statistics 
Results are expressed as mean ±s.d. For all statistical analyses, I used a 2-tailed, 
unpaired Student’s t test. P values of less than 0.05 were considered significant. 
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Chapter 3 NRP1 IS REQUIRED IN ENDOTHELIUM, BUT 
DOES NOT FUNCTION EXCLUSIVELY AS A VEGF-A 
RECEPTOR DURING DEVELOPMENTAL ANGIOGENESIS 
3.1 Introduction 
NRP1 is critical for developmental angiogenesis, and endothelial Nrp1 
knockouts display similar vascular defects to full Nrp1 knockouts (Kawasaki et al., 
1999, Gu et al., 2003). However, the vascular defects of endothelial Nrp1 mutants 
are less severe than those of full knockouts. It is therefore interesting that NRP1 is 
also expressed by multiple other cell types within the immediate environment of the 
developing vasculature such as macrophages and neurons (Fantin et al., 2010, 
Cariboni et al., 2011). To analyse if NRP1 has non-endothelial functions that 
complement endothelial NRP1 functions during developmental angiogenesis, Dr 
Alessandro Fantin and Dr Joaquim Vieria, former PhD students in the Ruhrberg 
group, decided to closely compare angiogenesis in the hindbrain of cell type-specific 
Nrp1 knockouts affecting ECs, macrophages and neurons (see 1.5.1). This project 
was already in progress when I started my PhD, and I contributed to it by repeating 
the experiments outlined below to generate statistically significant data (Figure 3.1, 
Figure 3.2,Figure 3.3). The results of this study were published in (Fantin et al., 
2013a) (see Appendix – co-authored publications). 
At the start of my PhD, the most widely accepted role for endothelial NRP1 
during developmental angiogenesis had been attributed to the fact that NRP1 binds 
to VEGF164 to initiate complex formation with and therefore signalling through 
VEGFR2 (Soker et al., 2002). However, no study had formally investigated, whether 
NRP1 functioned as a VEGF-A receptor during angiogenesis in vivo. To address this 
question, we collaborated with Prof Ian Zachary (Rayne Institute, UCL), who had 
generated mice with a Y297A mutation in the VEGF-A binding b1 domain of the 
NRP1 receptor (Nrp1
Vegfa/Vegfa
) (see Figure 1.2). This mutation abolished VEGF-A 
binding to NRP1, as demonstrated using VEGF-AP binding assays on Nrp1
Vegfa/Vegfa
 
hindbrains (Fantin et al., 2014). Unexpectedly, analysis of these mice revealed that 
mutants only displayed very mild defects in developmental angiogenesis. Thus, 
quantitation of vessel branchpoints in the SVPs of E12.5 Nrp1
Vegfa/Vegfa
 hindbrains by 
Dr Alessandro Fantin revealed only a small reduction compared to wildtype 
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littermates (Fantin et al., 2014), which was in contrast to the severe vascular 
phenotype observed in Nrp1-nulls and Tie2-Cre;Nrp1
fl/-
 mutants (see Figure 3.1). 
Furthermore, unlike the Nrp1
-/-
 and Tie2-Cre;Nrp1
fl/-
 embryos which are embryonic 
lethal, Nrp1
Vegfa/Vegfa
 mutants were viable at birth. Nevertheless, these mutants 
displayed a reduced birth weight and only 75% survival within the first two weeks 
after birth. My aim was to investigate the underlying cause of the increased mortality 
demonstrated by Nrp1
Vegfa/Vegfa
 mice. The results of this analysis were published in 
(Fantin et al., 2014) (see Appendix – co-authored publications). 
3.2 Results 
3.2.1 NRP1 functions cell autonomously in endothelium to promote 
developmental angiogenesis  
3.2.1.1 EC-specific NRP1 mutants display similar albeit milder vascular defects 
compared to Nrp1-nulls 
The embryonic hindbrain is vascularised by angiogenic vessel sprouts, which 
enter from the pial side at E9.5 and branch to form the SVP from E10.5 onwards 
(Fantin et al., 2013c, Plein et al., 2015b). During this process, NRP1 is expressed on 
ECs, as well as several other cell types closely associated with the developing SVP, 
including tissue macrophages that promote vascular anastomosis and neuronal 
progenitors that secrete VEGF-A (Fantin et al., 2013b).  
To discern the role of endothelial versus non-endothelial NRP1 during 
embryonic angiogenesis, Dr Fantin, and I isolated the hindbrains from endothelial-, 
macrophage-, and neuronal-specific Nrp1 mutants, and visualised the SVPs by 
PECAM immunolabelling. We first examined the SVP in E12.5 Nrp1
-/-
 hindbrains, 
which confirmed a prior report that the vascular network failed to form in Nrp1
-/- 
hindbrains (Gerhardt et al., 2004); instead, vessel sprouts generated vascular tufts 
(clear arrowheads, Figure 3.1D). Furthermore, instead of branching within the 
subventricular zone, vessels formed rare interconnections within the deeper layers of 
the hindbrain (arrows, Figure 3.1D). We next compared this phenotype to hindbrains 
from endothelial-specific Nrp1 knockouts by crossing the conditional Nrp1-null 
allele (Nrp1
fl
) to mice carrying one Nrp1-null allele together with a well-established 
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endothelial-specific transgene, Tie2-Cre. This approach was used in a previous 
publication to efficiently delete Nrp1 in the endothelium of the CNS (Gu et al., 
2003). We decided to generate the endothelial-specific mutants on a Nrp1
fl/-
 
background, because this prior study had reported that Nrp1 targeting was more 
efficient with one conditional Nrp1-null allele on a heterozygous, constitutive Nrp1-
null background (Nrp1
fl/-
) than with two conditional Nrp1-null alleles (Nrp1
fl/fl
) (Gu 
et al., 2003).  
In comparison to Nrp1-nulls, the SVPs of E12.5 Tie2-Cre;Nrp1
fl/-
 mice 
displayed abnormal SVPs. For example, they contained vascular tufts similar to the 
ones observed in the hindbrain vasculature of Nrp1-nulls (clear arrowheads, Figure 
3.1C). Surprisingly, however, the phenotype in the Tie2-Cre;Nrp1
fl/-
 mutants 
appeared to be milder than in the full Nrp1-nulls. Thus, the Tie2-Cre;Nrp1
fl/-
 
hindbrains contained a few vascular branchpoints within the SVPs (clear arrows, 
Figure 3.1C). Quantitation of the number branchpoints in mutant and control Nrp1
fl/- 
hindbrains confirmed that there was a significantly reduced number of branchpoints 
in Tie2-Cre;Nrp1
fl/-
 mutants (Figure 3.1C). We used Nrp1
fl/-
 as a control, as we 
unexpectedly observed a reduction in branchpoints in Nrp1
fl/-
 mice compared to 
Nrp1
fl/+
 controls (Figure 3.1E). Nevertheless, we also demonstrated that Tie2-
CreNrp1
fl/-
 SVPs contained significantly more branchpoints than Nrp1-nulls 
suggesting that NRP1 expressed by non-ECs might be additionally required for 
developmental angiogenesis (Figure 3.1E). 
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Figure 3.1 Endothelial NRP1 is required for developmental angiogenesis. 
(A-D) E12.5 Nrp1
-/-
, Tie2-Cre;Nrp1
fl/-
, Nrp1
fl/-
 and control hindbrains were immunolabelled 
for PECAM and the SVPs imaged. Clear arrowheads indicate examples of vascular tufts; 
clear arrows and solid arrows indicated examples of vascular interconnections in the SVP 
versus deeper brain layers, respectively. (E) Quantitation of SVP branchpoints in Nrp1
fl/+
 
(n= 12), Nrp1
fl/-
 (n= 16), Tie2-Cre;Nrp1
fl/-
 (n= 5) and Nrp1-null (n= 8) E12.5 hindbrains. 
Mean ± s.d.; the asterisks indicate p values; **≤ 0.001, ***≤ 0.0001. Scale bar: 100 
µm. 
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3.2.1.2 Non EC-derived NRP1 is not required for developmental angiogenesis 
To establish whether macrophage-derived NRP1 was required for 
developmental angiogenesis, we crossed Nrp1
fl/fl
 mice carrying the conditional Nrp1-
null allele to Nrp1
+/-
 mice expressing the macrophage Cre transgene Csf1r-Cre 
(Deng et al., 2010). Analysis of E12.5 Csf1r-Cre;Nrp1
fl/-
 and control hindbrains 
immunolabelled for PECAM revealed that the SVPs appeared normal compared to 
their control littermates (Figure 3.2B). Furthermore, quantitation of branchpoints 
demonstrated that the number of vessel branch points was similar between mutant 
and control hindbrains (Figure 3.2C).  
To address whether NRP1 expressed by the neuronal progenitors was 
involved in embryonic angiogenesis, we crossed Nrp1
fl/fl
 mice to Nrp1
+/-
 mice 
carrying the transgene Nes-Cre, which had been used previously to efficiently target 
neuronal progenitors (Petersen et al., 2002). Having immunolabelled the hindbrains 
of the resulting Nes-Cre;Nrp1
fl/-
 embryos and their control littermates for PECAM, 
we observed that the mutant SVPs displayed no vascular abnormalities (Figure 
3.3B). Furthermore, quantitation of branchpoints revealed that there was no 
significant difference between mutants and controls (Figure 3.3C). Together with 
the lack of a phenotype in Csf1r-Cre;Nrp1
fl/-
 mice, these results demonstrated that, 
whilst endothelial NRP1 is required for embryonic angiogenesis, macrophage- and 
neuronal-derived NRP1 is dispensable. 
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Figure 3.2 Macrophage-derived NRP1 is not required for developmental angiogenesis. 
E12.5 Csf1r-Cre;Nrp1
fl/-
 and control hindbrains were immunolabelled for PECAM and the 
SVP imaged (A,B). Quantitation of SVP branchpoints in Nrp1
fl/+
 (n= 6), Nrp1
fl/-
 (n= 6) and 
Csf1r-Cre;Nrp1
fl/-
 (n= 5) E12.5 hindbrains (C). Mean ± s.d.; n.s., not significant. Scale bar: 
100 µm.  
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Figure 3.3 NRP1 derived from neuronal progenitors is not required for developmental 
angiogenesis. 
E12.5 Nes-Cre;Nrp1
fl/-
 and control hindbrains were immunolabelled for PECAM and the 
SVP imaged (A,B). Quantitation of SVP branchpoints in Nrp1
fl/+
 (n= 3), Nrp1
fl/-
 (n= 5) and 
Nes-Cre;Nrp1
fl/-
 (n= 8) E12.5 hindbrains (C). Mean ± s.d.; n.s. not significant. Scale bar: 
100 µm.  
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3.2.2 NRP1 does not function as an exclusive VEGF-A receptor during 
developmental angiogenesis 
Nrp1
Vegfa/Vegfa
 pups display a reduced body weight and an increased mortality 
rate compared to control litter mates (Fantin et al., 2014). To investigate the 
underlying cause of the increased mortality of these mutants, Dr Fantin and I, 
performed post-mortem examinations on Nrp1
Vegfa/Vegfa
 mutants, which had deceased 
within the first two weeks after birth. This analysis revealed that mutants had 
enlarged hearts and blood-filled lungs indicative of congestive heart failure (Gavalas 
et al., 2003). To examine, whether heart development was defective in these mice, I 
analysed heart sections from P7 Nrp1
Vegfa/Vegfa
 mice and control littermates after 
immunolabelling for endomucin, which visualises capillaries as well as veins, and 
SMA, which labels the SMCs surrounding the coronary arteries. This revealed that 
the myocardium from Nrp1
Vegfa/Vegfa
 mice contained fewer endomucin
+
 capillaries 
(Figure 3.4B,D). In addition, the capillaries appeared abnormal and were 
particularly sparse within the subendomyocardium, consistent with reports that 
angiogenesis occurs in an epicardial-to-endocardial fashion (Tomanek, 1996). 
Furthermore, there were less SMA
+ 
endomucin
-
 coronary arteries within mutant 
hearts compared to controls, whereas the number of veins was not affected 
(arrowheads, clear arrowheads, respectively, Figure 3.4A,C). Thus, VEGF-A 
signalling through NRP1 is required for normal vascularisation of the myocardium, 
which in turn is a requisite of proper cardiac function.  
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Figure 3.4 Nrp1
Vegfa/Vegfa
 hearts display reduced myocardial vascularisation 
Sections of Nrp1
Vegfa/Vegfa
 and wildtype P7 hearts were immunolabelled for endomucin, SMA 
and counterstained with DAPI. Single SMA channel is shown in (A’,C’). High 
magnification of areas indicated in (A,C) are shown in (B,D). Solid arrowheads indicate 
SMA
+
endomucin
-
 arteries, clear arrowheads SMA
low
endomucin
+
 veins. Scale bar: 100 µm.  
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3.3 Discussion 
Examination of endothelial versus non-endothelial NRP1 mutants 
demonstrated that all essential functions of NRP1 during embryonic angiogenesis are 
mediated within the endothelium, raising the question as to why the endothelial-
specific Nrp1 mutants display milder defects compared to the full Nrp1 knockouts. 
Further investigation by our group demonstrated that this can be explained by the 
inefficient recombination of the Tie2-Cre transgene allowing unrecombined ECs to 
acquire tip cell properties and thus promote some residual angiogenesis (Fantin et al., 
2013a, Gerhardt et al., 2004).  
Whilst macrophage-derived NRP1 is dispensable for developmental 
angiogenesis, studies have shown that it is required for the attraction of pro-
angiogenic macrophages during tumour angiogenesis (Casazza et al., 2013). Thus, 
tumours were found to secrete SEMA3A, which attracts NRP1-expressing 
macrophages and in turn promotes tumour vascularisation (Casazza et al., 2013). In 
contrast, no role for neuronal-derived NRP1 during developmental or pathological 
angiogenesis has been described to date; instead, this receptor is required for 
neuronal survival, migration and patterning (Tillo et al., 2015, Gu et al., 2003, 
Cariboni et al., 2011). 
Analysis of Nrp1
Vegfa/Vegfa
 hearts revealed that the vascularisation of the 
myocardium was defective in these mutants, suggesting that VEGF-A signalling 
through NRP1 is required for this process. This phenotype was similar to the defect 
displayed by Vegfa
120/120
 mice, which also have a reduction in myocardial 
vascularisation resulting in an increased perinatal mortality (Carmeliet et al., 1999). 
The similarity of defects in myocardial vascularisation observed in Nrp1
Vegfa/Vegfa
 and 
Vegfa
120/120
 hearts suggests that the perinatal vascularisation of the myocardium 
depends on VEGF-A binding to NRP1. Future studies using conditional Nrp1 and 
Vegfa mutants may wish to examine the cell type-specific requirements of these 
molecules. Furthermore, as the occurrence of enlarged hearts and blood-filled lungs 
can also be indicative of pulmonary deficiencies, future studies should also examine 
the lungs of Nrp1
Vegfa/Vegfa
 mice to determine whether the decreased survival of these 
mutants might also be attributed to decreased lung vascularisation and/or branching.  
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3.4 Summary 
At the beginning of my PhD the role of endothelial versus non-endothelial NRP1 
had not yet been defined. My analysis confirmed that non-endothelial NRP1 was 
dispensable for developmental angiogenesis, whilst endothelial NRP1 was essential. 
 Furthermore, I demonstrated that Nrp1
Vegfa/Vegfa
 mutants display impaired 
myocardial vascularisation, which presumably contributes to the occurrence of 
ischemic cardiomyopathy and thus increased perinatal mortality in these mice.    
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Chapter 4 NEURAL CREST-DERIVED SEMA3C ACTIVATES 
AN ENDOTHELIAL-TO-MESENCHYMAL TRANSITION 
THAT IS ESSENTIAL FOR CARDIAC OUTFLOW TRACT 
SEPTATION 
4.1 Introduction 
As detailed in the introduction, the OFT of the embryonic heart needs to 
septate and remodel to generate the base of the aorta and the pulmonary artery. This 
septation is essential for the formation of the double circulation that sustains adult 
mammalian life. Several prior studies have elucidated molecular signals that regulate 
the interactions of the three cell types involved in OFT remodelling, the ECs, the 
cardiac NCCs and the SHF-derived myocardium (see 1.4.3). Yet, the precise 
molecular and cellular regulatory hierarchies remain ill-defined, and the sequence of 
events that enable vascular remodelling and septal bridge formation are not yet 
understood. Accordingly, NRP1 is essential for OFT remodelling (Kawasaki et al., 
1999), but its precise function in this process has not been fully defined. Thus, 
previous studies suggested that VEGF-A signalling through endothelial NRP1 is 
essential for OFT remodelling, as the endothelial-specific deletion of Nrp1 results in 
OFT defects (Gu et al., 2003, Zhou et al., 2012). Furthermore, mice lacking the 
NRP1-binding isoforms of VEGF-A (Vegfa
120/120
) display defective OFT septation 
(Stalmans et al., 2003). Nevertheless, a recent publication that I contributed to (see 
Chapter 3) demonstrated that mice lacking the VEGF-A binding site in their NRP1 
receptor (Nrp1
Vegfa/Vegfa
) are viable, implying that another ligand must be signalling 
through the endothelial NRP1 (Fantin et al., 2014).  
In addition, SEMA3C is known to be critical for OFT septation (Feiner et al., 
2001) and studies have suggested that it is required to guide migrating cardiac NCCs 
into the OFT (Feiner et al., 2001, Kirby and Hutson, 2010). NRP1 is thought to 
function as a SEMA3C receptor in cardiac NCCs, where it is partially redundant 
with its homolog NRP2 (Toyofuku et al., 2008, Gu et al., 2003). To convey 
semaphorin signals in cardiac NCCs, it has been postulated that NRPs form a 
complex with a co-receptor termed PLXNA2, a member of the plexin family that is 
also expressed in cardiac NCCs (Brown et al., 2001). Nevertheless, a role for NRPs 
in cardiac NCCs has never been demonstrated directly for mammalian OFT 
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remodelling. Furthermore, another study showed that a different plexin, PLXND1, 
which binds SEMA3C and forms a receptor complex with NRPs, is required on the 
endothelium for OFT septation (Gitler et al., 2004). Thus, the tissue-specific 
functions, as well as the ligand requirements of NRP1 during OFT septation are not 
fully understood. 
Given the conflicting results regarding NRP1’s involvement in OFT 
remodelling, I have re-investigated the role of this receptor by taking advantage of 
tissue-specific Nrp1 knockout mice. I have thus compared OFT development in mice 
lacking NRP1 in OFT endothelium (Tie2-Cre;Nrp1
fl/-
) versus mice lacking NRP1 in 
cardiac NCCs (Wnt1-Cre;Nrp1
fl/fl
). I have also investigated knockin mice with 
mutations in NRP1 that selectively target VEGF-A (Nrp1
Vegfa/Vegfa
; (Fantin et al., 
2014) versus SEMA3 (Nrp1
Sema/Sema
; (Gu et al., 2003) binding to distinguish the 
relative contribution of both ligands to NRP1 signalling during OFT septation. 
Finally, I have also investigated tissue-specific ligand requirements using mice 
containing a conditional VEGF-A allele (Vegfa
fl/fl
; (Gerber et al., 1999). To 
investigate tissue-specific SEMA3C knockout mice, I collaborated with Prof Peter 
Scambler at the Institute of Child Health (UCL), as his group had generated mice 
containing a conditional SEMA3C allele (Sema3c
fl/fl
, unpublished).  
I have examined these complementary mouse mutants by combining a variety 
of techniques, including detailed analyses of immunolabelled histological sections, 
comparison of gene expression, as well as the investigation of in vitro assays. 
Amelie Calmont, a postdoctoral research fellow in Prof Pete Scambler’s group, 
contributed towards the analysis of Wnt1-Cre;Sema3c
fl/fl
 mice.  
4.2 Results 
4.2.1  NRP1, not NRP2, has multiple essential roles during OFT remodelling  
A prior study (Kawasaki et al., 1999) demonstrating that NRP1 is required 
for OFT remodelling, used ink injections to show that Nrp1-null mutants display 
defective OFT septation, a technique that does not reveal which aspect of OFT 
development is impaired. To analyse the OFT defect in Nrp1
-/-
 mice in more detail, I 
cut serial, orthogonal (20 µm) sections of mutant and control E12.5 embryos and 
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stained them with the endothelial marker PECAM and the SMC marker SMA, as 
previous experiments from our lab as well as previous studies had demonstrated that 
SMA also labels the embryonic myocardium (Clement et al., 2007). By examining 
sections through the distal and proximal OFT at this time point, I was able to analyse 
endocardial cushion swelling and endothelial fusion, as well as myocardialisation of 
the septal bridge and valve formation (Compare Figure 4.1A with Figure 4.1B-D).  
Using this experimental approach, I observed that none of the wildtypes 
(9/9), but all mutants (5/5) displayed a complete CAT, i.e. a lack of septation 
throughout the entire OFT (Figure 4.1E). In addition, I found that the proximal 
sections of mutant OFTs displayed disorganised endocardial cushions (asterisks, 
Figure 4.1G), which resulted in their abnormal orientation relative to the heart 
(dotted line, Figure 4.1F). Thus, wildtype OFTs contained two opposing endocardial 
cushions (asterisks, Figure 4.1D), whereas in mutants the endocardium associated 
with the myocardium in ectopic positions generating additional cushion “leaflets” or 
“fingers” (asterisks, Figure 4.1G). Furthermore, myocytes in the mutant OFTs failed 
to migrate towards the centre of the vessel; instead, these cells appeared to “stall” in 
the lateral part of the endocardial cushions (open arrowheads, Figure 4.1E,L). 
Finally, valve formation was completely absent in mutant OFTs (Figure 4.1E). In 
contrast, Nrp2
-/-
 mutants did not show any defects in OFT remodelling (Figure 
4.1H-J,M). 
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Figure 4.1. NRP1, not NRP2, is required for multiple steps of OFT remodelling. 
Schematic representation of the E12.5 mouse OFT at distal (1), medial (2) and proximal (3) 
positions relative to the heart (A). Serial sections of wildtype, Nrp1
-/- 
and Nrp2
-/-
 E12.5 OFTs 
immunolabelled for PECAM and SMA, and imaged at corresponding proximal, medial and 
distal levels (B-J). Solid arrowheads indicate the septated endothelium, solid arrows 
demonstrate septal bridge myocardialisation and clear arrows the absence of septal bridge 
formation. Dotted lines indicate the angle of septal bridge formation and asterisks highlight 
endocardial cushion position. Magnification of areas indicated by brackets in (C,F,I) are 
shown in (K-M). Curly arrows label migrating myocytes and open arrowheads denote 
stalled myocytes. Scale bar: 200 µm.   
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4.2.2 Expression pattern of NRP1 during OFT remodelling 
To understand how NRP1 might be required for the multiple steps in OFT 
septation, I examined the expression pattern of both NRP1 and NRP2 at E11.5 and 
E12.5. By labelling medial OFT sections of wildtype embryos with a previously 
validated antibody for NRP1 (Fantin et al., 2010) together with SMA and the 
vascular endothelial marker IB4, I found that NRP1 was expressed on the IB4
+
 OFT 
endothelium at both E11.5 and E12.5 (arrowheads, Figure 4.2A-B’). Furthermore, 
NRP1 was expressed on migrating myocytes at E12.5, but not at E11.5, at which 
point myocytes migration has not yet begun (curly arrow, clear curly arrow, 
respectively, Figure 4.2A-B’). In contrast, there was no obvious NRP1 expression 
within the region occupied by the post-migratory cardiac NCCs (asterisk, Figure 
4.2B,B’).  
Analysis of wildtype OFT sections immunolabelled for NRP2, SMA and IB4 
demonstrated that NRP2 and NRP1 expression overlapped only partially. Thus, 
unlike NRP1, NRP2 was only found on the OFT endothelium at E12.5. However, 
like NRP1 no NRP2 detection was found within myocytes at E11.5 (clear curly 
arrow, Figure 4.2C,C’) or in the septal bridge at E12.5 (asterisk, Figure 4.2D,D’). 
In addition, NRP2 was weakly expressed on migrating myocytes at E12.5 (curly 
arrow, Figure 4.2D,D’).  
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Figure 4.2. NRP1 and NRP2 expression in E11.5 and E12.5 OFT. 
Medial OFT sections at E11.5 and E12.5 were immunolabelled for SMA and IB4 together with NRP1 (A-B’) or NRP2 (C,D’); Solid arrowheads denote NRP 
expression within endothelium, curly arrows expression within migrating myocytes, whilst clear curly arrows indicate a lack of NRP expression in myocytes; 
asterisks highlight the lack of NRP expression within the septal bridge that is colonised by cardiac NCCs. Scale bar: 100 µm. 
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4.2.3 EndoMT and NCCs give rise to distinct parts of the OFT 
To examine the cell-specific requirements for NRP1 in OFT septation, I 
performed a detailed analysis of mice lacking endothelial- versus NCC-derived 
NRP1. For this experiment, I first validated the Tie2-Cre and Wnt1-Cre transgenes 
as suitable tools for endothelial versus NCC targeting by crossing the transgene to 
the floxed Rosa
Yfp
 reporter. YFP immunolabelling of serial sections through E12.5 
OFTs from Wnt1-Cre;Rosa
Yfp
 and Tie2-Cre;Rosa
Yfp
 mice also allowed me to 
determine the relative positions of endothelial and NCC progeny via lineage tracing.  
As expected, Tie2-Cre targeted the endothelium (arrowhead, Figure 4.3H), 
whereas Wnt1-Cre did not (clear arrowhead, Figure 4.3D). In addition, YFP staining 
revealed a substantial number of Tie2-Cre-labelled cells within the endocardial 
cushions of the OFT and, to a lesser extent, within the semilunar valves (curved 
arrow, Figure 4.3G,H), consistent with the occurrence of endoMT. Interestingly, the 
areas, where endoMT had occurred within the endocardial cushions, overlapped with 
the areas occupied by the cardiac NCCs (compare asterisk and curved arrow, Figure 
4.3C and Figure 4.3G, respectively). Analysis of YFP labelling in Wnt1-Cre;Rosa
Yfp
 
OFTs showed that the progeny of cardiac NCCs formed the septal bridge (arrow, 
Figure 4.3B) and additionally made a major contribution to the two semilunar valve 
leaflets in the central part of the OFT (open arrowheads, Figure 4.3A). Thus, this 
analysis validated the suitability of both transgenes to target NRP1 in endothelium 
versus NCCs and confirmed the distinct contributions of ECs and cardiac NCCs to 
OFT remodelling.   
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4.2.4 NRP1 is not required for cardiac NCC migration into the OFT 
Because a role for NRP1 in cardiac NCC migration had been reported 
previously in chick (Toyofuku et al., 2008), I compared the distribution of cardiac 
NCCs in wildtype and Nrp1-null OFTs with the cardiac NCC reporter Wnt1-
Cre;Rosa
LacZ 
(Jiang et al., 2000) (Figure 4.3I,J). I observed that cardiac NCCs 
migrated through the PAAs and into the OFT in two prong-shaped streams, as 
expected (see schematic, Figure 4.3K); unexpectedly, however, the migration 
pattern was similar in both wildtype (n= 4) and Nrp1-null mutant (n= 3) mice 
(arrowheads, Figure 4.3I,J). This result established that cardiac NCCs do not require 
NRP1 to reach their target tissues and implies that the OFT phenotype of Nrp1
-/-
 
mutants is not caused by defective cardiac NCC migration. 
4.2.5 NCC-derived NRP1 is not required for OFT septation in the mouse 
Because the normal cardiac NCC migration pattern in Nrp1-nulls suggested 
that cardiac NCC-derived NRP1 was dispensable for OFT septation, even though 
previous studies had implied that it was required (Toyofuku et al., 2008), I examined 
the OFTs from Wnt1-Cre;Nrp1
fl/fl
 mice. This genetic cross targets Nrp1 efficiently in 
the NCC lineage, as Wnt1-Cre;Nrp1
fl/fl
 mutants demonstrate severe defects in the 
sympathetic nervous system similar to those of full Nrp1
-/-
 mice (Maden et al., 
2012). Nevertheless, serial sections through E12.5 mutant and control OFTs 
demonstrated that, in contrast to the phenotype of Nrp1
-/-
 mice, the OFTs of neural 
crest-specific NRP1 mutants were septated properly with a normal appearance and 
rotation of the endocardial cushions and typical myocardialisation of the septal 
bridge in 4/4 of mutants analysed (Figure 4.4D-F). As several ligands of NRP1 can 
also signal through NRP2, I crossed Wnt1-Cre;Nrp1
fl/fl
 mutants onto a Nrp2-null 
background to address whether NRP2 was compensating for the lack of NRP1 in 
cardiac NCCs, as previously proposed (Gu et al., 2003, Toyofuku et al., 2008). 
However, 3/3 mutants examined also showed normal OFT septation, rotation and 
myocardialisation (Figure 4.4G-I). Thus, these findings established that contrary to 
prior hypotheses, NRP1 and NRP2 expression by cardiac NCCs is not required for 
OFT remodelling. 
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4.2.6 Endothelial NRP1 is essential for OFT septation in the mouse 
Like the original studies demonstrating a requirement for NRP1 during OFT 
remodelling (Kawasaki et al., 1999), ink injections were also used to demonstrate 
that mice lacking NRP1 in the vascular endothelium (Tie2-Cre;Nrp1
fl/-
) have 
defective OFT septation (Gu et al., 2003, Zhou et al., 2012). My histological 
approach confirmed this finding; thus, serial sections immunolabelled for PECAM 
and SMA showed that 6/6 Tie2-Cre;Nrp1
fl/-
 mutants had defective OFT septation 
(Figure 4.4J-L). In addition, I was also able to demonstrate that the defects included 
septation failure both in the proximal and distal part of the OFT, as well as 
disorganised endocardial cushion formation and impaired myocardialisation (Figure 
4.4J-L). Taken together with my analysis of the NCC-specific NRP1 mutants, these 
observations suggest that all essential NRP1 signalling during OFT remodelling 
takes place in the vascular endothelium.  
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Figure 4.3. NRP1 is not required for cardiac NCC migration into the OFT. 
Serial sections of Tie2-Cre;Rosa
Yfp
 and Wnt1-Cre;Rosa
Yfp
 E12.5 OFTs at corresponding 
distal, medial and proximal levels immunolabelled for YFP and counterstained with DAPI 
(A-H). Arrows indicate the contribution of cardiac NCCs to the septal bridge, whereas the 
open arrowheads highlight the contribution to the valves. Insets show a higher magnification 
of the valves, where arrowheads show the targeting or absence of targeting of the 
endothelium (full arrowhead and clear arrowhead, respectively) and curved arrows indicate 
endoMT within the valves. Wholemount Xgal staining of Wnt1-Cre;Rosa
LacZ
 E10.5 OFTs on 
a wildtype or Nrp1-null background; arrowheads indicate the paired streams of migrating 
cardiac NCCs (I,J). Schematic representation of cardiac NCC migration at E10.5 (K). 
Cardiac NCCs (green) migrate from neural tube (blue), along PAAs and into OFT in two 
streams. CNCC: Cardiac NCCs. Scale bars: 100 µm (A-H), 200 µm (I,J). 
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Figure 4.4. Endothelial, not NCC-derived NRP1 is required for OFT septation. 
Serial sections of wildtype (A-C), Wnt1-Cre;Nrp1
fl/-
(D-F), Wnt1-Cre;Nrp1
fl/fl
;Nrp2
-/-
(G-I) 
and Tie2-Cre;Nrp1
fl/-
 (J-L) E12.5 OFTs immunolabelled for PECAM and SMA. Solid 
arrowheads indicate the septated endothelium, solid arrows demonstrate septal bridge 
myocardialisation and clear arrows the absence of septal bridge formation. Curly arrows 
denote migrating myocytes and open arrowheads stalled myocytes. Dotted lines indicate the 
angle of septal bridge formation and asterisks highlight endocardial cushion position. Scale 
bar: 200 µm. 
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4.2.7 Cardiac NCC-derived VEGF-A is not important for OFT remodelling 
VEGF-A has been shown to be an important NRP1 ligand for OFT septation. 
Thus, prior studies observed that Vegfa
120/120 
mice, which express only VEGF120 at 
the expense of the heparin/NRP-binding isoforms of VEGF-A (Stalmans et al., 
2003), had OFT septation defects. Furthermore, another study observed that mice 
lacking NRP1 in the endothelium display defective OFT septation (Gu et al., 2003). 
As previous studies had suggested that NRP1’s only role in the endothelium is to 
enhance VEGF-A signalling through its receptor, VEGFR2, the phenotype of these 
mice was interpreted as evidence for an essential role of VEGF-A signalling through 
NRP1 in OFT remodelling (Gu et al., 2003). However, neither study was able to 
directly address the role of VEGF-A as a NRP1 ligand in OFT development, because 
a mouse mutant defective in VEGF-A binding to NRP1 was not available at the 
time; moreover, the Vegfa expression pattern had not been analysed to determine 
whether NCCs provide an important source of this growth factor for OFT 
remodelling. To investigate, which ligand is required to signal to the endothelial 
NRP1 during OFT remodelling, I decided to first analyse the expression of VEGF-A 
within the OFT.  
Using an established Vegfa
LacZ
 reporter mouse (Miquerol et al., 1999), I 
observed weak VEGF-A expression by the OFT endothelium within the valve 
leaflets, and strong expression by the SHF-derived myocardial OFT cuff at E12.5 
(arrowhead and curly arrow, respectively, Figure 4.5A-C). In contrast, VEGF-A 
appeared to be absent from the area occupied by cardiac NCCs (arrow, Figure 4.5B).  
As the defects in great vessel remodelling observed in Vegfa
120/120
 mutants 
are reminiscent of the phenotype found in mice with defective cardiac NCC 
behaviour, I decided to investigate whether cardiac NCCs are an essential source of 
VEGF-A. Thus, I introduced the Wnt1-Cre transgene into mice with a conditional 
Vegfa-null allele (Vegfa
fl/fl
; (Gerber et al., 1999). In agreement with the lack of 
obvious Vegfa expression in OFT NCCs, 3/3 Wnt1-Cre;Vegfa
fl/fl
 embryos revealed 
normal OFT septation (arrow, Figure 4.5G-I).  
To address, whether VEGF-A binds to cardiac NCCs during OFT 
remodelling, I labelled E12.5 serial sections with an AP-tagged VEGF-A probe. This 
analysis revealed that VEGF-A binds strongly to the OFT endothelium (arrowheads, 
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Figure 4.5J-L). In addition, VEGF-A also bound to cells undergoing endoMT in the 
semilunar valves (curly arrows, Figure 4.5J,K). In contrast, no VEGF-A binding 
was observed within the myocardial cuff and septal bridge (open arrowheads, arrow, 
respectively, Figure 4.5J,K). Together, these findings demonstrated that cardiac 
NCCs do not express VEGF-A to induce OFT septation; instead, the SHF-derived 
cells appeared to be the major source of VEGF-A. Furthermore, VEGF-A mainly 
bound to ECs, but not to cardiac NCCs suggesting that the functions of VEGF-A are 
mainly within the endothelium. The observation that VEGF-A also bound strongly to 
cells undergoing endoMT implies that VEGF-A might play a role in endocardial 
cushion and semilunar valve formation.  
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Figure 4.5. Cardiac NCCs are not an essential source of VEGF-A for OFT remodelling. 
Serial sections through E12.5 Vegfa
LacZ
 OFTs stained with Xgal (A-C). Arrowheads indicate 
Vegfa expression on OFT endothelium, arrow highlights lack of Vegfa expression in the 
septal bridge area; curly arrows indicate Vegfa expression on the OFT myocardium. Serial 
sections of wildtype and Wnt1-Cre;Vegfa
fl/fl
 E12.5 OFTs immunolabelled for PECAM and 
SMA (D-I). Arrowheads indicate the septated endothelium and arrows highlight septal 
bridge myocardialisation. Dotted lines indicate the angle of septal bridge formation, curly 
arrows migrating myocytes and asterisks highlight endocardial cushion position. Serial 
sections through E12.5 wildtype OFTs labelled with a VEGFA-AP probe (J-L). Arrowheads 
indicate VEGF-A binding to the OFT endothelium, arrows highlight lack of binding within 
in the septal bridge area; curly arrows indicate VEGF-A binding to cells undergoing 
endoMT, whereas open arrowheads label lack of binding to the myocardial cuff. Scale bars: 
200 µm.  
 123 
 
4.2.8 VEGF-A signalling through NRPs is dispensable for OFT septation 
To examine whether the defects observed in Nrp1-null and Tie2-Cre;Nrp1
fl/-
 
were caused by a lack of VEGF-A signalling through NRP1, I first compared the 
OFT phenotype of Vegfa
120/120
 mice to the phenotype observed in Nrp1-null mice by 
analysing serial sections through the E12.5 OFTs. 
In contrast to the phenotype observed in Nrp1-null mice, Vegfa
120/120
 OFTs 
showed normal endocardial cushion organisation (asterisk, Figure 4.6F). 
Furthermore, endothelial fusion took place in Vegfa
120/120
 OFTs, albeit only in the 
distal segment in 1/4 mutants analysed (clear arrow, arrow Figure 4.6D,E), whereas 
all Nrp1-null mutants displayed a complete lack of OFT septation. In addition, the 
pulmonary segment of the OFT appeared hypoplastic and lacked semilunar valves in 
1/4 Vegfa
120/120
 mutants analysed (open arrowhead, Figure 4.6D), whereas 2/4 of 
Vegfa
120/120
 mutants displayed no OFT phenotype (data now shown), which agreed 
with the partially penetrant heart defects described in Vegfa
120/120
 mice in previous 
studies (Stalmans et al., 2003), but differed from the defect observed in Nrp1-null 
mutants. This analysis therefore revealed that the Vegfa
120/120
 and Nrp1-null mutant 
phenotypes are different, which implies that the defective OFT septation in Nrp1
-/-
 
mice is not caused by a lack of VEGF-A signalling through NRP1 
To confirm that VEGF-A signalling through NRP1 is indeed dispensable for 
OFT remodelling, I took advantage of mice with a knockin mutation that impairs 
VEGF-A binding to NRP1 (Fantin et al., 2014), designated here as Nrp1
Vegfa/Vegfa
 
mutants (see Chapter 3). Immunolabelling of serial sections for PECAM and SMA 
revealed that septation, OFT rotation and myocardialisation were normal in 4/4 
Nrp1
Vegfa/Vegfa
 mutants examined (Figure 4.6G-I). Moreover, 3/3 Nrp1
Vegfa/Vegfa
 mice 
on a Nrp2-null background also had normal OFT septation, rotation and 
myocardialisation (Figure 4.6J-L), excluding the possibility that a lack of defect in 
Nrp1
Vegfa/Vegfa
 mutants is caused by NRP2 compensating for the Nrp1
Vegfa
 mutation. 
Thus, contrary to prior hypotheses, endothelial NRP1 does not act as a VEGF-A 
receptor during OFT septation.  
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Figure 4.6. VEGF-A signalling through NRPs is dispensable for OFT remodelling. 
Serial sections of wildtype (A-C), Vegfa
120/120 
(D-F), Nrp1
Vegfa/Vegfa
 (G-I) and 
Nrp1
Vegfa/Vegfa
;Nrp2
-/-
 (J-L) E12.5 OFTs immunolabelled for PECAM and SMA. 
Solid arrowheads indicate the septated endothelium, solid arrows highlight septal 
bridge myocardialisation and clear arrows the absence of septal bridge formation. 
Dotted lines indicate the angle of septal bridge formation, curly arrows migrating 
myocytes, asterisks highlight endocardial cushion position and open arrow heads 
denote a hypoplastic pulmonary artery. Scale bar: 200 µm. 
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4.2.9 The expression pattern of VEGFR2 suggests a role for this VEGF-A 
receptor in OFT remodelling 
To investigate whether VEGFR2 functions as the critical VEGF-A receptor 
during OFT remodelling, I examined VEGFR2 expression in E12.5 OFTs by 
immunolabelling serial sections for VEGFR2, SMA and IB4. This experiment 
demonstrated that VEGFR2 was strongly expressed by OFT ECs (arrowhead, Figure 
4.7A,B,D). In addition, VEGFR2 appeared to be expressed by ECs undergoing 
endoMT and thus invading the endocardial cushions (curly arrow, Figure 4.7D,D’), 
which agreed with my observation that the VEGFA-AP probe binds to ECs as well 
as cells adjacent to the endothelium in E12.5 OFT (see Figure 4.5). However, I 
observed no VEGFR2 staining within the septal bridge that contains cardiac NCCs 
(arrow, Figure 4.7E,E’). This finding also agreed with the VEGFA-AP binding 
pattern in the OFT (see Figure 4.5). Altogether, the pattern of VEGFR2 expression 
is consistent with VEGF-A signalling though endothelial VEGFR2 during OFT 
septation. Because Vegfr2-null mice are embryonic lethal by E9.5 (Shalaby et al., 
1995), future studies could ablate endothelial VEGFR2 at E10.5 with an inducible 
Cre/LoxP approach (see 2.2.1.6), followed by analysis of OFT remodelling in the 
mutants.  
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Figure 4.7. VEGFR2 is only expressed on EC lineage in the OFT. 
(A-C) Serial sections of wildtype E12.5 OFTs immunolabelled for SMA, VEGFR2 and IB4. 
(D-E’) Magnification of indicated areas in (A) and (B). Solid arrowheads indicate expression 
on endothelium; whereas asterisks highlight lack of expression in septal bridge. Curly arrows 
label expression in cells undergoing endoMT. Scale bar: 100 µm. 
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4.2.10 SEMA3C is expressed by myocardial cuff cells and cardiac NCCs in the 
septal bridge  
Given my observation that VEGF-A signalling through NRP1 is dispensable 
for OFT remodelling, I next investigated whether SEMA3C might be the ligand that 
is required by endothelial NRP1 for OFT septation. I chose to focus on SEMA3C, as 
genetic knockout studies had shown that SEMA3C is essential for OFT septation 
(Feiner et al., 2001, Gitler et al., 2004); however, its precise function during this 
process had not yet been established. To gain an understanding into the role of 
SEMA3C during OFT remodelling, I first analysed SEMA3C expression by in situ 
hybridisation. In agreement with prior findings (High et al., 2009, Feiner et al., 
2001), I found that Sema3c was strongly expressed within the myocardial cuff that 
surrounds the aortic segment of the OFT and in the area where cardiac NCCs are 
located (arrowhead and arrow, respectively, Figure 4.8A-C). Prior studies 
interpreted this expression pattern as an indication that SEMA3C attracts cardiac 
NCC into the OFT (Feiner et al., 2001, Toyofuku et al., 2008). In contrast, other 
studies hypothesised that Sema3c may also be expressed by cardiac NCCs 
themselves (High et al., 2009, Vallejo-Illarramendi et al., 2009). To resolve this 
controversy, I performed Sema3c in situ hybridisation on E12.5 OFT sections from 
Wnt1-Cre;Rosa
Yfp 
embryos. This analysis suggested that Sema3c is expressed by a 
subpopulation of cells in the cardiac NCC lineage (arrows, Figure 4.8D,D’). Double 
immunolabelling of sections from Wnt1-Cre;Rosa
Yfp 
embryos for YFP and PLXNA2, 
an established marker for a subset of postmigratory cardiac NCCs in the OFT 
(Brown et al., 2001), showed that the position of the SEMA3C-expressing 
subpopulation corresponded to that of cardiac NCCs expressing PLXNA2 (compare 
areas indicated with arrows in Figure 4.8D with Figure 4.8E).  
To demonstrate directly that cardiac NCCs are a source of SEMA3C, we 
collaborated with Prof Pete Scambler at the UCL Institute of Child Health (ICH), 
who had generated mice with a conditional Sema3c-null allele (Sema3c
fl/fl
) and bred 
them to Wnt1-Cre mice. Dr Calmont, a postdoctoral research fellow in his group, 
performed in situ hybridisation for Sema3c on Wnt1-Cre;Sema3c
fl/fl
 OFTs to show 
that Sema3c expression was abolished in the septal bridge at E12.5 (asterisk, Figure 
4.8G), demonstrating that they had generated a cardiac NCC-specific Sema3c 
knockout and further that cardiac NCCs do indeed provide a source of SEMA3C in 
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the OFT. In contrast, Wnt1-Cre;Sema3c
fl/fl
 mutants preserved Sema3c expression in 
the myocardial cuff (arrowhead, Figure 4.8G), which is of SHF origin. Together, 
these findings raised the possibility that SEMA3C, rather than attracting cardiac 
NCCs into the OFT, is instead secreted by cardiac NCCs to promote OFT septation.  
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Figure 4.8. Cardiac NCCs are a source of SEMA3C within the OFT. 
Sema3c in situ hybridisation of serial sections through E12.5 OFTs (A-C). White arrowheads 
indicate Sema3C expression within the myocardial cuff and arrows Sema3c expression in the 
septal bridge area. (D-E’) E12.5 Wnt1-Cre;RosaYfp OFT sections were immunolabelled for 
YFP and counter-stained after in situ hybridisation for Sema3c (D,D’) or double labelled for 
PLXNA2 (E,E’). White arrowheads highlight SEMA3C expression in the myocardial cuff; 
arrows indicate partial co-localisation of SEMA3C or PLXNA2 with YFP. E12.5 Wnt1-
Cre;Rosa
Yfp
 OFT sections from Sema3c
fl/fl
 mice lacking or containing Wnt1-Cre were 
labelled by in situ hybridisation for Sema3c (F,G). Solid arrowheads indicate SEMA3C 
expression within the myocardial cuff, arrows indicate SEMA3C expression in the septal 
bridge and asterisks demonstrate absent SEMA3C expression due to genetic deletion of 
Sema3c within the cardiac NCCs. Scale bar: 100 µm.  
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4.2.11 Cardiac NCC-derived SEMA3C is essential for proximal OFT septation 
Having established that cardiac NCCs are a source of SEMA3C within the 
OFT, Amelie and I next investigated whether SEMA3C secreted by these cells is 
important for OFT remodelling. Immunolabelling of E12.5 serial sections through 
Wnt1-Cre;Sema3c
flfl
 OFTs for PECAM and SMA revealed that septation was 
defective in the proximal OFT of 20/20 mutants examined (clear arrow, Figure 9B), 
whereas the septal bridge did form distally in 18/20 mutants analysed (not shown). In 
the proximal OFT a lack of septation was accompanied by impaired myocyte 
migration, which instead appeared to stall within the endocardial cushions in the 
peripheral OFT (compare open arrowheads, Figure 4.9B with Figure 4.9E). Thus, 
the phenotype within the proximal OFT was reminiscent of the defect observed in the 
proximal segment of Nrp1
-/-
 and Tie2-Cre;Nrp1
fl/-
 OFTs (compare Figure 4.1 and 
Figure 4.4), suggesting that in this part of the vessel SEMA3C is required to signal 
to endothelial NRP1 for normal remodelling to occur. 
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4.2.12 SEMA3C signalling through NRP1 promotes NCC-dependent septal 
bridge formation 
To test the hypothesis that SEMA3C signals through NRP1 to enable 
proximal OFT septation, I cut serial sections through the OFT of E12.5 mice with a 
mutated version of NRP1 unable to bind to SEMA3s (Nrp1
Sema/Sema
; (Gu et al., 2003) 
and immunolabelled them for PECAM and SMA. As observed in prior studies, these 
mice displayed normal OFT remodelling. Nevertheless, SEMA3C is known to bind 
to NRP1 and NRP2 (Chen et al., 1998) and thus NRP2 is able to compensate for 
NRP1. To analyse whether SEMA3C signalling through either NRP is essential for 
OFT septation, I generated Nrp1
Sema/Sema
 mice on a Nrp2-null background, 
Nrp1
Sema/Sema
;Nrp2
-/-
. I cut serial sections through the E12.5 OFTs of 
Nrp1
Sema/Sema
;Nrp2
-/- 
mutants and labelled them for PECAM and SMA to compare 
them to mutants lacking NCC-derived SEMA3C. This analysis showed that 3/3 
Nrp1
Sema/Sema
;Nrp2
-/-
 OFTs showed similar anatomical defects as the Wnt1-
Cre;Sema3c
fl/fl
 mutants, including a failure of proximal OFT septation (clear arrow, 
Figure 4.10) that was accompanied by impaired myocardialisation. This observation 
is consistent with the idea that cardiac NCC-derived SEMA3C signals through NRP 
enable OFT septation.  
Because PLXND1 is a known co-receptor for NRP1 and mice lacking 
endothelial PLXND1 have OFT defects (Gitler et al., 2004), I also analysed OFTs of 
Plxnd1
-/-
 mice. This analysis revealed that 3/3 Plxnd1
-/-
 mutants displayed a 
completely unseptated OFT, similar to endothelial Nrp1-null mutants (compare 
Figure 4.10G-I with Figure 4.4J-L). In addition, the Plxnd1
-/-
 phenotype within the 
proximal OFT also phenocopied that observed in all other mutants deficient in 
SEMA3C or NRP1 signalling analysed thus far (see Figures 4.1, 4.9).  
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Figure 4.9. Cardiac NCC-derived SEMA3C is required for proximal OFT septation. 
Serial sections of wildtype (A-C) and Wnt1-Cre;Sema3c
fl/fl
 (D-F) E12.5 OFTs 
immunolabelled for PECAM and SMA. Solid arrowheads indicate the septated endothelium; 
solid arrows demonstrate septal bridge myocardialisation, clear arrows the absence of septal 
bridge formation and open arrowheads indicate stalled myocytes. Dotted lines indicate the 
angle of septal bridge formation, curly arrows label migrating myocytes and asterisks 
highlight endocardial cushion position. Scale bar: 200 µm.  
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Figure 4.10. SEMA3C signals through NRP1 and PLXND1 to regulate OFT septation. 
Serial sections of wildtype (A-C), Nrp1
Sema/Sema
;Nrp2
-/-
 (D-F) and Plxnd1
-/-
 (G-I) E12.5 
OFTs, immunolabelled for PECAM and SMA. Solid arrowheads indicate the septated 
endothelium; solid arrows highlight septal bridge myocardialisation and clear arrows the 
absence of septal bridge formation. Dotted lines indicate the angle of septal bridge formation 
and asterisks highlight endocardial cushion position. Curly arrows label migrating myocytes 
and open arrowheads denote stalled myocytes. Scale bar: 200 µm.  
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4.2.13 SEMA3C signalling through NRP1 and PLXND1 promotes NCC-
dependent septal bridge formation 
Having established that SEMA3C signalling through the endothelial 
NRP/PLXND1 complex is important for proximal OFT septation, I next sought to 
elucidate the mechanism underlying the observed defect. Thus, I analysed cardiac 
NCC behaviour in mice with defective NRP1 signalling by immunolabelling E12.5 
OFT sections with the cardiac NCC marker PLXNA2 (High et al., 2009). This 
analysis revealed that at this stage cardiac NCCs had migrated towards the centre of 
the OFT for septal bridge formation (arrow, Figure 4.11A). Moreover, the entry of 
cardiac NCCs into the septal bridge appeared to precede the invasion of myocytes 
from the myocardial cuff into this area, and invading myocytes seemed to orientate 
themselves towards the cardiac NCCs (curved arrow, Figure 4.11A). These findings 
suggest a role for cardiac NCCs in attracting myocytes into the bridge area to initiate 
the process of myocardialisation.  
PLXNA2 immunostaining showed that cardiac NCCs had reached the OFT in 
Nrp1-null and endothelial Nrp1-null mutants (arrowheads, Figure 4.11B,C). This 
observation agreed with the Wnt1-Cre lineage trace I had performed at E10.5 in 
Nrp1-null mutants, which demonstrated that NRP1 was not required for cardiac NCC 
migration into the OFT (see above, Figure 4.3). However, PLXNA2
+
 NCCs 
remained separated in two lateral columns both in Nrp1-null and endothelial Nrp1-
null OFTs, rather than fusing in a central position as seen in wildtypes (arrowheads, 
Figure 4.11B,C). The location of the cardiac NCCs in the mutants corresponded to 
the position of the two NCC prongs seen at earlier stages in wildtypes, indicating a 
failure of translocation to the central area (see above, Figure 4.3). 
In addition to a failure of cardiac NCCs moving into the central bridge area, 
Nrp1-null and endothelial Nrp1-null mutants showed defective myocyte migration. 
Thus, myocytes were no longer orientated towards the central area of the OFT like in 
wildtypes, but appeared to orientate themselves towards the mispositioned cardiac 
NCCs in the Nrp1 mutants (curly arrows, Figure 4.11B,C), providing further 
evidence for the hypothesis that cardiac NCCs attract myocytes into the bridge area 
to initiate the process of myocardialisation. 
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The findings above are consistent with the idea that NRP1 is dispensable for 
cardiac NCC attraction into the OFT, but is required within the OFT for NCC 
guidance from a lateral area into a central position and the ensuing attraction of 
myocytes for septal bridge formation. In agreement with this model, and 
demonstrating that the NRP1 ligand directing cardiac NCC translocation is SEMA3C 
rather than VEGF-A, NCC migration into the central OFT was normal in mice 
lacking VEGF-A signalling through NRPs (Nrp1
Vefa/Vegfa
;Nrp2
-/-
), but absent in mice 
lacking semaphorin signalling through neuropilins (Nrp1
Sema/Sema
;Nrp2
-/-
) (Figure 
4.11D,E, respectively). Moreover, mice lacking NCC-derived SEMA3C also lacked 
central NCC localisation, with NCCs located in two lateral columns and abnormal 
myocyte migration towards the stalled NCCs (Figure 4.11F).  
To investigate how ablation of SEMA3C/NRP1 signalling in the OFT affects 
the behaviour of the total cardiac NCC population, including cardiac NCCs which do 
not express SEMA3C or PLXNA2, I introduced the Wnt1-Cre;Rosa
Yfp
 reporter into 
Nrp1-null mice and in collaboration with Prof Scambler into Sema3c
fl/fl
 mice. I 
subsequently analysed OFT sections of E12.5 Wnt1-Cre;Rosa
Yfp
;Nrp1
-/-
 or Wnt1-
Cre;Rosa
Yfp
;Sema3c
fl/fl
 embryos stained for YFP and the early SMC marker SM22α. 
As observed with PLXNA2 and Xgal staining, the YFP analysis suggested that a 
similar amount of cardiac NCCs had migrated into the OFT of Nrp1
-/-
 mice and 
wildtype littermates (Figure 4.12B,E). However, despite having reached the OFT, 
most YFP
+
 cells in mutants had failed to translocate into the central area at E12.5 
(arrowheads, Figure 4.12E). This defect was also present in the proximal OFT of 
Wnt1-Cre;Rosa
Yfp
;Sema3c
fl/fl
 mutants (Figure 4.12H). These observations suggest 
that the SEMA3C-expressing cardiac NCCs are able to influence the behaviour of 
the entire cardiac NCC population in the OFT. Whereas NCC-derived SEMA3C was 
essential for cardiac NCC relocalisation in the proximal OFT, cardiac NCCs had 
successfully migrated into the central area in the distal OFT of Wnt1-
Cre;Rosa
Yfp
;Sema3c
fl/fl
 mutants, similar to wildtype littermates (Figure 4.12G). This 
observation agrees with the incomplete penetrance of OFT septation within the distal 
OFTs of the Wnt1-Cre;Sema3c
fl/fl
 and Nrp1
Sema/Sema
;Nrp2
-/-
 mutants and suggests that 
NRP1 might have an additional role within the distal OFT. 
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All together, these findings demonstrate that semaphorin, not VEGF-A 
signalling through NRP1 is a major driving force underlying NCC-mediated OFT 
septation. Moreover, they imply that SEMA3C signals to endothelial NRP1 to 
promote cardiac NCC migration towards the centre of the proximal OFT, which then 
leads to myocyte invasion and therefore the formation of a myocardialised septal 
bridge.   
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Figure 4.11. SEMA3C signals through NRP1 to promote the fusion of the SEMA3C 
expressing cardiac NCCs and promote the myocardialisation of the septal bridge. 
E12.5 OFT sections of the indicated genotypes were labelled for PLXNA2 and SMA. 
Arrows indicate the central position of cardiac NCCs in the septal bridge that is present in 
the wildtype OFT and the OFT of mice lacking VEGF-A signalling through neuropilins; 
arrowheads highlight the abnormal lateral position of PLXNA2
+
 cardiac NCCs in all other 
mutant genotypes. Curved arrows denote myocytes migrating to the central NCCs, curly 
arrows those migrating towards abnormal lateral NCCs. Scale bar: 100 µm.  
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Figure 4.12. NCC-derived SEMA3C is required for cardiac NCC fusion and septal 
bridge myocardialisation in the proximal OFT. 
E12.5 OFT sections from wildtype (A-C), Nrp1
-/-
 (D-F) and Sema3c
fl/fl
 (G-I) mice 
containing the
 
Wnt1-Cre;Rosa
Yfp
 reporter were co-labelled for YFP and SM22α. Arrows 
indicate cardiac NCCs in the septal bridge of the control and distal mutant OFT, the 
arrowheads highlight abnormal lateral positioning of cardiac NCCs in the mutant OFT. Note 
that the failure of NCCs to re-localise in the proximal OFT is similar in both Nrp1
-/-
 and 
Wnt1-Cre;Sema3c
fl/fl
 mutants, but only Nrp1-nulls show defective OFT rotation, as indicated 
by the position of the arrowheads relative to the atria. Scale bar: 200 µm. 
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4.2.14 NRP1 is not required for cardiac NCC survival or proliferation within 
the OFT 
Prior studies have shown that deletion of the BMP receptor ALK2 or the TGF 
β receptor ALK5 increase NCC apoptosis within the OFT and cause OFT defects 
(Kaartinen et al., 2004, Wang et al., 2006a). In addition, loss of the retinoid X 
receptor alpha promotes apoptosis in the endocardial cushions and therefore 
compromises OFT remodelling (Kubalak et al., 2002). Conversely, loss of FOX1P 
reduces apoptosis in the endocardial cushions and also causes OFT septation defects 
(Wang et al., 2004). I therefore investigated whether apoptosis was affected in 
mutants lacking NRP1 by immunolabelling E11.5 OFT sections for activated caspase 
3 (aCAS3) (Porter and Janicke, 1999, Sabine et al., 2012). Because the OFT 
phenotype in NRP1 mutants is already overt at E12.5, apoptosis should be present 
prior to this stage, if it were the underlying cause. However, consistent with previous 
studies (Sharma et al., 2004, Barbosky et al., 2006), we observed little apoptosis in 
the OFT at E11.5 (Figure 4.13A). Furthermore, there was no significant difference 
in the number of apoptotic cells between Nrp1-null mutants and control OFTs 
(Figure 4.13B, n= 3 each). Defects in proliferation can also cause OFT defects. 
Thus, deletion of the BMP type 1 receptor in NCCs reduces proliferation in the 
endocardial cushions and causes defective OFT remodelling (Nomura-Kitabayashi et 
al., 2009). To examine whether proliferation was affected in Nrp1-null embryos, I 
immunolabelled E11.5 OFT sections for the proliferation marker phosphohistone H 3 
(pHH3) (Hendzel et al., 1997, Tapia et al., 2006). However, there was no significant 
difference in the number of proliferating cells between Nrp1-null mutants and control 
OFTs (Figure 4.13C,D, n= 3 each). 
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Figure 4.13. NRP1 is not required for cardiac NCC survival or proliferation. 
Sections through E11.5 OFTs from Nrp1-nulls and wildtype littermates were 
immunolabelled for PECAM, DAPI and aCAS3 or pHH3, respectively. Arrowheads 
indicate aCAS3
+
 and arrows pHH3
+
 cells. (B,D). Quantitation of aCAS3
+
 or pHH3
+
 
cells in the proximal OFT of Nrp1-nulls (n= 3) and control littermates (n= 3). Mean 
± s.d., n.s., not significant. Scale bar: 100 µm (A,C). 
.   
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4.2.15 SEMA3C signals through NRP1 to induce endoMT in the OFT in vitro  
My analyses had revealed that mice with impaired SEMA3C/NRP1 signalling 
display disorganised endocardial cushions and lack proximal OFT septation, two 
processes known to rely on endoMT (Bai et al., 2013, Ma et al., 2013, Timmerman et 
al., 2004). This observation raised the possibility that cardiac NCC-derived SEMA3C 
signalling through endothelial NRP1 is essential to induce normal levels of endoMT 
in the OFT. I therefore investigated next, how the onset of endoMT relates to the 
timing of cardiac NCC immigration into the OFT, and asked, whether cardiac NCC-
derived SEMA3C signalling through endothelial NRP1 is essential for endoMT in 
the OFT.  
To determine the onset of endoMT within the OFT, I immunolabelled E10.5 
Tie2-Cre;Rosa
Yfp
 OFT sections for YFP and PECAM. This analysis showed that the 
PECAM
+
 endothelium was effectively labelled by YFP, but that only few single cells 
around the endothelium were YFP
+
 suggesting that endoMT was only just beginning 
at this stage (arrowhead and arrow, respectively, Figure 4.14A,A’). Similar analysis 
of sections through E10.5 Wnt1-Cre,Rosa
Yfp
 OFTs confirmed that cardiac NCCs had 
already colonised the OFT at this stage (arrow, Figure 4.14B,B’), consistent with my 
wholemount stains (Figure 4.3) and as previously shown (Jiang et al., 2000, Epstein 
et al., 2000). Even though the Tie2-Cre;Rosa
Yfp
 OFT at E10.5 contained only few 
single cells that were YFP
+
 and lacked PECAM expression, it contained many such 
cells at E12.5 (arrowhead, Figure 4.14C,C’). Together, these observations suggest 
that endoMT is induced around E10.5, coincident with cardiac NCC migration into 
the OFT, and has produced many cushion cells by E12.5.  
To investigate if SEMA3C induces endoMT in the OFT in a NRP1-dependent 
manner, I used an established explant assay (Bai et al., 2013). In this assay, OFT 
tissue from E10.5 embryos is explanted and the ensuing endoMT is measured as F-
actin
+
 cellular outgrowth. To confirm that this assay is a good model of endoMT in 
the OFT, I first explanted E10.5 Tie2-Cre;Rosa
Yfp
 OFT tissue, because endoMT was 
only just beginning at this stage (see above, Figure 4.14A). Consistent with the idea 
that the outgrowing cells arise through endoMT, I found that the vast majority of 
these outgrowth cells were YFP
+
 (arrowheads, Figure 4.15A). Importantly, the 
outgrowth cells lacked PECAM expression (arrowhead, Figure 4.15B,B’), similar to 
cells that have undergone endoMT in vivo (Figure 4.14C,C’). These findings 
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confirmed that the OFT explant assay recapitulates key features of endoMT. 
Furthermore, the lack of PECAM expression in the cellular outgrowth also validated 
that these cells were not forming angiogenic sprouts, as found in aortic rings when 
they are cultured on collagen (Baker et al., 2012). To determine whether endoMT 
depends on NCC-derived SEMA3C and NRP1, I first investigated whether SEMA3C 
was able to induce endoMT by culturing E10.5 serum-starved wildtype explants with 
400 ng/ml recombinant SEMA3C and comparing it to untreated explants (n= 3 each; 
Figure 4.16A,B). I chose this amount of SEMA3C, as previous studies had validated 
that this concentration can elicit a biological response (Vadivel et al., 2013).This 
revealed that SEMA3C significantly increased cellular outgrowth by approx. 180% 
(n= 3 each, p≤ 0.01; Figure 4.16I). To investigate whether the lack of NCC-derived 
SEMA3C affected endoMT, Amelie Calmont used the explant assay on E10.5 Wnt1-
Cre;Sema3c
flfl
 OFT tissue mice (Figure 4.16C,D). She observed significantly 
reduced outgrowth in mutant compared to control explants (Sema3c
fl/+
 n= 14 versus 
Wnt1-Cre;Sema3c
fl/fl
 n= 6, p≤ 0.01; Figure 4.16I). I next examined whether endoMT 
was also deficient in Nrp1-nulls. I, thus, explanted E10.5 OFT tissue from wildtype 
and Nrp1-null mutants (Figure 4.16E,F) and observed that outgrowth was 
significantly reduced in mutant compared to control explants (Nrp1
+/+
 n= 4 versus 
Nrp1
-/-
 n= 5, p≤ 0.001; Figure 4.16J). To determine directly if the SEMA3C-
mediated induction of endoMT was NRP1-dependent, I next treated OFT explants 
from Nrp1-null mutants and littermate controls with SEMA3C (Figure 4.16D,E). 
This experiment demonstrated that SEMA3C promoted outgrowth in wildtype, but 
not in Nrp1-null mutant explants. Thus, the amount of cellular outgrowth remained 
reduced in Nrp1-nulls compared to wildtype littermates (n= 3 each; p≤ 0.05; Figure 
4.16J). Furthermore, the amount the cellular outgrowth was reduced by in Nrp1-nulls 
treated with SEMA3C, was not significantly changed from the amount outgrowth 
was reduced by in untreated Nrp1 mutants (p> 0.05). Together, these experiments 
showed that cardiac NCC-derived SEMA3C promotes endoMT in the OFT via 
NRP1. 
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Figure 4.14. EndoMT occurs after OFT colonisation by NCCs. 
Sections of E10.5 and E12.5 Tie2-Cre;Rosa
Yfp
 and 10.5 Wnt1-Cre;Rosa
Yfp
 OFTs 
immunolabelled for YFP and PECAM. Arrowheads indicate endothelial targeting of YFP at 
E10.5 and E12.5. The solid arrows in (A,C) highlight mesenchymal cells of endothelial 
origin, which are targeted by Tie2-Cre, whereas the clear arrow in (C’) indicates a lack of 
PECAM expression in these cells. The solid arrow in (B,B’) denotes Wnt1-Cre-labelled 
NCCs that have colonised the OFT. Curly arrows highlight PECAM
+
 capillaries within the 
OFT. Scale bars: 100 µm.  
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Figure 4.15. E10.5 OFT explants recapitulate endoMT. 
E10.5 Tie2-Cre;Rosa
Yfp
 and wildtype OFTs immunolabelled for YFP (A,A’) or PECAM 
(B,B’), F-actin and DAPI. Arrowheads label cells, which have undergone endoMT and are 
targeted by Tie2-Cre (A,A’) or lack PECAM (B,B’). Scale bars: 200 µm.  
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Figure 4.16. SEMA3C induces endoMT through NRP1. 
E10.5 wildtype, Wnt1-Cre;Sema3c
fl/fl
 and Nrp1-null OFTs were cultured for 72 h with 
(B,G,H) or without 400 ng/ml SEMA3C (A,C-F), and immunolabelled for F-actin and 
counterstained with DAPI. The number of F-actin
+
DAPI
+
 emigrated cells per explant was 
quantitated (I,J). Mean ± s.d.; the asterisks indicate p values; *≤ 0.05, **≤ 0.01, ***≤ 0.001; 
n.s., not significant. Scale bars: 200 µm.  
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Reduced endoMT in the OFT of mice lacking SEMA3C or NRP1 in vivo 
To confirm that NRP1 is required for endoMT in vivo, I investigated the 
expression of two genes, Slug and Snail, which encode transcription factors 
important for endoMT (Niessen et al., 2008, Leong et al., 2007). Quantitative PCR 
analysis revealed that Slug and Snail expression was reduced in Nrp1-null mice 
compared to control littermates on Nrp1-null and control E10.5 OFTs. Thus, as 
expected, Nrp1 expression was reduced in Nrp1-null mutants; moreover, Slug was 
also significantly reduced in mutants compared to littermate controls (Figure 4.17A; 
n= 3 each, p≤ 0.05). Furthermore, Snail also appeared reduced in mutants, albeit this 
analysis did not reach statistical significance presumably due to the variability of 
gene expression and low n number (Figure 4.17A; n= 3 each, p> 0.05). Similarly, 
Slug was significantly reduced in the E10.5 OFTs from Wnt1-Cre;Sema3c
fl/fl 
mutants 
compared to control littermates, whereas Snail appeared reduced, albeit without 
significance (Figure 4.17B; controls lacking Cre n= 3; Wnt1-Cre;Sema3c
fl/fl
 n= 7; p≤ 
0.01, p> 0.05, respectively).  
I next validated this finding by performing immunostaining of serial OFT 
sections for SLUG and PECAM at E11.25, when endoMT is in progress. By 
comparing Tie2-Cre;Nrp1
fl/-
 and control sections, I found that there were fewer 
SLUG
+
 single cells immediately adjacent to the OFT endothelium in mutants 
compared to littermate controls (arrowheads, Figure 4.18A). Instead, many SLUG
+
 
cells appeared to be retained within the OFT endothelium (arrow, Figure 4.18D). 
This observation raised the possibility that the defective induction of the endoMT 
programme at E10.5 results in the retention of cells that are normally destined for 
endoMT within the OFT endothelium. Reduced Slug expression at E10.5 and the 
abnormal distribution of SLUG
+
 cells at E11.25 predicted fewer mesenchymal cells 
of endothelial origin in the absence of endothelial NRP1 activation. To test this idea, 
I analysed cells that had arisen by endoMT in the E12.5 OFT through lineage tracing 
with the Tie2-Cre;Rosa
Yfp
 transgene. Consistent with impaired endoMT, 
immunostaining of serial sections showed fewer YFP
+
PECAM
-
 cells in the 
endocardial cushions in 3/3 mutants compared to controls (Figure 4.18B). Taken 
together, these observations show that endothelial NRP1 is required for endoMT in 
vivo.  
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Figure 4.17. Reduction of endoMT markers Snail and Slug in Nrp1-null and Wnt1-
Cre;Sema3c
fl/fl
 OFTs. 
Quantitation of Nrp1, Slug and Snail mRNA expression relative to GAPDH in E10.5 OFTs 
from Nrp1
-/-
 (n= 3, grey bars) and control litter mates (n= 3, white bars) by SybrGreen qPCR 
(A). Quantitation of Slug and Snail mRNA expression relative to Gapdh in E10.5 OFTs from 
Wnt1-Cre;Sema3c
fl/fl
 (n= 7, grey bars) and control litter mates (n= 3, white bars) by 
SybrGreen qPCR (B). Mean ± s.d.; the asterisks indicate p values; *≤ 0.05, **≤ 0.01 ***≤ 
0.001; n.s., not significant.  
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Figure 4.18. NRP1 is required for endoMT in vivo. 
Serial sections of Tie2-Cre;Nrp1
fl/-
 and control E11.25 OFTs stained with PECAM and 
SLUG. Arrowheads indicate cells expressing SLUG in the OFT; curved arrow in high 
magnification illustrates endoMT, whereas arrows shows SLUG
+
 cells retained in the 
endothelium. Dotted lines outline the endothelium (e) (A-D). Serial sections of Tie2-
Cre;Rosa
Yfp
 E12.5 OFTs on a Nrp1
fl/+
 and Nrp1
fl/-
 background at corresponding distal, medial 
and proximal levels immunolabelled for YFP, SMA and PECAM. Solid arrowheads indicate 
the septated endothelium and solid arrows septal bridge myocardialisation; clear arrows 
highlight the absence of septal bridge formation in mutants. Dotted lines indicate the angle of 
septal bridge formation (E-J). Schematic representation of SEMA3C induced endoMT. 
Cardiac NCCs (green) secrete SEMA3C (blue), which binds to endocardial NRP1 (purple) 
and induces endoMT resulting in NCC clustering and septal bridge formation (K). Scale 
bars: 50 µm (A-D), 100 µm (E-J).  
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4.3 Discussion 
Even though the importance of NRP1 for OFT remodelling and therefore 
cardiovascular function has been recognised for more than a decade (Kawasaki et al., 
1999), its mechanism of action was not previously understood. A widely accepted 
hypothesis postulated that NRP1 contributes to OFT remodelling in a dual fashion: 
firstly, by enabling the SEMA3C-mediated attraction of NRP1-expressing cardiac 
NCCs into the OFT, and secondly, by acting as a VEGF-A receptor in NRP1-
expressing OFT endothelium to induce an unidentified endothelial function. By 
taking advantage of a previously unavailable repertoire of tissue-specific and ligand-
selective Nrp1 mutants and analysing them through both in vivo and in vitro 
approaches, I, together with my collaborators, was able to overhaul the prior working 
model and identify novel roles for NRP1 during OFT septation. Firstly, I found that 
neither NRP1 nor NRP2 are required to guide cardiac NCCs into the OFT. Secondly, 
I demonstrated that endothelial NRP1 is not required as a receptor for VEGF-A 
during OFT remodelling, but that it instead binds to SEMA3C, which is essential for 
this process. Thirdly, I identified a hitherto unrecognised role for NCC-derived 
SEMA3C and endothelial NRP1 in promoting endoMT in the OFT and therefore the 
generation of mesenchymal cells for the endocardial cushions. Finally, I found that 
SEMA3C signalling through NRP1 is required for the fusion of the bilateral cardiac 
NCC columns in the central OFT to enable the formation and myocardialisation of 
the septal bridge that separates the emerging aortic and pulmonary trunks.  
 Out of all SEMA3s the only SEMA3 known to be a critical factor for OFT 
septation is SEMA3C (reviewed in Worzfeld and Offermanns, 2014), as Sema3c
-/-
 
mice display CAT (Feiner et al., 2001). Thus genetic knockouts of SEMA3A, which 
binds to NRP1 with strong affinity, display enlarged atria, but otherwise show no 
defects in vascular development (Behar et al., 1996). In contrast to SEMA3A, 
SEMA3C binds both NRPs with similar affinity (Chen et al., 1997, Chen et al., 
1998), and therefore the occurrence of CAT in Nrp1
Sema/Sema
;Nrp2
-/-
, but not 
Nrp1
Sema/Sema
 mice, supports the idea that SEMA3C acts on cells that express both 
NRPs. In common with their well-characterised role as axon guidance cues, it was 
suggested that these SEMA3C-dependent cells are cardiac NCCs (Gu et al., 2003, 
Toyofuku et al., 2008), which require SEMA3C to migrate into the OFT. In 
accordance with this prior model, mice with cardiac NCCs lacking NRP1 and NRP2 
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should show impaired cardiac NCC migration into the OFT and therefore defective 
OFT septation, similar to Sema3c-null mice. To test this idea, I analysed Wnt1-
Cre;Nrp1
fl/fl
;Nrp2
-/-
 mice, where Wnt1-Cre was shown to effectively delete NRP1 
within the cardiac NCCs in studies analysing the development of the sympathetic 
nervous system (Maden et al., 2012). However, in disagreement with the previous 
model, Wnt1-Cre;Nrp1
fl/fl
;Nrp2
-/- 
mutants had normal OFT septation, excluding the 
possibility that SEMA3 signalling through NRPs is required for cardiac NCC 
immigration into the OFT of the developing mouse. My finding disagreed with prior 
studies in chick, in which siRNA-mediated targeting of NRP1 impaired cardiac NCC 
migration (Toyofuku et al., 2008). This discrepancy might be due to species 
differences in cardiac NCC behaviour. In support of this idea, the misregulation of 
SDF1 or its receptor CXCR4 perturbs cardiac NCC migration in chick (Escot et al., 
2013), whereas mouse mutants showed only mild anomalies, such as ventricular 
septal defects (Tachibana et al., 1998, Nagasawa et al., 1996). Alternatively, the 
siRNA-mediated knockdown technology used for the chick studies may have 
sensitised NCCs in such a manner that they became more prone to developmental 
defects caused by NRP1 knockdown.  
In contrast to Wnt1-Cre;Nrp1
fl/fl
;Nrp2
-/-
 mice, Tie2-Cre;Nrp1
fl/-
 mutants fully 
recapitulated the defects I had observed in Nrp1-null mice. This finding suggested 
that all major NRP1-dependent steps during OFT remodelling are orchestrated by 
endothelial NRP1. Furthermore, my NRP2 expression analysis showed that NRP2 is 
also expressed on the endothelium demonstrating that instead of the cardiac NCCs, 
ECs could be the cells requiring SEMA3C signals during OFT remodelling. 
However, I also found expression of NRP1 and NRP2 within the migrating myocytes 
s within the OFT (Figure 4.2), raising the possibility that NRPs might play an 
additional role in OFT development by guiding myocytes during myocardialisation.  
 Given the essential role of NRP1 in OFT septation, it is not immediately 
obvious why NRP2 is able to compensate for the loss of SEMA3 binding to NRP1, 
as observed for mice carrying the Nrp1
Sema/Sema
 mutation (Gu et al., 2003), whilst it is 
unable to compensate for the lack of NRP1 in Nrp1
-/-
 or Tie2-Cre;Nrp1
fl/-
 mice. One 
possibility is that NRP2 and NRP1 form a heterodimer, in which both NRPs function 
redundantly as receptors for SEMA3C (Figure 4.19A). In agreement, heterodimer 
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formation has been demonstrated in Cos7 cells in vitro, where NRP1 and NRP2 pre-
assemble in a ligand-independent fashion (e.g. Chen et al., 1997, Chen et al., 1998, 
Takahashi et al., 1998). In a heterodimeric complex, NRP2 may be sufficient to bind 
SEMA3C even if the semaphorin binding domain of NRP1 is disrupted; however, the 
remainder of the NRP1 receptor, which is present in Nrp1
Sema/Sema
 mice but absent in 
Nrp1
-/-
, may be indispensable for downstream signalling (Figure 4.19B,C). For 
example, NRP1 may be absolutely required to transduce appropriate signals for OFT 
septation, with NRP2 being unable to compensate for this function. In support of this 
model, Nrp2
-/-
 mutants do not display defects in OFT remodelling (Chen et al., 
2000), even though NRP2 can rescue the Nrp1
Sema
 mutation (Gu et al., 2003).  
NRP1 signalling in OFT endothelium appears to depend on the recruitment of 
a signal transducing co-receptor (Figure 4.19A), because mice lacking the 
cytoplasmic tail of the NRP1 receptor are viable and are therefore unlikely to have 
OFT defects (Fantin et al., 2011). This co-receptor is likely PLXND1, because both 
NRP1 and NRP2 form complexes with PLXND1, and PLXND1 enhances SEMA3C 
binding to NRP-expressing Cos7 cells (Gitler et al., 2004). Moreover, Plxnd1 
knockouts recapitulate the OFT phenotype observed in NRP1 and SEMA3C 
knockout mice (Figure 4.10). Furthermore, studies reported that endothelial-specific 
deletion of PLXND1, similar to the endothelial deletion of NRP1, result in OFT 
defects (Zhang et al., 2009), supporting the hypothesis that the essential function of 
such a NRP1/PLXND1 complex receptor occurs in OFT endothelium.  
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Figure 4.19. Working model of SEMA3C signalling through NRPs and PLXND1 to 
induce endoMT in the OFT. 
In wildtypes, SEMA3C binds to NRP1 and the complex transduces signals through PLXND1 
to induce endoMT and NCC translocation (A). Signalling is impaired in EC-specific and full 
Nrp1-nulls, as the NRP1 receptor cannot activate PLXND1 (B,C). In Nrp1
Sema/Sema
 mice, 
SEMA3C signals through NRP2, perhaps because it binds to NRP1 but induces PLXND1 
activation through NRP2 (D; not that I have not specifically investigated this possibility). In 
Nrp1
Sema/Sema
;Nrp2
-/-
 OFTs, SEMA3C cannot induce endoMT as there is no receptor binding 
site (E), whereas in Wnt1-Cre,Sema3c
fl/fl
 endoMT is not induced, because SEMA3C is not 
secreted by NCCs (F).  
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I also tested the prior hypothesis that NRP1 acts as a VEGF-A receptor in 
OFT endothelium (Gu et al., 2003). This hypothesis was an extrapolation of in vitro 
findings, in which NRP1 forms a complex with VEGFR2 in ECs to enhance VEGF-
A signalling through VEGFR2 (e.g. Soker et al., 2002). However, the importance of 
this pathway has so far only been demonstrated in vivo for arteriogenesis, where 
NRP1 tethers a VEGF-bound NRP1/VEGFR2 complex to an intracellular trafficking 
machinery that ensures the enrichment of activated VEGFR2 in signalling 
endosomes (Lanahan et al., 2013). In contrast, the results presented here show that 
mice lacking VEGF-A binding to NRP1 have normal OFT remodelling, even in the 
absence of NRP2. This finding was particularly unexpected, because Vegfa
120/120
 
mice lacking the NRP1-binding VEGF164 isoform have defective OFT septation 
(Stalmans et al., 2003). My observations therefore imply that the phenotype of 
Vegfa
120/120
 mice is not linked to NRP1’s ability to bind VEGF-A. Instead, impaired 
ECM retention of VEGF120, known to be responsible for vascular patterning defects 
in other tissues (Ruhrberg et al., 2002), may also contribute to the OFT defect of 
Vegfa
120/120
 mice. In this context, future studies may wish to investigate whether 
Vegfa
LacZ/LacZ
 mice, which have increased VEGF-A levels (Miquerol et al., 1999), 
display OFT defects reminiscent of the defect observed in Vegfa
120/120
.  
 To determine the specific role of SEMA3C signalling through NRP1 in OFT 
remodelling, I collaborated with Prof Pete Scambler (ICH, UCL) who had generated 
a conditional Sema3c-null mouse. We were able to delete SEMA3C expression from 
the cardiac NCCs by mating these mutants to mice expressing the Wnt1-Cre 
transgene. Using this genetic approach in combination with expression studies, we 
found that Sema3c is expressed by cardiac NCCs. This finding disagrees with the 
prior hypothesis that SEMA3C is an attractive cue for NCCs to migrate into the OFT, 
but supports a role for SEMA3C as a signal secreted by NCCs. In agreement with the 
idea that myocardial cuff derived-SEMA3C is not sufficient for OFT septation, the 
NCC-specific deletion of Gata6, which drives SEMA3C expression, causes OFT 
defects (Lepore et al., 2006). 
Even though SEMA3C was not required for the colonisation of the OFT by 
cardiac NCCs, the cells were indirectly affected by loss of endothelial 
SEMA3C/NRP1 signalling once they had reached the OFT. Thus, cardiac NCCs 
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were abnormally positioned in paired columns in the lateral parts of the endocardial 
cushions, in locations where NCCs are located in both wildtypes and mutants at 
earlier stages (see Figure 4.3). These observations suggest that the process by which 
NCCs normally fuse in the central OFT at E12.5 to enable formation of the septal 
bridge had failed in the mutants. 
The incomplete penetrance of distal, as opposed to proximal OFT septation 
defects observed in Wnt-1;Sema3c
fl/fl 
and Nrp1
Sema/Sema
;Nrp2
-/-
 mice may be due to a 
number of factors. Thus, variability in my analyses may be secondary to less than 
100% efficient Cre-mediated targeting of Sema3c. In addition, the ligand binding 
mutation may have residual activity. Additionally, the variation may be secondary to 
stochastic or genetic background effects. Previous reports of Sema3c-null mutants 
described partially penetrant (75%) and partially expressed (i.e. incomplete) OFT 
septation defects (Feiner et al., 2001). Indeed previous studies showed that postnatal 
mortality of Sema3c-null mice was 50% lower on a C57Bl6 background (Feiner et 
al., 2001). In contrast, both Nrp1-null and Tie2-Cre;Nrp1
fl/- 
mice displayed CAT in 
all mutant OFTs analysed, which implies that there is an additional, 
SEMA3C/VEGF-A-independent pathway involved in OFT remodelling, which is 
less susceptible to genetic perturbations. Evidence for such a pathway was provided 
in a recent study by our lab, which showed that NRP1 is required for postnatal 
angiogenesis due to its role in regulating the cytoskeleton of ECs through ABL 
(Raimondi et al., 2014). Such a pathway seems plausible, as the cytoskeletal 
remodelling of the endothelium is known to be critical for OFT remodeling (Sakabe 
et al., 2006).  
Previous studies as well as our endothelial lineage tracing have shown that 
endoMT contributes significantly to the endocardial cushions of the proximal OFT. 
Moreover, mice with reduced BMP signalling, a known inducer of endoMT, lack 
proximal septation (Delot et al., 2003), a defect similar to that observed in Wnt1-
Cre;Sema3c
fl/fl
 mutants. To address whether SEMA3C/NRP1 signalling promotes 
endoMT in the OFT, Amelie and I used an explant assay which showed that 
SEMA3C induced endoMT, that NCC-derived SEMA3C and NRP1 were both 
required for endoMT, and that loss of endoMT in NRP1 mutants could not be 
rescued by exogenous SEMA3C. Furthermore, expression of the transcription factor 
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SLUG, which is a known marker of endoMT (Niessen et al., 2008, Leong et al., 
2007), as well as the process of endoMT, was markedly reduced in the OFTs of mice 
lacking endothelial NRP1. The finding that SLUG was down-regulated in mutants 
with defective SEMA3C/NRP1 signalling agreed with recent studies, which showed 
that the enhanced expression of SEMA3C (Herman and Meadows, 2007) or NRP1 
(Peng et al., 2014) in cancer cells results in an increased level of tumour 
invasiveness- a process in which tumour cells acquire mesenchymal properties 
reminiscent of endoMT. Thus, SEMA3C-dependent NRP1 signalling may represent 
a conserved mechanism that promotes the conversion of cells bound into non-
invasive epithelial or endothelial monolayers into migratory single cells. 
The SHF has been found to be a source for several molecules, which are 
required for endoMT in the OFT such as FGF8 (Frank et al., 2002, Park et al., 2006) 
and BMP4 (McCulley et al., 2008, Liu et al., 2004, Bai et al., 2013). Furthermore, 
loss of notch signalling in the SHF was shown to reduce FGF8 and BMP4 secretion, 
and this was accompanied by impaired cardiac NCC immigration and endoMT and 
caused failure of OFT septation (High et al., 2009). These prior studies concluded 
that SHF-derived mesoderm communicates with both cardiac NCCs and ECs to 
induce OFT septation. In contrast, my study has revealed an additional mechanism 
by which the endothelium is able to instruct the cardiac NCCs and thereby contribute 
to OFT remodelling. Thus, I have shown that a subpopulation of cardiac NCCs 
secretes SEMA3C to instruct the NRP1
+
 endocardium to undergo endoMT during 
OFT morphogenesis. Further work will therefore be necessary to determine how the 
endothelial SEMA3C/NRP1 pathway we have identified interacts with or 
complements notch, FGF8 and BMP4 signalling in the OFT. Interestingly, defective 
endoMT observed within the OFT cushions of the notch, FGF8 and BMP4 mutants is 
also accompanied with faulty migration of cardiac NCCs, reinforcing the link 
between endoMT and NCC relocalisation.  
4.4 Summary 
In this chapter I have investigated OFT development in tissue-specific 
knockout mice to compare the requirement of NRP1 in OFT endothelium versus 
cardiac NCCs. I have also examined the relative contribution of both ligands to 
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NRP1 signalling during OFT septation by analysing NRP1 knockin mice with 
mutations that selectively target VEGF-A versus SEMA3. Unexpectedly, this 
analysis revealed that NRP1 expression by cardiac NCCs and VEGF-A binding to 
NRP1 are both dispensable for OFT remodelling, even when NRP2 is additionally 
ablated. Instead, I found that loss of endothelial NRP1 was sufficient to recapitulate 
the complete OFT phenotype of Nrp1-null mice and that NRP1 served as a receptor 
for SEMA3C in ECs. Thus, working in collaboration with a Prof Pete Scambler’s 
group, we found that cardiac NCCs, contrary to prior hypotheses, do not respond to 
SEMA3C, but instead provide an essential source of SEMA3C and that NCC-derived 
SEMA3C promotes endoMT, a prerequisite for septal bridge formation. I also found 
that SEM3C signalling through NRP1 in endothelium indirectly causes cardiac NCC 
relocalisation within the OFT, another requirement for septal bridge formation in the 
proximal OFT. These findings demonstrate a mechanism by which cardiac NCCs 
communicate with OFT endothelium to orchestrate the septation of the embryonic 
OFT and therefore the separation of the arterial and pulmonary circulation for life 
after birth. 
I have, thus, replaced a previous model of NRP signalling to illustrate the 
complexity of developmental events that ensure proper OFT septation and involve 
multiple signalling events between the contributing cell lineages. Unravelling these 
interactions at the molecular and cellular level in mouse models will inform our 
interpretation of human genetic data obtained from patients with congenital heart 
defect patients, where a heterozygous single gene mutation is rarely found to be 
causative. In support of the idea that defective NRP1 signalling also contributes to 
human congenital heart disease, recent GWAS studies have shown that a non-
synonymous single nucleotide polymorphism (SNP) in the oligomerisation domain 
of NRP1 sequence is associated with Tetralogy of Fallot (Cordell et al., 2013).  
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Chapter 5 CSF1R-CRE TARGETS A SUBPOPULATION OF 
ENDOTHELIAL CELLS THAT CONTRIBUTES TO 
DEVELOPMENTAL AND PATHOLOGICAL 
ANGIOGENESIS  
5.1 Introduction 
Even though vasculogenesis mainly gives rise to the first embryonic and extra-
embryonic vessels and the remaining vascular network largely arises through 
angiogenic sprouting, several studies have suggested that angioblast-like endothelial 
precursors might contribute to the growth of organ-specific vessel beds in the 
embryo and to vascular repair in the adult (Nishikawa et al., 1998, Gehling et al., 
2000). The adult precursors have been termed endothelial progenitor cells (EPCs) 
and were first described by Asahara et al., who isolated single cells with the ability to 
differentiate into EC in vitro and in vivo from adult human peripheral blood (Asahara 
et al., 1997). These circulating EPCs were proposed to play a role in adult vascular 
homeostasis and repair by inserting into the blood vessel endothelium in response to 
endothelial injury or dysfunction, for example during atherosclerosis (Asahara et al., 
1997, Hill et al., 2003). Furthermore, studies have suggested that these cells might 
contribute to pathological angiogenesis, for instance during tumour vascularisation 
(Plummer et al., 2013, Nolan et al., 2007, Mellick et al., 2010). 
Despite several other studies since demonstrating that single cells within the 
blood or other tissues have the potential to differentiate into ECs in vitro and 
contribute to vascular growth in vivo (Quirici et al., 2001, Peichev et al., 2000, 
Gehling et al., 2000), the lack of a definite marker of EPCs has created controversy 
regarding the origin and nature of these cells. For example, it has been suggested that 
EPCs are derived from a stem cell population within the bone marrow and released 
into the blood stream, as transplanted murine bone marrow was shown to give rise to 
ECs in the host mouse (Asahara et al., 1999).  
Some studies have implied that the putative bone marrow-derived EPC 
precursor is of hematopoietic origin. Thus, the bone marrow contains hematopoietic 
stem cells (HSCs), which are the main source of all postnatal blood cells (Pietras et 
al., 2011). After isolation from the bone marrow using markers such as CD133 and 
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VEGFR2, these HSCs can differentiate into ECs in vitro and contribute to vessel 
growth in vivo (Ria et al., 2008, Reyes et al., 2002). Nevertheless, CD133 and 
VEGFR2 are not exclusively expressed by HSCs, and some studies have postulated 
that they are also expressed by EPCs (Peichev et al., 2000, Salven et al., 2003). 
Therefore, these experiments do not conclusively show whether EPCs are derived 
from a hematopoietic precursor. In fact, another study observed that CD133
+
 cells, 
which were also positive for the hematopoietic marker CD45 (Nakano et al., 1990, 
Van Craenenbroeck et al., 2013), did not differentiate into ECs in vitro, whereas 
CD133
+
CD45
-
 cells did develop into ECs, suggesting that EPCs are not of 
hematopoietic origin (Case et al., 2007).  
In addition to the bone marrow, some papers have argued the existence of 
tissue-resident EPCs. For example, in the retina, which is not vascularised until after 
birth, several studies have described stellate precursors that precede the growing 
vasculature and were proposed to function as angioblasts (Ashton, 1970, Kretzer et 
al., 1984). A recent genetic study using Cre/LoxP lineage tracing has provided 
compelling evidence for spindle-shaped cells that differentiate into ECs in vitro and 
contribute to the retinal vasculature (Kubota et al., 2011). 
Furthermore, several studies have suggested that the endothelium itself can 
give rise to EPCs that enter the blood stream and maintain vascular homeostasis and 
contribute to tissue remodelling and repair (Alvarez et al., 2008, Ingram et al., 2005). 
These cells, termed endothelial colony forming cells (ECFCs), differ from normal 
ECs in their proliferative and colony forming potential and were initially observed 
within the aorta (Schwartz and Benditt, 1976, Schwartz and Benditt, 1977). Since 
then, ECFCs have also been described within the microvasculature of several organs 
such as the lung (Schniedermann et al., 2010, Alvarez et al., 2008).  
Finally, some studies have postulated that macrophages may function as EPCs 
by transdifferentiating into ECs that contribute to vessel growth. For instance, it was 
reported that macrophages express endothelial markers and adopt an endothelial 
morphology to contribute to tumour angiogenesis (McKenney et al., 2001, Yan et al., 
2011). Furthermore, some studies reported that overexpression of the angiogenic 
molecules pleiotrophin or VEGF-A caused macrophages to express endothelial 
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markers such as VEC or CD31 and to form vascular structures both in vitro and in 
vivo, which may suggest vascular mimicry (Yeh et al., 1998, Chen et al., 2009a, Yan 
et al., 2011). Finally, as monocytes/macrophages are known to promote vascular 
growth by releasing pro-angiogenic factors such as VEGF-A or VEGF-C (McLaren 
et al., 1996, Tammela et al., 2005), they can also act as pro-angiogenic accessory 
cells that home to sites of active angiogenesis to create a pro-angiogenic environment 
(Grunewald et al., 2006).  
Considering the vast number of studies that differ in the molecular definition 
and proposed origin of EPCs (reviewed in Timmermans et al., 2009), the existence 
and function of these cells have remained contentious, with several studies 
suggesting that EPCs do not exist, but instead constitute pro-angiogenic monocytes 
that do not transdifferentiate into ECs (Rohde et al., 2006, Rehman et al., 2003). 
Nevertheless, considering the extensive evidence for a role of EPCs in both adult 
blood vessel formation and vascular homeostasis, it appears to me more likely that 
EPCs comprise a heterogeneous group of precursor cells, which can be found in 
different niches such as the bone marrow, vascular wall and blood and differ in their 
expression of markers as well as functional contribution to vascular repair and 
perhaps homeostasis. 
Our group has recently become interested in the role of EPCs, as previous 
observations by Dr Alessandro Fantin from our group observed an unusual type of 
EC that expresses CRE recombinase under the control of the promoter of Csf1r 
(Csf1r-Cre) (Deng et al., 2010), when he analysed the role of macrophages during 
developmental angiogenesis in the mouse. Thus, to observe the targeting efficiency 
of the Csf1r-Cre transgene in tissue macrophages, he introduced this gene into mice 
carrying a floxed Rosa
Yfp
 reporter (Srinivas et al., 2001). As expected, he observed 
many YFP
+
 macrophages, for example in the E11.5 hindbrain (Fantin et al., 2010). 
Unexpectedly, however, he also observed YFP
+
 cells that resembled ECs within the 
vasculature of E11.5 hindbrains (A. Fantin, unpublished). This observation raised the 
possibility that the Csf1r-Cre transgene was expressed in ECs or, alternatively, that 
the progeny of cells expressing the Csf1r-Cre transgene at some point in their 
development subsequently incorporated into the endothelium. My aim was to 
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investigate the nature and origin of these Csf1r-Cre-targeted ECs and to understand 
whether they contribute to vascular development. 
5.2 Results 
5.2.1  Csf1r-Cre labels ECs during embryonic angiogenesis 
To confirm Dr Fantin’s observations of endothelial targeting with Csf1r-Cre, 
I initially analysed E10.5 Csf1r-Cre;Rosa
Yfp
 hindbrains. At this time point, 
angiogenic sprouts have reached the subventricular side of the tissue and formed a 
vascular network termed the SVP (Fantin et al., 2013c, Plein et al., 2015b) (see 
Chapter 3). To visualise Csf1r-Cre targeting within hindbrains, I labelled them for 
YFP and the vessel/macrophage marker isolectin B4 (IB4) (Fantin et al., 2010, 
Sorokin and Hoyt, 1992). I also included the macrophage marker F4/80 (Austyn and 
Gordon, 1981, Rogove et al., 2002) to accurately distinguish ECs and yolk sac-
derived macrophages, which are known to migrate into the subventricular zone from 
E10.5 onwards to interact with endothelial tip cells and promote vessel anastomosis 
(Fantin et al., 2010). As published previously (Deng et al., 2010, Fantin et al., 
2013a), I confirmed that Csf1r-Cre targets almost all IB4
+
 and F4/80
+
 macrophages, 
(arrowhead, Figure 5.1B). In addition, I observed that YFP was sporadically 
expressed, albeit less strongly, in a small number of cells within the blood vessels, as 
previously seen by Dr Fantin. These cells did not appear to have the rounded 
morphology of circulating cells, but instead they resembled ECs in their elongated 
cell morphology (arrow, Figure 5.1B). Furthermore, they were not positive for 
F4/80, suggesting that these cells were macrophages adopting an endothelial 
morphology, as reported in previous studies of pathological angiogenesis (Scavelli et 
al., 2008).  
Quantitation of the number of YFP
+
 macrophages (defined as IB4
+
F4/80
+
 
single cells) and ECs (defined as IB4
+
F4/80
-
 vessel-bound cells) revealed that 
approximately 20% of YFP
+
 cells were ECs (Figure 5.1G). As the number of YFP
+
 
ECs was relatively low at E10.5, I next analysed Csf1r-Cre labelling in hindbrains at 
later stages. At E11.5, the number of YFP
+
 macrophages as well as Csf1r-
Cre;Rosa
Yfp
-labelled ECs had roughly doubled (Figure 5.1C,G). By E12.5, the 
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number of Csf1r-Cre;Rosa
Yfp
-targeted macrophages in the SVP had decreased. This 
finding agreed with prior studies, which showed that the amount of macrophages 
peaks at E11.5, when vascular anastomosis takes place, but that macrophages appear 
to move to deeper hindbrain layers after this stage (Fantin et al., 2010). In contrast to 
the decrease in macrophages in the subventricular zone, the amount of YFP
+
 ECs had 
increased by roughly 2.5 fold (Figure 5.1E,G). 
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Figure 5.1. Csf1r-Cre;Rosa
Yfp
 targets ECs during embryonic hindbrain angiogenesis. 
E10.5, E11.5 and E12.5 Csf1r-Cre;Rosa
Yfp
 hindbrains were wholemount labelled for YFP, 
F4/80 and IB4. High magnification of the boxed areas indicated in (A,C,E) are shown in 
(B,D,F) and in (B’,D’,F’) without the green channel. Arrowheads indicate Cre-targeted 
macrophages, arrows highlight Cre-targeted ECs and clear arrows denote unlabelled 
endothelium. The density of YFP
+
 macrophages (MΦ) and ECs in Csf1r-Cre;RosaYfp 
hindbrains was determined, where macrophages were defined as IB4
+
F4/80
+
 single cells and 
ECs as IB4
+
F4/80
-
 cells within vessels (G). Mean ± s.d., n= 3 each. Scale bars: 100 µm (A), 
50 µm (C).  
 163 
 
Having established that the Csf1r-Cre;Rosa
Yfp
-labelled cells within the 
hindbrain vasculature did not express F4/80 and did not morphologically resemble 
macrophages, I next investigated whether the Csf1r-Cre;Rosa
Yfp
-targeted vascular 
cells were located within the endothelium or were surrounding the endothelium like 
pericytes. Pericytes are mural cells that are embedded within the basement 
membrane of the vessel (reviewed in Armulik et al., 2011). The close spatial 
association of pericytes and ECs within blood vessels makes it difficult to discern 
between these two cell types in z stack confocal projections. Furthermore, pericytes 
are recruited to angiogenic sprouts in the brain as soon as they are formed 
(Abramsson et al., 2007) and would therefore be associated with SVP vessels at all 
time points analysed. To overcome these challenges in assigning an EC versus 
pericyte identity to the Csf1r-Cre;Rosa
Yfp
-targeted vascular cells, I stained Csf1r-
Cre;Rosa
Yfp
 E12.25 hindbrains for YFP together with the pericyte marker NG2 
(Ozerdem et al., 2001) and the vessel/macrophage marker IB4, acquired confocal 
scans and generated both z stack projections and x/y or y/z optical slices. Using this 
method, I confirmed that the hindbrain vasculature was extensively covered by NG2
+
 
pericytes (wavy arrows, Figure 5.2B), which were never YFP
+
. These NG2
+
 
pericytes wrapped around the vessels (solid wavy arrow, Figure 5.2C,D), whilst 
NG2
-
YFP
+
 cells were integrated into the endothelium (clear wavy arrow, solid 
arrow, Figure 5.2C-D).  
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Figure 5.2 Csf1r-Cre;Rosa
Yfp
 targets ECs, not pericytes in the mouse embryo hindbrain. 
E12.25 Csf1r-Cre;Rosa
Yfp
 hindbrain tissue was wholemount labelled for YFP, the pericyte 
marker NG2 and IB4 (A,B). The projection of a confocal z stack is shown in (A), with a 
higher magnification of the boxed area in (A) in (B), and the corresponding single channel 
for YFP in (A’,B’). A single optical x/y section from the boxed area in (B) is displayed in 
(C), and a y/z cross-section through the z stack at the level indicated with a dotted line in (C) 
is shown in (D). Corresponding single channels for YFP and NG2 are shown, as indicated. 
Arrowheads indicate Cre-targeted macrophages, wavy arrows NG2
+
 pericytes and arrows 
YFP
+
 endothelium. Clear wavy arrows highlight a lack of YFP expression in pericytes, 
whereas the clear arrow shows a lack of NG2 in the YFP
+
 ECs. Note that the YFP
+
 EC 
(arrow) lines the vessel, whilst the NG2
+
 pericyte (wavy arrow) is located on the outside. 
Scale bars: 100 µm (A), 50 µm (B).  
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5.2.2 Csf1r-Cre labels ECs during postnatal angiogenesis 
Having confirmed the endothelial identity of the Csf1r-Cre;Rosa
Yfp
-labelled 
cells, I next investigated whether Csf1r-Cre;Rosa
Yfp 
also targeted ECs in other tissues 
undergoing angiogenesis. I thus analysed YFP expression in the Csf1r-Cre;Rosa
Yfp
 
retina, as this tissue is a well established postnatal model of angiogenesis (Fruttiger, 
2007, Stahl et al., 2010) (see 1.5.2.1). In the murine retina, vascularisation begins 
immediately after birth, when vessels enter the most superficial retinal layer from the 
optic nerve head. Between P0 and P7, these vessels extend from this central point to 
cover the entire inner layer of the retina with an elaborate vascular network before 
sprouting into the deeper layers to form the deep and then the intermediate vascular 
plexus in the second and third weeks after birth (Connolly et al., 1988, Milde et al., 
2013). I first investigated P4 Csf1r-Cre;Rosa
Yfp
 retinas by staining them for YFP and 
IB4 together with F4/80. Analysis of YFP expression demonstrated that at this time 
point Csf1r-Cre;Rosa
Yfp
 targeted nearly all F4/80
+
 retinal macrophages, but there was 
no apparent YFP expression in ECs either in the more mature vessels of the central 
retina or the nascent vessels at the vascular front (arrowhead, clear arrow, Figure 
5.3B,C). I next investigated whether Csf1r-Cre;Rosa
Yfp
 targeted ECs in the retina at 
P7 by staining for YFP, F4/80 and IB4. This analysis demonstrated that, in contrast 
to retinas at P4, YFP was expressed by a large number of ECs within the central 
retina (arrow, Figure 5.3E). I also observed YFP expression in ECs of nascent 
vessels at the vascular front (arrow, Figure 5.3F). Similar observations had 
previously been made by Dr Fantin, demonstrating their reliability. 
Interestingly, Csf1r-Cre;Rosa
Yfp
 did not only label macrophages and ECs in 
the angiogenic retina, but also labelled stellate cells that were mainly located at the 
vascular front. This observation was intriguing, because several early studies had 
reported cells with a spindle-shaped morphology at the retinal vascular front and 
suggested that they contribute as angioblasts to retinal vascular growth (Ashton, 
1970, Kretzer et al., 1984, Okuno et al., 2011). However, the existence of such 
retinal angioblasts is contentious; for example, it has been suggested that they are 
immature astrocytes (see discussion).   
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Figure 5.3. Csf1r-Cre;Rosa
Yfp
 labels ECs during postnatal angiogenesis. 
P4 and P7 Csf1r-Cre;Rosa
Yfp
 retinas were wholemount labelled for YFP, the macrophage 
marker F4/80 and IB4. High magnification of boxed areas in (A,D) are shown in (B,C and 
E,F), respectively. The F4/80 and IB4 channels of images (D-F) are shown in (D’-F’). 
Arrowheads indicate Cre-targeted macrophages, solid arrows YFP
+
 and clear arrows YFP
-
 
endothelium. Scale bars: 200 µm (A), 50 µm (B). 
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In comparison to the vascularisation of the hindbrain, pericytes are recruited 
to the nascent vessels in the retina and are thus present from P0 (Fruttiger, 2002). To 
establish whether YFP expression within retinal blood vessels indicated endothelial 
rather than pericyte targeting, I labelled Csf1r-Cre;Rosa
Yfp
 retinas at P4 and P7 for 
YFP, NG2 and IB4. In agreement with my findings in the hindbrain, I did not 
observe YFP
+
 pericytes at either time point (clear wavy arrows, Figure 5.4C,E,F).  
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Figure 5.4. Csf1r-Cre;Rosa
Yfp
 targets ECs, not pericytes in the postnatal retina. 
P4 and P7 Csf1r-Cre;Rosa
Yfp
 retinas were wholemount labelled for YFP, NG2 and IB4. High 
magnification of the boxed areas in (A,D) and in (B,E) are shown in (B,E) and (C,F), 
respectively. Arrowheads indicate Cre-targeted macrophages, arrows YFP
+
 endothelium and 
clear wavy arrows YFP
-
NG2
+
 pericytes. Scale bars: 200 µm (A), 50 µm (B).  
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5.2.3 Csf1r-Cre;RosaYfp labels spindle-shaped cells at the vascular front, which 
are not astrocytes 
Because it has been suggested that stellate cells at the retinal vascular front 
are immature astrocytes (Fruttiger, 2002) and that Csf1r mRNA is expressed in a 
subpopulation of astrocytes (Sawada et al., 1993), Dr Fantin and I investigated 
whether the Csf1r-Cre;Rosa
Yfp
-labelled spindle-shaped cells at the vascular front are 
indeed astrocytes. For this experiment, we labelled P7 Csf1r-Cre;Rosa
Yfp
 retinas for 
YFP, IB4 and the astrocyte marker glial fibrillary acid protein (GFAP) (Dyer et al., 
2000). This revealed that Csf1r-Cre did target IB4
-
 cells at the vascular front that 
were non-endothelial and non-myeloid in character (clear wavy arrow, Figure 
5.5B’,C’). Some of these cells were GFAP+ and thus constituted astrocytes (wavy 
arrow, Figure 5.5B’’’). Nevertheless, there were other IB4-, spindle-shaped cells at 
the vascular front that were not GFAP
+
, suggesting that not all stellate cells targeted 
by Csf1r-Cre are astrocytes (double arrow, Figure 5.5C’’). These cells may be 
astrocyte precursors that have not yet begun to express GFAP (see discussion). 
Alternatively, they may comprise stellate cells that are vascular precursors, perhaps 
similar to those identified by Kubota et al. (Kubota et al., 2011).  
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Figure 5.5. Csf1r-Cre;Rosa
Yfp
 labels both GFAP
+
 and GFAP
-
 spindle-shaped cells at the 
retinal vascular front.  
P7 Csf1r-Cre;Rosa
Yfp
 retinas were wholemount labelled for YFP, IB4, and the astrocyte 
marker GFAP. The single YFP channel is shown in (A’-C’), single IB4 channel in (A’’-C’’) 
and single GFAP channel in (A’’’-C’’’). High magnification of areas indicated in (A-A’’) 
are shown in (B-B’’) and (C-C’’). Wavy arrows label YFP+GFAP+ and double arrows YFP+ 
GFAP
-
 spindle-shaped cells. Scale bar: 50 µm (A). Image courtesy of Dr Fantin.  
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5.2.4 Csf1r-Cre-targeted ECs do not express CSF1R or Csf1r-eGFP 
The endothelial YFP expression might reflect the existence of Csf1r-
Cre;Rosa
Yfp
-labelled single cells that insert into the endothelium to complement 
sprouting angiogenesis in the hindbrain and retina. Alternatively, Csf1r-Cre;Rosa
Yfp
 
labelling of the endothelium might reflect CSF1R expression by ECs, even though, 
to date, endothelial expression of CSF1R has not been described. In contrast, ECs are 
known to be a source of the CSF1R ligand, CSF1 (He et al., 2012).To investigate 
whether CSF1R is expressed by ECs in the embryonic hindbrain, I labelled E11.5 
Csf1r-Cre;Rosa
Yfp
 hindbrains for YFP, IB4 and CSF1R. As expected, macrophages 
were positive for both CSF1R and YFP (arrowhead, Figure 5.6A-B’’); however, 
none of the YFP
+
 ECs in the hindbrain expressed CSF1R (solid and clear arrow, 
Figure 5.6B-B’’). I made similar observations in the retina (not shown).  
As certain genes such as the gene encoding the myelin protein P0 are only 
transcribed and not translated during early stages of development (Kubota et al., 
2011) and a recent paper detected CSF1R expression in the neural linage by in situ 
hybridisation but not immunolabelling (Luo et al., 2013), I next investigated if the 
Csf1r promoter can drive gene expression in ECs. For this experiment, I took 
advantage of the Csf1r-eGFP transgene (Sasmono et al., 2003), in which GFP 
expression faithfully recapitulates Csf1r gene expression (Abtin et al., 2014, Chen et 
al., 2011a, Lin et al., 2006). This transgene contains an eGFP construct fused to the 
Csf1r promoter and it thus labels cells in which the Csf1r promoter is currently 
active, in contrast to the Csf1r-Cre;Rosa
Yfp
 transgene, which labels the Csf1r-Cre 
lineage, including cells that activated the Csf1r promoter at some point in their 
development independently of whether they activate it presently.  
By staining E11.5 Csf1r-eGFP hindbrains and retinas for GFP, CSF1R and 
IB4, using the same method employed to label Csf1r-Cre;Rosa
Yfp 
tissues, I observed 
that that all GFP
+
 cells were also CSF1R
+
 and thus macrophages (Figure 5.6D,F). In 
contrast, there was no GFP labelling of ECs (Figure 5.6D,F), similar to the lack of 
CSF1R immunolabelling. Together, these observations suggest that CSF1R is neither 
expressed at protein nor mRNA level in hindbrain endothelium. Future work should 
include an analysis by in situ hybridisation for Csf1r mRNA to validate this finding.   
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Figure 5.6. Csf1r-Cre;Rosa
Yfp
 targeted, YFP
+
 ECs do not express CSF1R. 
E11.5 Csf1r-Cre;Rosa
Yfp
 (A-B’’) and Csf1r-eGFP hindbrains (C-D’’) and P7 retinas (E-F’’) 
were wholemount labelled for YFP, CSF1R and IB4. High magnifications of the boxed areas 
indicated in (A,C,E) are shown in (B,D,F) together with the corresponding single channels 
for YFP (B’,D’,F’) and CSF1R (B’’,D’’,F’’), respectively. Arrowheads indicate CSF1R+ 
macrophages, solid arrows YFP
+
 ECs and clear arrows a lack of either YFP (F’,H’) or 
CSF1R (C’’,F’’,H’’) expression. HB: hindbrain. Scale bars: 100 µm (A), 50 µm (B,F), 200 
µm (E).  
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5.2.5 Unregulated RosaYfp activation cannot explain the presence of Csf1r-Cre 
targeted ECs in the retina 
Because other labs using Csf1r-Cre in combination with the Z/EG reporter 
transgene (Novak et al., 2000) did not report endothelial targeting (Stefater et al., 
2011), I next asked whether YFP
+
 labelling of ECs in Csf1r-Cre;Rosa
Yfp 
mice is an 
artefact caused by spontaneous recombination within the endothelium, independently 
of Cre expression and CRE-mediated excision of the Rosa
Yfp
 stop cassette. To 
address this possibility, I analysed YFP expression in hindbrains from E11.5 Csf1r-
Cre;Rosa
Yfp 
embryos lacking the Cre transgene, but carrying the Rosa
Yfp
 allele. This 
experiment showed that, YFP expression depended on the presence of CRE (Figure 
5.7D), demonstrating that Rosa
Yfp
 is only activated following the expression of Csf1r-
Cre and that it is therefore a faithful reporter of Cre expression.  
To confirm this finding, I also investigated YFP expression in Rosa
Yfp
 mice 
expressing Cre under the control of another transgene, Sm22a-Cre, which targets 
vascular myocytes  (Solway et al., 1995, Lepore et al., 2005) and pericytes 
(Anastasia et al., 2014, Daniel et al., 2012). I, thus, labelled P7 Sm22a-Cre;Rosa
Yfp
 
retinas for YFP, IB4 and the smooth muscle marker SMA and compared them to P7 
retinas from Csf1r-Cre;Rosa
Yfp
 mice stained for YFP, NG2 and IB4. As expected, 
Sm22a-Cre;Rosa
Yfp
 retinas expressed YFP strongly in the SMA
+
 myocytes of the 
artery (Figure 5.8D) as well as in the perivascular cells surrounding the capillaries 
(wavy arrows, Figure 5.8E-F’’). I did not, however, observe any EC-targeting in 
these retinas (clear arrows, Figure 5.8E-F’’). In contrast, the Csf1r-Cre;RosaYfp 
retinas displayed extensive endothelial Cre-targeting with no apparent YFP 
expression in pericytes (solid arrows and clear wavy arrows, respectively, Figure 
5.8A-C’’). Together, these experiments suggest that endothelial YFP expression is 
not due to the unspecific recombination of the Rosa
Yfp
 reporter. It also suggests that 
the Rosa
Yfp
 knockin allele is a more sensitive reporter than the Z/EG transgene.  
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Figure 5.7. Rosa
Yfp
 is not activated unspecifically in Csf1r-Cre-negative E11.5 
hindbrains. 
E11.5 Csf1r-Cre;Rosa
Yfp
 Cre-positive and Cre-negative hindbrains were wholemount 
labelled for YFP, CSF1R and IB4. Higher magnification of the boxed areas in (A,C) are 
shown in (B,D) together with the corresponding single channels for YFP in (B’,D’) and 
CSF1R (C’’,D’’). Solid arrowheads and arrows in (B’) indicate Cre-targeted macrophages 
and ECs, respectively, whereas clear arrowheads and arrows in (D’) highlight the absence of 
YFP in macrophages or ECs, respectively, in Cre-negative hindbrains. HB: hindbrain. Scale 
bars: 100 µm (A), 20 µm (B).  
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Figure 5.8. Sm22a-Cre targeting of the Rosa
Yfp
 reporter yields YFP
+
 mural cells but not 
ECs, whilst Csf1r-Cre targeting yields YFP
+
 ECs but not mural cells. 
P7 Sm22a-Cre;Rosa
Yfp
 and Csf1r-Cre;Rosa
Yfp
 retinas were wholemount labelled for YFP, 
IB4 and SMA or NG2. Higher magnification of the boxed areas in (A,D) are shown in (B,E), 
respectively. The dotted lines in (B,E) indicate the position of the high magnification y/z 
cross-sections shown in (C,F). (B,C,E,F) are shown as a single YFP channel in 
(B’,C’,E’,F’). Arrowheads indicate Cre-targeted macrophages, solid arrows YFP+ and clear 
arrows YFP
-
 endothelium. Solid wavy arrows highlight YFP
+
 and clear wavy arrows YFP
-
 
pericytes. Scale bars: 200 µm (A), 25 µm (B), 10 µm (C).  
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5.2.6 Csf1r-Cre;RosaYfp-labelled ECs are not of macrophage origin 
Having established that Csf1r-Cre;Rosa
Yfp
-targeting of ECs during embryonic 
and postnatal angiogenesis does not reflect endogenous CSF1R expression, and that 
it is not caused by ectopic activation of the Csf1r promoter in the transgene or a 
“leaky” RosaYfp locus, it appears likely that YFP+ ECs are derived from Csf1r-Cre-
targeted cells that are recruited into the vasculature during the process of 
angiogenesis. To identify the origin of these hypothetical Csf1r-Cre;Rosa
Yfp
-labelled 
progenitor cells, I first asked if they were derived from tissue macrophages (see 
1.3.3). Thus, tissue macrophages are known to promote developmental and 
pathological angiogenesis (Fantin et al., 2010, Nakao et al., 2005, Lewis et al., 1995, 
Wu et al., 2012), and several studies have suggested that this is partly due to their 
ability to transdifferentiate into ECs in vitro and contribute to tumour vascularisation 
(Chen et al., 2009a, Scavelli et al., 2008).  
To address whether Csf1r-Cre;Rosa
Yfp
-labelled ECs in the hindbrain were 
indeed derived from macrophages inserting into the angiogenic endothelium, Dr 
Fantin crossed Csf1r-Cre;Rosa
Yfp
 mice onto a Pu.1-null background. PU.1 is a 
member of the Ets family of transcription factors that is critical for myeloid and 
lymphoid differentiation, and mice with a mutation abolishing the DNA binding 
domain of this gene are therefore deficient in macrophages (McKercher et al., 1996, 
Scott et al., 1994). Dr Fantin’s initial analysis of E11.5 Csf1r-Cre;RosaYfp;Pu.1-/- and 
control hindbrains labelled for YFP and IB4 had suggested that YFP
+
 ECs were still 
present in mice lacking macrophages. To confirm this finding, I labelled E11.5 
Csf1r-Cre;Rosa
Yfp
 hindbrains on a Pu.1
+/+
 versus Pu.1
-/-
 background for YFP and 
IB4 together with F4/80. This experiment confirmed a lack of macrophages in the 
hindbrain of Pu.1
-/-
 embryos and further showed that YFP expression was retained in 
a subset of ECs in the Pu.1-null mutants (arrows, Figure 5.9D). Quantitation of the 
number of YFP
+
 ECs on a Pu.1-null versus wildtype background demonstrated that 
the amount of YFP
+
 ECs was unaffected by the loss of macrophages (Figure 5.9E). 
Together, these observations suggest that the YFP
+
 ECs in Csf1r-Cre;Rosa
Yfp
 
hindbrains are not macrophage-derived. 
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Unfortunately, Pu.1-null mutants die perinatally due to their compromised 
immune system (McKercher et al., 1996), and I was therefore not able to determine 
whether the Csf1r-Cre;Rosa
Yfp
-labelled ECs contributing to retinal vascularisation 
are also of non-macrophage origin.   
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Figure 5.9. Csf1r-Cre;Rosa
Yfp
-targeted ECs are not macrophage-derived. 
E11.5 Csf1r-Cre;Rosa
Yfp
 hindbrains on a Pu.1
+/+
 (A-B’) and Pu.1-/- (C-D’) background were 
wholemount labelled for YFP, F4/80 and IB4. High magnification of boxed areas indicated 
in (A,C) are shown in (B,D) and as a single F4/80 channel in (B’,D’). Arrowheads indicate 
Cre-targeted macrophages and arrows YFP
+
 endothelium. Note the absence of F4/80 in 
YFP
+
 endothelium. Quantitation of YFP
+
 ECs in 0.72 mm
2
 of E11.5 Csf1r-Cre;Rosa
Yfp
 
hindbrains on a Pu.1
+/+
 (n= 4) and Pu.1
-/-
 (n= 4) background (E). Mean ± s.d.; n.s., not 
significant. HB: hindbrain. Scale bars: 100 µm (A), 20 µm (B).  
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5.2.7 Postnatal induction of Csf1r-Cre results in YFP+ ECs 
To understand if Csf1r-Cre;Rosa
Yfp
-targeted ECs in the angiogenic retina are 
derived from an embryonic or postnatal Csf1r-Cre-labelled progenitor, I used mice 
containing the tamoxifen-inducible transgene Csf1r-Cre
ERT
 (Qian et al., 2011). This 
transgene enables the spatiotemporal control of Cre-mediated gene recombination, 
because Csf1r-Cre
ERT
 is only active in cells expressing the Csf1r promoter after 
tamoxifen administration (see 2.2.1.6) (Mattioni et al., 1994, Picard, 1994). Dr Fantin 
and I injected Csf1r-Cre
ERT
;Rosa
Yfp
 pups with tamoxifen from P4 to P6, collected 
retinas at P7 or P21, and stained them for YFP, F4/80 and IB4. Unexpectedly, even 
though macrophages expressed CSF1R (Figure 5.6E) and were abundant in the 
retina at both stages, tamoxifen induction led to the targeting of only a small number 
of macrophages at P7 and P21 (arrowhead, Figure 5.10B,D). Low frequency 
targeting of retinal macrophages was likely explained by tamoxifen’s inability to 
effectively cross the blood-retinal barrier (Noguchi et al., 1988) to reach the retinal 
macrophages, which under physiological conditions are mostly tissue-resident 
microglia rather than being derived from circulating monocytes (Caicedo et al., 
2005). The sparse YFP
+
 macrophages may, thus, be derived from tissue-resident 
microglia exposed to a small local source of tamoxifen that entered the retina across 
leaky patches of blood-retina-barrier. Alternatively, the targeted cells may be derived 
from extravasated monocytes that were targeted whilst still in the circulation. In 
support of this possibility, a low number of blood-derived monocytes were shown to 
be present in the healthy adult retina (Caicedo et al., 2005). 
Even though tamoxifen normally targets ECs with good efficiency due to 
their ready exposure to blood-borne agents (e.g. Pitulescu et al., 2010, Raimondi et 
al., 2014), there was no YFP expression apparent in ECs of P7 retinas (n= 4). By 
P21, however, some YFP
+
 ECs were present in the retinal vasculature, albeit at a low 
frequency, alongside a few YFP
+
 macrophages (arrowhead and arrow, respectively, 
Figure 5.10D). Because CSF1R is not usually expressed in retinal ECs (see Figure 
5.6), the presence of YFP
+
 ECs in Csf1r-Cre
ERT
;Rosa
Yfp
 mice suggests that the YFP
+
 
ECs are derived from a CSF1R-expressing precursor. Moreover, the fact that EC-
targeting was achieved with two independently generated transgenic lines, Csf1r-
Cre
ERT
 and Csf1r-Cre, argues against unspecific Cre activation caused by host 
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regulatory elements at the transgene integration site, because both transgenes should 
have randomly inserted into different genomic loci. In the absence of CSF1R 
expression by retinal ECs (Figure 5.6F), endothelial targeting by constitutive Csf1r-
Cre in the retina therefore implies the existence of an endothelial progenitor that 
expresses CSF1R, whilst postnatal targeting by Csf1r-Cre
ERT
 additionally shows that 
the progenitor population persists postnatally.  
A study investigating the P0-Cre lineage trace had demonstrated that P0-Cre-
labelling of the endothelium is caused by P0-expressing stellate cells at the retinal 
vascular front (Kubota et al., 2011). Analysis of Csf1r-Cre;Rosa
Yfp
 retinas had 
revealed cells with a similar morphology at the vascular front suggesting that Csf1r-
Cre might also label tissue-resident vascular precursors. Thus, the low frequency of 
YFP
+
 ECs might reflect the small amount of tamoxifen that enters the retinal 
parenchyma and reaches the tissue-resident progenitors. Nevertheless, given the 
delay between the induction of Cre
ERT
 and the appearance of YFP
+
 ECs in the retina, 
the Csf1r-Cre-labelled progenitors most likely do not arise locally within the retina, 
but elsewhere in the body and are subsequently recruited into the retina, presumably 
from the blood. For example, they might arise in the bone marrow from a precursor 
that releases progeny, in analogy to HSCs giving rise to circulating monocytes that 
can invade tissues and differentiate in accordance with local requirements. To 
support this hypothesis, further experiments should address whether the bone marrow 
is efficiently and immediately targeted in Csf1r-Cre
ERT
;Rosa
Yfp
 mice after tamoxifen 
administration.  
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Figure 5.10. Postnatal induction of Csf1r-Cre
ERT
 yields YFP
+
 retinal ECs. 
P7 and P21 retinas from Csf1r-Cre
ERT
;Rosa
Yfp
 mice that were injected with tamoxifen from 
P4 to P6 to induce Cre-recombination were wholemount labelled for YFP, F4/80 and IB4, 
and flatmounted (A-D). High magnification of the boxed areas indicated in (A,C,E) are 
shown in (B,D,F), respectively. Solid arrowheads indicate Cre-targeted macrophages, clear 
arrowheads non-recombined macrophages and arrows YFP
+
 ECs. Scale bars: 100 µm (A,C), 
20 µm (B), 50 µm (D).  
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5.2.8 A Csf1r-Cre-targeted cell population in blood and bone marrow 
expresses previously published markers of endothelial progenitors. 
Given my observations, which suggested that Csf1r-Cre labelled circulating 
vascular precursors that contribute to postnatal vascular development, I next 
investigated whether Csf1r-Cre targeted cells in the bone marrow and blood that 
resembled previously published endothelial progenitor populations within the adult 
mouse bone marrow (e.g. Asahara et al., 1999) (see 1.1.2.4). I, thus, immunolabelled 
the bone marrow of Csf1r-Cre;Rosa
Yfp
 adult mice with antibodies for YFP and the 
proto-oncogene KIT (CD117), which is a marker for hematopoietic stem cells but 
has also been used as a marker of endothelial progenitors (e.g. Suzuki et al., 2014, 
Fang et al., 2012, Dentelli et al., 2007). I found that YFP labelled numerous cells 
within the bone marrow, of which a subset was also KIT
+
 (open arrowheads, Figure 
5.11B).  
Because KIT also labels hematopoietic progenitors in the bone marrow (Shin 
et al., 2014) and Csf1r-Cre targets myeloid precursors, which are present in the bone 
marrow (Akashi et al., 2000), I next sought to distinguish hematopoietic progenitors 
from non-hematopoietic cells by FACS on adult Csf1r-Cre;Rosa
Yfp
 bone marrow 
cells stained for KIT and the hematopoietic marker CD45 (e.g. Case et al., 2007). 
Analysis of the FACS-sorted cells according to the gating strategies outlined in 
(Figure 5.11C-E) revealed that the majority of bone marrow cells from Csf1r-
Cre;Rosa
Yfp
 mice was CD45
+
 and therefore hematopoietic (80%), whereas the CD45
-
 
(non-hematopoietic) population constituted roughly 20% of bone marrow cells 
(Figure 5.11C,F). I next quantitated the number of KIT
+
 cells in these two 
populations and found that 2.8% of hematopoietic cells and only 0.5% of CD45
-
 
cells were positive for this progenitor marker (Figure 5.11D,G). This observation 
agreed with previous studies showing that CD45
-
 progenitors are rare within the 
bone marrow (Kucia et al., 2005). Strikingly, almost all of the non-hematopoietic 
KIT
+
 progenitors were YFP
+ 
(Figure 5.11G), consistent with the idea that Csf1r-
Cre;Rosa
Yfp
 does indeed label cells akin to previously described bone marrow-
resident EPCs (e.g. Case et al., 2007). 
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Intriguingly, Csf1r-Cre;Rosa
Yfp
 also appeared to label almost all (99%) of the 
hematopoietic progenitors within the bone marrow. As the myeloid precursors only 
constitute a subset of all bone marrow progenitors (Akashi et al., 2000), this result 
implied that Csf1r-Cre labelled haematopoietic progenitors other than those that give 
rise to myeloid cells. In agreement, 98.1% of all blood cells were YFP
+
 in Csf1r-
Cre;Rosa
Yfp
 adults (Figure 5.11H). These results agree with prior observations that 
Csf1r-Cre;Rosa
Yfp
 labels non-myeloid hematopoietic cells such as T lymphocytes 
(Deng et al., 2010).  
I next investigated by FACS whether the peripheral blood also contained 
Csf1r-Cre;Rosa
Yfp
-labelled KIT
+
CD45
-
 cells. As expected, most of the blood cells 
were CD45
+
 and therefore part of the hematopoietic lineage (98.4%) (Figure 5.11I). 
The remaining 1.6% CD45
-
 cells contained a small fraction of KIT
+
 cells (0.15%) 
(Figure 5.11I). Strikingly, all of these cells were YFP
+
, i.e. targeted by Csf1r-
Cre;Rosa
Yfp
 (Figure 5.11J). These results show that Csf1r-Cre labels a population of 
non-haematopoietic progenitor cells within the peripheral blood, albeit the number of 
these cells is much lower than in the bone marrow. Previous studies have suggested 
that the number of EPCs correlates with the level of neoangiogenesis (see 1.1.2.4) 
(Gill et al., 2001, Massa et al., 2005). Accordingly, the number of EPCs is thought to 
be low when the endothelium is mostly quiescent, which is usually the case in the 
adult (Heiss et al., 2005). In contrast, the number of these cells is thought to increase 
in response to endothelial injury, following myocardial infarction, for example 
(Massa et al., 2005). Thus, future studies should analyse whether the number of 
YFP
+
KIT
+
CD45
-
 cells is higher in pups with ongoing postnatal angiogenesis or 
adults with induced neovascularisation.  
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Figure 5.11. Csf1r-Cre;Rosa
Yfp
 targets cells expressing KIT in bone marrow and blood. 
Adult Csf1r-Cre;Rosa
Yfp
 bone marrow sections were immunolabelled for YFP and the 
progenitor marker KIT and counterstained with DAPI (A,B). A high magnification of the 
boxed area in (A) is shown in (B). Open arrowheads indicate KIT
+
YFP
+
 cells. FACS 
analysis of adult Csf1r-Cre;Rosa
Yfp
 bone marrow (n= 2) (C-G) and blood (H-J). Gating 
strategy for the intensity of CD45 (C), KIT (D) and YFP (E). Quantitation of indicated bone 
marrow and blood cell populations (F,G) and (I,J), respectively. Scatter plot showing Csf1r-
Cre;Rosa
Yfp
-labelling of blood cells (H). Mean ± s.d. Scale bars: 200 µm (A), 50 µm (B).  
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5.2.9 Csf1r-Cre targets ECs during pathological angiogenesis 
To investigate whether Csf1r-Cre-targeted progenitors also contribute to 
pathological angiogenesis, I used the OIR model (Smith et al., 1994) on Csf1r-
Cre;Rosa
Yfp
 pups (see 1.5.2.3). OIR is a useful tool to examine vascular pathologies 
in the retina, as the sequential exposure of neonatal mice to hyperoxia and then 
normoxia causes the formation of pathologic neovascular tufts similar to those seen 
in diseases such as retinopathy of prematurity (Chen and Smith, 2007) or diabetic 
retinopathy (Archer, 1976).  
OIR was performed as published previously (Connor et al., 2009) (see 
Chapter 2). Briefly, Csf1r-Cre;Rosa
Yfp
 pups were placed into a high oxygen 
chamber (>80% oxygen) from P7 until P12, which caused the vessels within the 
central retina to regress. They were then returned to normoxia (20% oxygen), which 
resulted in the formation of normal vessels as well as neovascular tufts within the 
central retinas (Lange et al., 2009). As the number of tufts peaks at P17, I collected 
the retinas at P17 and labelled them for YFP and IB4 together with CD45, which 
labels all cells of the haematopoietic system including macrophages. Analysis of 
YFP expression within these retinas revealed a large number of Csf1r-Cre-targeted 
cells in the OIR-induced vascular tufts (Figure 5.12A,B). Many of these cells were 
CD45
+
 macrophages (arrowheads, Figure 5.12A,B), consistent with prior reports 
that monocytes recruited from the blood closely associate with OIR-induced 
neovascular tufts (Ritter et al., 2006, Naug et al., 2000, Shen et al., 2007). In 
addition, YFP was present in a large number of ECs within the vascular tufts, 
suggesting that Csf1r-Cre had targeted ECs or their progenitors (Figure 5.12B,B’). 
Strikingly, Csf1r-Cre;Rosa
Yfp
-labelling of ECs appeared to be more prevalent within 
the tuft vessels than in healthy-looking neighbouring vessels (compare Figure 5.12B 
and C), however I have yet to formally quantitate this. 
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Figure 5.12. Csf1r-Cre;Rosa
Yfp
-targeted cells contribute to pathological angiogenesis. 
P17 Csf1r-Cre;Rosa
Yfp
 retinas with pathological angiogenesis due to OIR were wholemount 
labelled for YFP, IB4 and CD45. High magnification of the indicated boxed areas in (A) are 
shown in (B,C). The YFP and CD45 channels of (A-C) are shown in (A’-C’). Arrows 
highlight YFP
+
 ECs and arrowheads Cre-targeted macrophages within the neovascular tufts 
(VTs). Scale bars: 100 µm (A), 20 µm (B). 
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5.2.10 Csf1r-Cre-labelled ECs in the neovascular tufts caused by OIR are 
derived from recruited vascular precursors, not proliferating ECs 
The increased number of YFP
+
 ECs within the vascular tufts could be caused 
either by enhanced proliferation of YFP
+
 ECs within the neovascular lesions or by an 
increased recruitment of YFP
+
 cells into the vascular tufts. To distinguish these 
possibilities, I first measured endothelial proliferation by injecting pups with 
bromodeoxyuridine (BrdU) each day from P13 to P16, i.e. for 4 days after their 
return from hyperoxia to normoxia (see 2.2.2.6). Immunostaining of P17 retinas for 
BrdU revealed moderate levels of proliferation throughout the retinal endothelium. 
Intriguingly, the amount of BrdU
+
 cells did not appear to be higher within the 
vascular tufts than in the healthy-looking vessels outside the lesion, even though they 
contained a higher number of YFP
+
 ECs. This result was surprising, because 
excessive endothelial proliferation in response to VEGF-A secreted from myeloid 
cells and astrocytes was previously suggested to be responsible for vascular tuft 
formation in OIR (Naug et al., 2000). Even more surprising, most Csf1r-Cre;Rosa
Yfp
-
labelled ECs appeared to be BrdU
-
 (arrows, Figure 5.13B’,B’’), suggesting that they 
had not arisen from proliferating ECs. Together, these results suggest that the bulk of 
ECs in OIR-induced vascular tufts may be derived from recruited vascular 
progenitors rather than local EC proliferation. Nevertheless, further quantitative 
experiments are required to validate this hypothesis (see Chapter 6).   
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Figure 5.13. YFP
+
 ECs in neovascular tufts are not proliferating. 
P17 Csf1r-Cre;Rosa
Yfp
 retinas with neovascular tufts due to OIR were wholemount labelled 
for YFP, IB4 and BrdU. High magnification of the indicated boxed areas indicated in (A) are 
shown in (B,C). The YFP and BrdU channels of (A-C) are show in (A’-C’). Arrows 
highlight YFP
+
BrdU
-
 ECs and arrowheads indicate YFP
-
BrdU
+
 ECs. Scale bars: 100 µm 
(A), 20 µm (B).  
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5.2.11 Csf1r-Cre-targeted ECs and cells resembling vascular precursors emerge 
in the yolk sac 
Having established that Csf1r-Cre;Rosa
Yfp
 labels a putative vascular 
progenitor population in embryonic and postnatal mice, I next investigated the origin 
of these cells within the embryo. The first ECs of the mouse conceptus arise in the 
yolk sac at E7.5 and are derived from angioblasts, which are generated in the 
mesoderm of the posterior primitive streak (reviewed in Ferkowicz and Yoder, 2005) 
and migrate into the yolk sac to enable vasculogenesis (Risau and Flamme, 1995) 
(see 1.1.2.1). To address whether Csf1r-Cre targets these initial ECs, I stained E7.5 
Csf1r-Cre;Rosa
Yfp
 embryos and their extra-embryonic membranes for YFP and the 
earliest known endothelial marker VEGFR2 (Flamme et al., 1995). However, this 
analysis failed to detect any YFP
+
VEGFR2
+
 cells in the primitive vascular plexus of 
the yolk sac (clear arrow, Figure 5.14A,B), which suggests that Csf1r-Cre;Rosa
Yfp
 
does not label the earliest angioblasts; instead, I observed that giant trophoblast cells 
(GTCs) were labelled by Csf1r-Cre;Rosa
Yfp
 (curved arrow, Figure 5.14B) at this 
stage, consistent with their known expression of CSF1R (Jokhi et al., 1993, 
Ovchinnikov et al., 2010, Ide et al., 2002).  
In addition to being the site where the first ECs differentiate and aggregate 
into blood vessels, the yolk sac is also the tissue where the first blood cells are 
generated (see 1.3). This first wave of haematopoiesis occurs around E7.5 and 
mainly gives rise to primitive erythroid cells (Yoder et al., 1997a,), whereas from 
E8.25 onwards a subset of macrophages arises within the yolk sac, which colonise 
the embryo and give rise to the tissue-resident macrophages (Schulz et al., 2012) (see 
1.3.3.2). In agreement with CSF1R’s role in myeloid differentiation, I did not detect 
any single YFP
+
 cells in the yolk sac at E7.5 (Figure 5.14A,B), whilst at E8.5 the 
VEGFR2
+
 vessels within the Csf1r-Cre;Rosa
Yfp
 yolk sacs contained many round 
YFP
+
 cells (arrowhead, Figure 5.14D,E). These cells presumably constituted the 
myeloid progenitors (see 1.3.1); however some of these cells might have also 
comprised the earliest circulating vascular precursors. In agreement with the fact that 
vascular precursors are present in the yolk sac at this stage, Csf1r-Cre;Rosa
Yfp
 also 
labelled a small number of cells that resembled ECs due to their flat morphology, and 
these cells appeared less bright for YFP (arrow, Figure 5.14D,E), similar to what 
was observed for YFP
+
 ECs in the hindbrain (e.g. Figure 5.1). By E9.5 the number 
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of YFP
+
 round cells within the yolk sac vasculature had substantially increased 
(arrowhead, Figure 5.14G). In addition and consistent with the notion that vascular 
precursors are emerging within the yolk sac at this stage, the number of ECs had also 
increased (arrow, Figure 5.14G).  
To analyse whether all of the YFP
+
 round cells within the vasculature of 
Csf1r-Cre;Rosa
Yfp
 yolk sacs constituted early yolk-sac derived macrophages or 
whether they in fact also comprised embryonic endothelial progenitors, I repeated 
my analysis in Csf1r-Cre;Rosa
Yfp
 mice on a Pu.1-null background, which lack cells 
of the myeloid lineage (see Figure 5.15). Analysis of 8.5 Csf1r-Cre;Rosa
Yfp
;Pu.1
-/-
 
yolk sacs labelled for YFP and VEGFR2 revealed that the number of small round 
YFP
+
 cells was reduced in these mutants, presumably due to the lack of myeloid 
progenitors in the yolk sac. Nevertheless, a small number of round YFP
+
 cells 
persisted in the Pu.1
-/-
 mutant yolk sacs (arrowhead, Figure 5.15B) and had 
increased by E9.5 (arrowhead, Figure 5.15D). In addition, I observed a similar 
number of flatter YFP
dim
 cells within the endothelium of Pu.1
-/-
 embryos compared to 
Pu.1
+/+
 yolk sacs, which again agreed with my analysis in the Csf1r-
Cre;Rosa
Yfp
;Pu.1
-/-
 E11.5 hindbrains (arrows, Figure 5.15D).  
To determine whether the YFP
+
 round cells in Csf1r-Cre;Rosa
Yfp
;Pu.1
-/-
 yolk 
sacs expressed markers associated with a precursor identity, I labelled E9.5 Csf1r-
Cre;Rosa
Yfp
;Pu.1
-/-
 yolk sacs for YFP and KIT, which has been published as a 
marker of EPCs (e.g. Suzuki et al., 2014, Fang et al., 2012, Dentelli et al., 2007). 
This revealed that all round cells were indeed KIT
+
 (arrowhead, Figure 5.15E,F), 
indicating that they might constitute vascular precursors. To investigate this 
hypothesis further, I FACS-sorted E9.0 Csf1r-Cre;Rosa
Yfp
 yolk sacs labelled for KIT, 
CD31 (to distinguish YFP
+
 ECs), and CD45 to label haematopoietic cells (Figure 
5.15G). This revealed that the majority (75%) of all YFP
+
 cells was CD45
+
, which 
agreed with the idea that Csf1r-Cre;Rosa
Yfp
 labels the myeloid cells emerging within 
the yolk sac. Out of the remaining CD45
-
 cells, a subset (5% of total YFP
+
 cells) was 
CD31
+
KIT
-
 and thus presumably constituted the bona fide ECs, as these cells do not 
express KIT (see Figure 5.15). Intriguingly, Csf1r-Cre also labelled a population of 
KIT
+
CD31
+
 cells (~18%), which most likely constituted the vascular precursors and 
the round YFP
+
 cells that persisted in the Pu.1-null mice. Nevertheless, as a study 
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suggested that some immature macrophages are still generated in the yolk sac on a 
Pu.1-null background (Olson et al., 1995, Lichanska et al., 1999) and these cells 
might not express CD45 but KIT, further experiments should analyse whether these 
cells express other early myeloid genes such as the gene encoding myeloperoxidase 
(Olson et al., 1995).   
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Figure 5.14. Csf1r-Cre;Rosa
Yfp
 labels ECs in the yolk sac. 
E7.5 (A,B), E8.5 (C-E) and E9.5 (F-G) Csf1r-Cre;Rosa
Yfp
 yolk sacs were wholemount 
immunolabelled for YFP and VEGFR2. High magnification of boxed areas indicated in 
(A,C,F) are shown in (B,D,G), respectively. A cross-section through the confocal z stack 
projection in (D) is shown in (E). The dotted line (e) indicates the level of cross-section. The 
clear arrow highlights the lack of YFP expression in ECs and the curved arrow Csf1r-
Cre;Rosa
Yfp
-labelled giant trophoblast cells (GTCs). Arrowheads highlight YFP
+
, round cells 
and solid arrows YFP
dim
 flattened cells within the yolk sac vasculature. Scale bars: 100 µm 
(A,C), 50 µm (B), 20 µm (D).  
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Figure 5.15. Csf1r-Cre;Rosa
Yfp
 labels non myeloid-derived cells and ECs in yolk sac. 
E8.5 and E9.5 Csf1r-Cre;Rosa
Yfp
;Pu.1
-/-
 yolk sacs were immunolabelled for YFP and 
VEGFR2 or KIT. High magnification of boxed areas indicated in (A,C) are shown in (B,D), 
respectively. A KIT single channel of (E) is shown in (F). Arrowheads highlight YFP
+
KIT
+
 
round cells and solid arrows YFP
dim
 flattened cells within the yolk sac vasculature. The clear 
arrow indicates a lack of KIT expression in a YFP
dim
 cell. FACS analysis of a E9.0 Csf1r-
Cre;Rosa
Yfp
 yolk sac labelled for CD45, CD31 and KIT (G). Scale bars: 100 µm (A), 20 µm 
(B,E).  
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5.2.12 Csf1r-Cre-targeted cells, which are not macrophage-derived, also 
contribute to lymphatic endothelium 
The lymphatic vasculature is a unidirectional network of blind-ended vessels, 
which absorbs excess interstitial fluid from the periphery and returns it to the veins, 
thus maintaining interstitial fluid homeostasis (reviewed in Schulte-Merker et al., 
2011). The lymphatic system also provides a conduit for patrolling lymphatic cells 
and therefore presents an important component of the immune system (reviewed in 
Liao and Padera, 2013). Similar to blood vessels, lymphatic vessels consist of a 
specialised endothelial layer that is covered by mural cells. The lymphatic ECs 
resemble blood vessel ECs in their morphology and apical-basal polarity; however, 
they differ in their specialised junctions, which allow the pressure-dependent 
absorption of the interstitial fluid (Leak and Burke, 1966).  
The lymphatic vasculature is first formed when venous cells acquire 
lymphatic properties and sprout from the cardinal vein (Srinivasan et al., 2007). The 
migrating lymphatic ECs then coalesce in areas, where VEGF-C is expressed by the 
mesenchyme, and form lymph sacs (Karkkainen et al., 2004). This process occurs at 
several positions along the anterior–posterior axis and results in the formation of the 
jugular, medial, and axial lymph sacs. Lymphatic vessels then sprout from the lymph 
sacs to give rise to the lymphatic vascular network (Figure 5.16A). The process of 
lymphatic sprouting, lymphangiogenesis, has many similarities to angiogenesis 
(reviewed in Adams and Alitalo, 2007). Thus, in both cases vessels led by tip and 
then stalk cells sprout from pre-existing ones (Xu et al., 2010, Gerhardt et al., 2003, 
Fantin et al., 2013a). Furthermore, in comparison to blood vessels, bone marrow-
derived lymphatic EPCs are thought to be involved in pathological lymph vessel 
growth (Lee et al., 2010, Kerjaschki et al., 2006). In addition, a recent publication 
has suggested that KIT
+
 cells derived from the hemogenic endothelium contribute to 
the development of the mesenteric lymphatic vessels (Stanczuk et al., 2015). 
Nevertheless, a study has reported that myeloid cells also contribute to the lymphatic 
endothelium during tumour lymphangiogenesis (Zumsteg et al., 2009).  
To investigate whether Csf1r-Cre;Rosa
Yfp
-labelled cells contribute to 
lymphatic vascular development, I sectioned through the jugular lymph sacs (JLS) of 
E15.5 Csf1r-Cre;Rosa
Yfp
 embryos on a wildtype and Pu.1-null background, and 
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labelled them for YFP, IB4 and the lymphatic/venous marker NRP2 (Lin et al., 2010, 
Xu et al., 2010, Yuan et al., 2002). In the Pu.1
+/+
 sections, YFP expression was 
observed in cells within the lymph (asterisk, Figure 5.16C-D’); additionally, YFP 
was also expressed within the lymphatic endothelium of the JLS as well as the 
superficial lymphatics (SLs) (arrow, Figure 5.16D,D’). In Pu.1-/- mice, no YFP+ 
lymph was apparent (delta symbol, Figure 5.16E-F’); nevertheless, Csf1r-
Cre;Rosa
Yfp
-targeting of the lymphatic endothelium persisted (arrows, Figure 5.16E-
F’). 
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Figure 5.16. Csf1r-Cre-targeted cells, which are not macrophage-derived, contribute to 
jugular lymph sac endothelium. 
Schematic representation of the superficial lymphatics (SLs) and jugular lymph sac (JLS) 
(green) (A) and a transverse section through the lymphatics within the head (B) in an E15.5 
embryo. (C-F) Transverse sections of E15.5 Csf1r-Cre;Rosa
Yfp
 embryos on a Pu.1
+/+
 (C-D’) 
or Pu.1
-/-
 (E-F’) background at the level of the JLSs were labelled for YFP, the lymph/vein 
marker NRP2 and IB4. High magnification of boxed areas in (C,E) are shown in (D,E) and 
as a GFP single channel in (D’,F’). Arrows indicate YFP+ endothelium within the JLS, the 
asterisk the Cre-targeted lymph and the delta the absence of lymph targeting on a Pu.1
-/-
 
background. Scale bars: 200 µm (C), 50 µm (D).  
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I next investigated whether Csf1r-Cre;Rosa
Yfp
-targeting of ECs is also present 
in other lymphatic beds by labelling E17.5 skin from Csf1r-Cre;Rosa
Yfp
;Pu.1
-/-
 
embryos for YFP, NRP2 and the venous/capillary marker endomucin (Liu et al., 
2001, Kuhn et al., 2002). As observed for the JLSs, YFP expression could be found 
in the lymphatic endothelium of Pu.1
-/-
 dermal lymphatics (arrows, Figure 
5.17A,B,B’). Interestingly, the targeting of the endothelium appeared to be higher in 
the E17.5 skin than the E15.5 JLS, suggesting that EC incorporation continues 
throughout lymphangiogenesis, as observed in the hindbrain and retina for blood 
vascular angiogenesis.   
I next investigated whether CSF1R was expressed by the lymphatic ECs. 
Staining of E17.5 Csf1r-eGFP skin for GFP, NRP2 and endomucin showed that 
CSF1R was widely expressed by macrophages (defined as CSF1R
+
 single cells), but 
not by lymphatic ECs (arrowhead, clear arrows, respectively, Figure 5.17C,D,D’). 
Whilst I have not yet conducted a thorough time course, this finding raised the 
possibility that a Csf1r-Cre-targeted vascular precursor contributes to 
lymphangiogenesis, similar to what I observed for blood vascular angiogenesis. 
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Figure 5.17. Csf1r-Cre;Rosa
Yfp
-targeted ECs of non-macrophage origin contribute to 
lymphatic endothelium in the skin. 
E17.5 skin from Csf1r-Cre;Rosa
Yfp
 mice on a macrophage-deficient Pu.1
-/-
 background (A-
B’) and from Csf1r-eGFP mice (C-D’) was labelled for YFP/GFP, NRP2 and the vascular 
marker endomucin. High magnification of boxed areas in (A,C) are shown in (B,D) and as a 
single YFP channel in (C’,D’). The solid arrows indicate YFP+ ECs and the double arrow a 
rare single, YFP
+
 cells in the tissue, possibly macrophage-like despite the Pu.1 deletion. The 
arrowheads highlight examples of GFP
+
 macrophages and the clear arrows GFP
-
 
endothelium. L: Lymphatic vessel, BV: Blood vessel. Scale bars: 100 µm (A), 200 µm (B), 
20 µm (C), 50 µm (D).  
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5.2.13 Csf1r-Cre-mediated cell death induction causes embryonic lethality by 
E10.5 
To understand the significance of Csf1r-Cre-targeted vascular precursors for 
embryonic vascular development, I introduced the Csf1r-Cre transgene into mice 
with a floxed Rosa
Dta
 knockin allele (Ivanova et al., 2005). Analogous to the Rosa
Yfp
 
reporter, this allele expresses the diphtheria toxin fragment A (DTA) only after Cre-
mediated stop cassette excision, which results in cell death and thus allows in vivo 
Cre-specific cell ablation (Breitman et al., 1990). By generating embryos, which 
expressed the Rosa
Dta
 allele under the control of the Csf1r-Cre transgene, I was 
therefore hoping to observe vascular development in mice lacking the myeloid 
lineage, as well as the Csf1r-Cre-labelled vascular precursor cells.  
As the Rosa
Dta
 allele contains a Yfp allele, which is constitutively expressed, I 
was unable to validate the Csf1r-Cre;Rosa
Dta
 targeting efficiency. Nevertheless, 
analysis of the number of Csf1r-Cre;Rosa
Dta
 embryos in litters from Rosa
Dta
 females 
crossed to Csf1r-Cre males revealed that no mutant embryos survived past E10.5, 
and already at E9.5, the mutants were noticeably smaller and developmentally 
delayed compared to their wildtype littermates (Figure 5.18A,C,E). This early 
embryonic lethality was unexpected, as the number of ECs labelled by Csf1r-
Cre;Rosa
Yfp
 is fairly low at this stage (see Figure 5.18). Furthermore, deletion of the 
myeloid lineage is known to only result in death perinatally (McKercher et al., 1996). 
Instead, the early lethality suggested placental insufficiency. In agreement, CSF1R is 
known to be expressed by GTCs (giant trophoblast cells), which are crucial for 
embryo implantation and post-implantation placental modulation (Jokhi et al., 1993, 
Ovchinnikov et al., 2010). It would therefore be of interest to analyse the placenta of 
these mutants.  
To understand whether vascular development was affected in these mutants, I 
could therefore only study early vascular development up to E9.5. Thus, I 
immunolabelled the embryos and yolk sacs from E9.5 Csf1r-Cre;Rosa
Dta
 mutants 
and their wildtype littermates for VEGFR2. In wildtype embryos and yolk sacs, 
VEGFR2 staining revealed an extensive network of vessels. In the mutants, vessels 
also formed in the embryo and yolk sac; however, they seemed much less 
remodelled. This vascular phenotype varied in its severity. Thus, one mutant 
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displayed a vascular phenotype that was likely due to a developmental delay of 1d, 
and the vasculature in one mutant yolk sac was abnormal resembling a sheet of ECs 
rather than a network of vessels (Figure 5.18F). Thus, I could not obtain any 
evidence that the Csf1r-Cre-targeted vascular precursors are important for early 
angiogenesis. 
Future work will be needed to establish the significance of losing the vascular 
precursor for hindbrain and retinal angiogenesis or lymphangiogenesis. As a recent 
publication showed that CSF1R expression in the GTCs is achieved by a promoter 
region distinct from the one driving myeloid CSF1R expression (Ovchinnikov et al., 
2010), it might be possible to generate a Cre driver that targets vascular precursors 
independently of GTC. This line could then be used to investigate whether 
embryonic development is affected in mice where DTA is expressed under the 
control of the Csf1r promoter without the trophoblast-specific sequence.  
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Figure 5.18. Diphtheria toxin A-mediated deletion of cells targeted by Csf1r-Cre results 
in substantial developmental delay at E9.5 and embryonic lethality by E10.5. 
E9.5 Csf1r-Cre;Rosa
Dta
 and wildtype control embryos (A,C,E) and their yolk sacs (B,D,F) 
were wholemount immunolabelled for VEGFR2. Note the developmental delay in Csf1r-
Cre;Rosa
Dta
 mutants. Scale bars: 200 µm (A), 50 µm (B).  
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5.3 Discussion 
Ever since the first description of EPCs in the peripheral human blood by 
Asahara et al., there has been great controversy regarding the origin and function of 
these cells (Asahara et al., 1997). Some studies have postulated that cells from 
several sources such as the bone marrow or endothelium can give rise to circulating 
vascular precursor cells that contribute to blood vessel growth or repair in vivo 
(Quirici et al., 2001, Peichev et al., 2000, Gehling et al., 2000). Other studies have 
dismissed the notion of EPCs completely, suggesting that prior in vitro findings are, 
for instance, experimental artefacts with no biological relevance (Rohde et al., 2007, 
Prokopi et al., 2009), or that the pro-angiogenic cells observed in vivo are in fact pro-
angiogenic monocytes (e.g. Rohde et al., 2006, Rehman et al., 2003). It has proven 
difficult to resolve the EPC controversy to a large part, because of the lack of a 
definite marker of such cells (reviewed in Timmermans et al., 2009). Accordingly, 
many studies aiming to demonstrate the nature or function of these cells have 
differed in their isolation procedures and molecular definition. This has greatly 
impaired the advancement of this field and, therefore, there is currently no consensus 
regarding the role or even existence of EPCs. 
I may have provided evidence for the existence of a population of vascular 
progenitors with the help of genetic tools, independently of identifying a definite 
EPC marker. Thus by analysing the lineage trace of the Csf1r-Cre transgene, I 
identified a subpopulation of ECs in both blood and lymphatic vessels that is likely 
derived from Csf1r-Cre-labelled vascular precursors. Thus, I demonstrated that 
Csf1r-Cre labels cell populations that share molecular and morphological 
characteristics with cells previously referred to as EPCs or vascular progenitors, e.g. 
Csf1r-Cre-labelled cells in the blood and bone marrow that are KIT
+
CD45
-
, and 
Csf1r-Cre-labelled spindle-shaped cells in the retina that are GFAP
-
 (see below, and 
Figures 5.5, 5.11 and 5.12). In addition, having excluded that Csf1r-Cre-mediated 
lineage tracing of a subset of ECs with the Rosa
Yfp
 is caused by endothelial Csf1r or 
ectopic CRE expression, or that is caused by unspecific spontaneous Rosa
Yfp
 
recombination (see Figures 5.6-5.8), the most likely explanation for the endothelial 
targeting with Csf1r-Cre is that these cells are derived from Csf1r-Cre-labelled 
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vascular progenitors. Below, I will discuss the evidence for this suggestion in more 
detail. 
My analysis revealed that Csf1r-Cre-labelled ECs persist on a macrophage-
deficient background (see Figure 5.9), implying that these progenitors are not of 
myeloid origin, at least during embryonic angiogenesis. This was surprising, as the 
only cells targeted by Csf1r-Cre and linked to EC differentiation described to date 
are macrophages (Schmeisser et al., 2001). For example, macrophages can adopt an 
endothelial morphology and contribute to tumour vascularisation (Chen et al., 2009a, 
Scavelli et al., 2008). Nevertheless, my observation that Csf1r-Cre labels a non-
myeloid progenitor population during developmental angiogenesis agrees with other 
studies, which have, in principle, shown that Csf1r is not exclusively expressed by 
cells of the myeloid lineage (Sawada et al., 1993, Luo et al., 2013). Thus, it was 
recently shown that the Csf1r gene is expressed by astrocytes as well as adult 
neurons, albeit only at mRNA level (Luo et al., 2013). Whilst I have excluded that 
the ECs lineage traced by Csf1r-Cre are of macrophage origin during embryonic 
angiogenesis, I would still need to examine whether the Csf1r-Cre-labelled ECs 
during pathological angiogenesis are also not myeloid-derived, for example, by 
showing that other macrophage-specific Cre-lines such as LysM-Cre (Clausen et al., 
1999) do not lineage trace ECs in neoangiogenic vessel beds.   
My analysis of CSF1R expression has thus far not detected any endothelial 
Csf1r expression in any of the developing tissues examined (e.g. Figures 5.6, 5.15). 
Accordingly, these experiments imply the existence of Csf1r-Cre-labelled vascular 
progenitors that at some point express Csf1r. These vascular progenitors appear to 
also exist postnatally, because I observed YFP
+
 retinal ECs after the postnatal 
induction of Csf1r-Cre
ERT
 expression with tamoxifen (see Figure 5.10). Moreover, 
my preliminary analysis (n= 1) identified Csf1r expression in an EPC-like 
CD31
+
CD45
-
KIT
+
YFP
+
 cell population isolated from the P10 Csf1r-Cre;Rosa
Yfp
 
brain (data not shown). Together, these experiments suggest that Csf1r is expressed 
by cells that serve as vascular precursors, but they would have to be repeated to 
derive a firm conclusion.  
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Whether CSF1R has a functional role in Csf1r-Cre-labelled vascular 
progenitors and/or their offspring is presently not clear. To address this possibility, 
one can attempt to draw inferences from the EPC literature; however, there is 
currently much controversy on this topic. On the one hand, some studies have 
suggested that CSF1 signalling through CSF1R induces EPC mobilisation, because 
CSF1 promotes tumour vascularisation (Eubank et al., 2003, Okazaki et al., 2005). 
On the other hand, this pro-angiogenic effect may in fact be caused by CSF1 acting 
on pro-angiogenic monocytes, but this possibility has not yet been addressed.  
Alternatively, CSF1R signalling might not play a functional role in EPCs at all, 
in analogy to the gene encoding the myelination protein P0, which is expressed in 
mesenchymal stem cells (Hagedorn et al., 1999) and vascular progenitors (Kubota et 
al., 2011), albeit only at mRNA level. Generally speaking, a gene may be part of a 
transcriptional programme consisting of some genes that are functionally required 
and therefore translated into protein, as well as other genes that are not required and 
whose translation may be actively suppressed, for example by inhibitory RNA. The 
dispensable expression of these genes might have persisted throughout evolution 
when their protein products are not harmful. Alternatively, if the protein products are 
of an evolutionary disadvantage, mRNA expression from these genes might have 
been able to persist because means have evolved to repress their translation. To 
investigate these hypotheses, future studies could, for instance, compare Csf1r 
mRNA and CSF1R protein expression in Csf1r-Cre-tagged progenitors after FACS 
sorting Pu.1-null embryos to obtain YFP
+
CD45
-
KIT
+
 non-endothelial (i.e. CD31
-
) 
cells. 
The finding that Csf1r-Cre labels a subset of ECs of non-myeloid origin raises 
the question of how reliable the Csf1r-Cre transgene is as a tool to distinguish roles 
for floxed target genes in macrophages versus ECs. For example, our group used this 
transgene to demonstrate that macrophage-derived NRP1 was not required for 
developmental angiogenesis, whilst endothelial NRP1 was essential (Fantin et al., 
2013a) (see Chapter 3). Despite Csf1r-Cre targeting most macrophages, it targets 
only a subset of ECs at the relevant developmental stages (see Chapter 3). In 
contrast, deletion of endothelial NRP1 using the Tie2-Cre transgene, which targets 
most ECs and tissue macrophages (Kisanuki et al., 2001), recapitulated the severe 
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vascular defects displayed by Nrp1-null embryos (Fantin et al., 2013a, Kawasaki et 
al., 1999). Thus, the comparative analysis of Csf1r-Cre;Nrp1
fl/-
 and Tie2-Cre;Nrp1
fl/-
 
embryos suggested an exclusive role of NRP1 in ECs rather than in macrophages 
during angiogenesis.  
Other studies have used the Csf1r-Cre transgene to investigate whether 
VEGFR1 is required by macrophages to regulate retinal vascularisation (Stefater et 
al., 2011). Thus at P18, Csf1r-Cre;Flt
fl/+
 mice demonstrate a higher vessel density in 
the deeper retinal plexi than their wildtype littermates. However, in my preliminary 
analysis (n= 1), I found that at P21, Csf1r-Cre extensively targeted ECs in all three 
retinal plexi, including the deep plexus (data not shown). Accordingly, if Csf1r-Cre 
were to delete Flt in the retinal endothelium in addition to macrophages, then it could 
not be excluded that an endothelial deletion of Flt was contributing or even 
responsible for the Csf1r-Cre;Flt
fl/+
 phenotype reported by Stefater et al. (2011). In 
fact, VEGFR1 is known to play a role in endothelial VEGF-A signalling (Gille et al., 
2001, Kanno et al., 2000, Autiero et al., 2003b).  
Given the widespread use of the Csf1r-Cre transgene as a tool that is meant to 
selectively target macrophages at postnatal stages, it is surprising that the endothelial 
targeting by this transgene has not been reported in previous studies (e.g. Stefater et 
al., 2011, Gordon et al., 2010, Deng et al., 2010). One explanation might be that 
other studies did not notice the endothelial targeting of this transgene, because of the 
type of analysis used, e.g. FACS of blood cells (Deng et al., 2010). It is also 
conceivable that others using immunostaining to visualise YFP expression were not 
able to discern labelled ECs from vessel-associated macrophages (e.g. Stefater et al., 
2011). 
An alternative explanation why endothelial targeting with Csf1r-Cre was 
previously missed might be that the reporter transgenes used in prior studies are less 
readily expressed in ECs than the Rosa
Yfp
 allele, which I have used in my 
experiments. Thus, other studies investigating Csf1r-Cre-targeting in the retina and 
lymphatics have used the Z/EG reporter allele (Novak et al., 2000, Stefater et al., 
2011, Gordon et al., 2010). As Rosa
Yfp
 is a knockin allele into the constitutively 
expressed Rosa26 locus (Soriano, 1999) (see 2.2.1.4), it is possible that the Rosa26 
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locus is more accessible to CRE recombinase in ECs than the Z/EG transgene, whose 
integration site into the genome is not well defined (Novak et al., 2000). For 
example, in zebrafish the insertion of transgenes into different loci within the 
genome resulted in varying levels of transgene activation (Feng et al., 2001). To test 
the hypothesis that Csf1r-Cre-labelling of endothelium depends of the recombination 
reporter used, one could directly compare Z/EG- and Rosa
Yfp
-mediated labelling with 
Csf1r-Cre and possibly other, well-established endothelial transgenes such as Tie2-
Cre (Kisanuki et al., 2001).  
Another explanation for our observation of EC-targeting, in contrast to reports 
from other laboratories using this line, is that the Csf1r-Cre transgene has been 
subject to epigenetic drift or is affected by genetic background differences in 
different host laboratories. Disagreeing with this hypothesis, I observed EC targeting 
also with freshly imported Csf1r-Cre
ERT
 mice from the JAX laboratories (see Figure 
5.10). To address whether EC labelling is somehow facilitated in the Rosa
Yfp
 mice, 
future work could investigate whether endothelial labelling also occurs in Csf1r-
Cre
ERT
 mice crossed to other, freshly imported reporter mice. However, my 
preliminary analysis (n= 2) using Csf1r-Cre mice crossed to Rosa
Tomato
 mice 
(Madisen et al., 2010) imported from a lab elsewhere at UCL suggested that this is 
not the case (data not shown).  
My analysis of the Csf1r-Cre;Rosa
Yfp
 lineage trace in the developing retina 
identified stellate cells at the vascular front, raising the question, as to whether they 
are in any way related to the stellate retinal cells described in prior reports. Thus, 
several studies postulated that spindle-shaped cells contribute to retinal vascular 
growth by vasculogenesis (Ashton, 1970, Kretzer et al., 1984). However, another 
study found that these stellate cells did not express the well-established EC and 
angioblast marker VEGFR2, but instead were positive for the astrocyte marker, 
PDGFRα (Fruttiger, 2002). Thus, the idea of spindle-shaped angioblasts within the 
retina was mostly dismissed, and any pro-angiogenic role of spindle-shaped retinal 
cells may have reflected astrocyte functions in guiding the growing retinal 
vasculature (Scott et al., 2010, Stenzel et al., 2011). 
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Nevertheless, a recent paper provided compelling evidence for tissue-resident 
vascular precursors with a stellate morphology in the murine retina (Kubota et al., 
2011). This study used P0-Cre lineage tracing to identify stellate cells at the vascular 
front with the potential to differentiate into ECs in vitro and further showed that P0-
Cre-labelled cells contributed to vessel growth in the retina (Kubota et al., 2011). 
The Csf1r-Cre-labelled cells at the vascular front resembled these P0-Cre-labelled 
retinal EPCs in their position relative to the growing retinal vessels as well as their 
stellate morphology. In addition, similar to the P0-Cre-labelled stellate cells (Kubota 
et al., 2011), the Csf1r-Cre-labelled spindle-shaped cells were negative for the 
astrocyte marker GFAP, suggesting that they are not astrocytes. However, because 
GFAP may only label mature astrocytes (Fruttiger, 2002), it would be important to 
use another astrocyte marker such as PDGFRα (Fruttiger et al., 1996). This analysis 
was already performed for the P0-Cre-labelled cells, which were shown not to 
express PDGFRα (Kubota et al., 2011). 
All together, the fact that Csf1r-Cre labels retinal ECs and stellate cells at the 
vascular front agrees with the idea that Csf1r-Cre targets a tissue-resident vascular 
precursor population similar to the one described by Kubota et al. (2011). Further 
experiments are therefore warranted to demonstrate that Csf1r-Cre and P0-Cre label 
the same type of spindle-shaped cells. For example, it could be examined whether 
there is Csf1r expression in P0-Cre-labelled vascular precursors and vice versa. In 
addition, it would be of interest to investigate whether the Csf1r-Cre-specific 
deletion of Vegfr2 results in a vascular phenotype, because the P0-Cre-mediated 
deletion of Vegfr2 impaired retinal vascularisation (Kubota et al., 2011). This 
experiment would provide evidence that Csf1r-Cre labels a vascular progenitor 
similar to P0-Cre, as VEGFR2 is not expressed by macrophages or astrocytes.  
Previous studies have suggested that adult lymphatic and blood vessel EPCs 
are derived from a non-hematopoietic progenitor population within the bone marrow, 
which release endothelial precursors into the blood (Religa et al., 2005, Lee et al., 
2010, Case et al., 2007). In addition, several studies demonstrated that circulating 
KIT
+
 cells are able to differentiate into ECs (Sandstedt et al., 2014, Fang et al., 2012, 
Russell and Brown, 2014). Interestingly, my analysis of the adult bone marrow and 
blood revealed that Csf1r-Cre;Rosa
Yfp
 indeed labelled almost all of the non-
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hematopoietic (CD45
-
) KIT
+
 cells in the bone marrow as well as the blood. 
Moreover, YFP
+
 ECs only appeared a few days after tamoxifen induction in the 
retina of Csf1r-Cre
ERT
;Rosa
Yfp
 pups, a finding that is consistent with Csf1r-Cre-
labelled cells having been recruited from the blood into the retinal vasculature, rather 
than having been derived from an already tissue-resident precursor. Of course this 
finding does not exclude that the tissue-resident precursors inactivate the Csf1r 
promoter, but maintain or upregulate P0 expression once they have left the blood 
stream to enter tissues. Alternatively, tissue-resident precursors may express Csf1r, 
but are not able to give rise to ECs immediately following tamoxifen administration, 
because tamoxifen fails to effectively cross the postnatal blood-retinal barrier. In 
agreement, only a small number of microglia within the retinal parenchyma was 
targeted by Csf1r-Cre
ERT
 after tamoxifen administration (see Figure 5.10), even 
though this transgene enables efficient tamoxifen-mediated recombination in other 
tissues (e.g. DeFalco et al., 2014, Qian et al., 2011). 
Given my observations in the bone marrow and retina, the vascular progenitor 
pool might thus be comprised of a bone marrow-derived (EPC-like) population, as 
well as a tissue-resident (stellate) cell population, a notion that would support the 
plethora of studies that have argued for the existence of either of these two 
populations (reviewed in Basile and Yoder, 2014). In analogy to the roles of tissue 
resident-macrophages versus bone marrow-derived monocytes, tissue-resident 
progenitors might have a role in vascular homeostasis, whilst the bone marrow-
derived populations might play a larger role in pathological angiogenesis. It would 
therefore be interesting to see whether transplantation of the YFP
+ 
putative bone 
marrow-derived EPCs from Csf1r-Cre;Rosa
Yfp
 mice into wildtype mice with 
irradiated bone marrow gives rise to YFP
+
 ECs in angiogenic vessel beds.  
Unfortunately, I was unable to determine, whether Csf1r-Cre-labelled vascular 
precursors are required for developmental vascular growth due to the early lethality 
of embryos in which the Csf1r-Cre lineage has been ablated. Thus, Csf1r-
Cre;Rosa
Dta
 embryos died by E10.5 (see Figure 5.18). This cannot be due to the loss 
of macrophages, as macrophage-deficient embryos survive until birth (McKercher et 
al., 1996). In addition, lethality was unlikely to be caused by the loss of ECs, because 
only few ECs are targeted by Csf1r-Cre at this stage (data not shown). Instead, the 
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early embryonic death is most likely caused by the ablation of trophoblast cells, 
which express CSF1R (Jokhi et al., 1993) and are critical for normal placentation 
(reviewed in Hu and Cross, 2010), although I have not formally investigated this 
possibility.  
Given that I observed a moderate contribution of Csf1r-Cre-labelled ECs to 
embryonic blood vessel growth, but higher contribution to perinatal or pathological 
angiogenesis; it seems likely that these cells play a larger role in scenarios where 
blood vessels grow more rapidly than is possible by an upregulation of EC 
proliferation alone. To investigate this hypothesis further, one would need to 
quantitate the amount of Csf1r-Cre-targeted ECs in developmental and pathological 
vessels, measure the growth rate of the endothelium during angiogenesis and relate it 
to the proliferation rate. Nevertheless, in support of the notion that proliferation alone 
is not sufficient for normal angiogenesis to occur, a paper analysing the number of 
proliferating cells in the retina at P5 demonstrated that a surprisingly small number 
of ECs were PHH3
+
 (Rocha et al., 2014).  
5.4 Summary 
In this chapter, using the macrophage-specific transgene Csf1r-Cre crossed to the 
Rosa
Yfp
 reporter, I have provided evidence for the existence of a Csf1r-Cre-labelled 
vascular precursor that contributes to embryonic and postnatal blood vessel growth. 
Thus, I have demonstrated that Csf1r-Cre labels ECs and that this is not caused by 
endothelial CSF1R or ectopic Csf1r-Cre or Rosa
Yfp
 expression. Furthermore, using 
macrophage-deficient mice, I have revealed that the Csf1r-Cre-labelled precursors 
are not derived from the myeloid lineage; instead, analysis of immunolabelled bone 
marrow and blood, as well as tamoxifen-inducible Csf1r-Cre mice suggested that 
Csf1r-Cre labels an adult bone marrow-derived population, which circulates in the 
blood. Importantly, Csf1r-Cre-targeted ECs were also found to contribute to 
pathological angiogenesis in the OIR model of retinal neoangiogenesis, suggesting 
that targeting the Csf1r-Cre-labelled precursors may be of therapeutic interest. 
However, future work is required to demonstrate that isolated Csf1r-Cre-targeted 
vascular precursors are indeed able to differentiate into ECs and required for 
developmental and pathological vessel growth (see Chapter 6).    
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Chapter 6  FINAL CONCLUSIONS AND FUTURE WORK 
6.1 Summary of Conclusions and Final Remarks 
During my PhD, my aims have been to understand the role of NRP1 during 
vascular development and OFT remodelling and to investigate why a lineage trace 
with the transgene Csf1r-Cre labels the vascular endothelium.  
My NRP1 research has firstly contributed to two studies by demonstrating that 
NRP1 expressed by non-ECs is dispensable for developmental angiogenesis and that 
VEGF-A signalling through NRP1 is required for myocardial vascularisation, 
respectively. Furthermore, my project examining OFT remodelling uncovered an 
essential and exclusive role for NRP1 within the endothelium, where it binds to 
cardiac NCC-derived SEMA3C to enable endoMT and NCC relocalisation for the 
septation of the OFT.  
My analysis of Csf1r-Cre;Rosa
Yfp
 mice has provided considerable evidence for 
the existence of a Csf1r-Cre-labelled vascular precursor that contributes to 
embryonic blood and lymphatic vessel growth as well as postnatal vessel growth. I 
have excluded that Csf1r-Cre activity is caused by ectopic Cre expression or 
unspecific Rosa
Yfp
 reporter activity. Moreover, I have demonstrated that this putative 
vascular precursor contributes to pathological neovascularisation within the retina. 
My findings have made a significant contribution towards the field of vascular 
biology. As such, my work investigating NRP1 signalling has so far contributed to 
two peer-reviewed primary research papers (Fantin et al., 2014, Fantin et al., 2013a), 
two peer-reviewed review articles (Plein et al., 2015a, Plein et al., 2014) and two 
method articles (Plein et al., 2015b, Fantin et al., 2013c) (see Appendix – co-
authored publications). Furthermore, a manuscript outlining my findings regarding 
the role of NRP1 in OFT remodelling has been accepted for publication pending 
revision. I hope that upon completion of the additional experiments outlined in (see 
6.2), the demonstration that Csf1r-Cre is a reliable marker of vascular precursors 
should also yield a publication.  
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6.2 Future Work 
6.2.1 Signalling pathways downstream of SEMA3C/NRP1 during endoMT 
Having established that SEMA3C induces endoMT through NRP1, future 
work could investigate the downstream signalling pathways that enable this process. 
Thus, future experiments could analyse, which pathways are activated in SEMA3C-
treated primary ECs and investigate whether siRNA-mediated NRP1 knockdown 
affects this activation in a PLXND1-dependent fashion. Moreover, to identify targets 
of SEMA3C/NRP1 signalling, immunoblotting could be used to investigate changes 
in protein phosphorylation and translation, whereas changes in gene transcription in 
candidate pathways could be examined by qPCR. In particular, it is known that 
endoMT relies on multiple signalling pathways such as the TGFβ and DLL4/Notch 
pathway (reviewed in Lamouille et al., 2014), and both of these pathways have 
previously shown to interact with NRP1 (Sorensen et al., 2009, Glinka et al., 2011). 
6.2.2 Role of endoMT in cardiac NCC translocation 
Defective SEMA3C/NRP signalling was found to impair endoMT both in 
vitro and in vivo and prevented the translocation of the bilateral cardiac NCC streams 
towards the lumen of the vessel. However, it is currently not clear if and in what way 
these two processes are linked. Thus, future work may wish to examine, whether 
endoMT-derived mesenchymal cells displace the cardiac NCCs thus pushing them 
towards the OFT lumen, or, whether they secrete molecules that mobilise the cardiac 
NCCs. For example, mesenchymal cells derived from the endothelium could be 
isolated from Tie2-Cre;Rosa
Yfp
 OFTs by sorting for YFP
+
F4/80
-
CD31
-
 cells. 
Subsequently, mRNA expression could be analysed by RNAseq and potential 
chemoattractants tested in vitro using NCC cultures (Etchevers, 2011).  
6.2.3 Additional roles of NRP1 during OFT remodelling 
Analysis of ligand-specific NRP1 mutants revealed that whilst VEGF-A 
signalling through NRP1 is dispensable, SEMA3C signalling through NRPs is 
required for OFT remodelling. Nevertheless, the OFTs of Nrp1
Sema/Sema
;Nrp2
-/-
 mice 
mostly displayed milder defects than Nrp1-null and Tie2-Cre;Nrp1
fl/-
 mice. In 
particular, Nrp1
-/-
 OFTs always displayed a complete CAT, whereas 
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Nrp1
Sema/Sema
;Nrp2
-/-
 and Wnt1-Cre;Sema3c
fl/fl
 embryos consistently lacked proximal 
septation, but only occasionally lacked distal septation. This observation suggests 
that there might be additional NRP1-dependent roles during OFT remodelling. In 
accordance, a recent publication by our group has demonstrated that NRP1 is 
activated by the ECM component fibronectin, which in turn activates ABL and thus 
paxillin-mediated focal adhesion turnover and also cytoskeletal remodelling. 
Fibronectin is expressed by cardiac NCC within the OFT, and mice deficient in 
fibronectin exhibit defective OFTs (Mittal et al., 2013, Dai et al., 2013). It is, 
therefore, conceivable that fibronectin/NRP1 signalling might also exert an essential 
function during OFT remodelling. Alternatively, the milder phenotype observed in 
Nrp1
Sema/Sema
;Nrp2
-/-
 mice might stem from residual ligand binding activity. Thus, 
future experiments could used AP-tagged SEMA3C probes to determine whether 
SEMA3C binding to NRPs in primary ECs from Nrp1
Sema/Sema
;Nrp2
-/-
 mice is 
completely abolished.  
6.2.4 Contribution of Csf1r-Cre-labelled precursors to vascular endothelium  
To demonstrate that Csf1r-Cre does indeed label cells with the ability to 
differentiate into ECs and contribute to neovascular growth, three experiments 
(outlined below) should be performed on the two putative vascular precursor 
populations. Thus, the Csf1r-Cre-targeted retinal stellate cells (see Figure 5.5), 
which resemble the vascular precursors described by Kubota et al. (2011), could be 
isolated from retinas using FACS to isolate YFP
+
CD31
-
F4/80
-
PDGFRα- cells. The 
potential bone marrow-derived vascular precursors could be isolated from bone 
marrow and blood using FACS to isolate YFP
+
KIT
+
CD45
-
 cells. These cell 
populations could then be used for further experiments. 
Firstly, to investigate whether the FACS-sorted vascular precursors are able 
to give rise to ECs in vitro, the cells could be cultured in endothelial growth medium 
and the generation of EC colonies assessed, as performed in previous studies (Kubota 
et al., 2011, Case et al., 2007). Secondly, the FACS-isolated vascular precursors 
could be injected into the tail vein of Csf1r-Cre-negative littermates. Following, the 
induction of neovascularisation using models such as the ear wound healing assay 
(Raimondi et al., 2014) or laser-induced CNV (Lambert et al., 2013), the presence of 
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YFP
+
 ECs within the neovascular lesions should be assessed. Thirdly, live imaging 
of explants, e.g. yolk sac (Jones et al., 2008) or retina (Sawamiphak et al., 2010), 
could be used to visualise the possible integration of the YFP
+
 vascular precursors 
into the endothelium as opposed to demonstrate ECs being not YFP
+
 only because of 
previously undetected sporadic endothelial Cre expression. Retinal explants would 
be suitable if Csf1r-Cre does indeed label tissue-resident vascular progenitors similar 
to those described by Kubota et al. (2011). To investigate the potential of circulating 
vascular precursors, YFP
+
KIT
+
CD45
-
 blood cells would have to be added to the 
explants, although this would only work if they normally extravasate and then 
incorporate from the tissue side, rather than incorporating from the luminal side.  
6.2.5 Expression profile of Csf1r-Cre-labelled vascular precursors  
To address whether the Csf1r-Cre-labelled KIT
+
CD45
-
 vascular precursors 
constitute bone marrow-derived circulating EPCs similar to those that have been 
described in other studies (Case et al., 2007, Nolan et al., 2007, Park et al., 2014), 
future work should analyse the expression of other previously published markers of 
these cells. Thus, circulating YFP
+
KIT
+
CD45
-
 cells could be isolated from the adult 
blood using FACS to measure the expression of markers such as CD133 (Hilbe et al., 
2004, Gehling et al., 2000), VEGFR2 (Friedrich et al., 2006, Peichev et al., 2000) 
and CD34 (Yang et al., 2011, Peichev et al., 2000). To address whether the Csf1r-
Cre-labelled stellate cells within the retina resemble the P0-Cre-labelled tissue-
resident vascular precursors described by Kubota et al. (2011), YFP
+
F4/80
-
CD31
-
PDGFRα- cells could be isolated using FACS to measure the expression of mRNA 
for P0, VEGFR2 and CXCR4, which are all expressed by the P0-Cre-labelled 
vascular precursors (Kubota et al., 2011).  
6.2.6 Requirement of Csf1r-Cre-labelled precursors to vascular growth  
Given the early embryonic lethality of mice lacking Csf1r-Cre-labelled cells 
(see Figure 5.17), which is presumably caused by the ablation of CSF1R-expressing 
trophoblasts, it is currently not clear whether Csf1r-Cre-labelled vascular precursors 
are essential for developmental or pathological angiogenesis. Future work should, 
therefore, attempt to generate a Csf1r-Cre allele that spares trophoblast cells, or 
analyse Csf1r-Cre
ERT
;Rosa
Dta
 mice, in which the Cre could be activated during late 
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gestation when CSF1R is no longer required by trophoblast cells (Jokhi et al., 1993). 
The use of Csf1r-Cre
ERT
;Rosa
Dta
 mice would also help determine whether the Csf1r-
Cre-labelled vascular precursors are essential for pathological vessel growth, which 
would be of great therapeutic interest (see 1.1.2.4). 
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